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Acute Febrile encephalopathy is a term commonly used by physicians to describe the 
clinical syndrome of short duration fever which is either accompanied or followed by 
altered mental status.(1) This is one of the syndromes frequently encountered by the 
physicians in the emergency department.(2) The emergency physician is always 
challenged with the task of identifying the etiology of this syndrome because it has 
serious implications on the management and the outcome. (2) 
 Routinely this syndrome of acute febrile encephalopathy is thought to be caused by 
various infectious etiology(2), however in practice we find that there are several non-
infectious etiologies like heat stroke  that presents with this syndrome. Understanding 
the different non-infectious etiology would help in quicker diagnosis and prompt 
initiation of appropriate management. The different spectrum of infections causing 
acute febrile encephalopathy viz bacterial, viral, fungal, and protozoal also needs to be 
studied    to aid early diagnosis and to initiate appropriate empirical therapy.  Delay in 
initiation of therapy would have serious implications in terms of poor outcome and 
severe neurological sequelae. Another important aspect to be considered is the 
geographical and seasonal variations that occur. Different etiologies need to be 
considered in different geographical areas and in different seasons in the same 
geographical area.(3) 
In this study we attempt to look at the different spectrum of etiology of acute febrile 
encephalopathy including both infectious and non-infectious and their outcome in a 
tertiary hospital in South India through a period of one year so as to learn the various 





 To study the clinical spectrum of patients presenting with acute febrile 




 To study the etiology of patients presenting with acute febrile encephalopathy. 
 To study the clinical and laboratory predictors in  the diagnosis of etiology  
(Infectious and non-infectious) of  acute febrile encephalopathy 
 To assess the outcome (Mortality and functional outcome) of patients with 
acute febrile encephalopathy using modified Rankin scale. 














REVIEW OF LITERATURE 
 
UNDERSTANDING TERMINOLOGIES 
As discussed in the introduction, acute febrile encephalopathy is a common syndromic 
presentation that physicians encounter in the emergency department. Prior to a 
detailed  discussion of the various aetiologies presenting with this syndrome it is 
imperative that the various terminologies mentioned in the literature to describe this is 
well understood.(4) 
 
Acute Febrile Encephalopathy (AFE) = Short duration fever + Encephalopathy 
ACUTE FEBRILE ENCEPHALOPATHY 
Acute Febrile encephalopathy is a term commonly used by the physicians to describe 
the clinical syndrome of acute febrile illness which is either accompanied or followed 
by altered mental status 
 
Acute febrile 
Encephalopathy  → 
Encephalopathy  → 





• Fever + 
• Encephalopathy 
• Altered mental status 





ENCEPHALOPATHY is a broad term for any diffuse disease of the brain that alters 
brain structure or function. The hall mark of encephalopathy is altered mental status. 
Encephalopathy may be caused by bacteria, virus, or prion, metabolic or 
mitochondrial dysfunction, ischemic or hypoxic ,brain tumour or increased 
intracranial pressure, long standing exposure to toxic substances like  drugs, radiation, 
solvents, paints, industrial chemicals, and certain metals, trauma,  poor nutrition, or 
lack of oxygen or blood flow to the brain.  
In febrile illness, multiple pathogenic mechanisms can contribute to the 
encephalopathy. Pathological process can directly affect the central nervous system or 
indirectly affecting the central nervous system through systemic complications such as 
hypovolemia, hypoglycaemia, hypoxia, anaemia, hepatic failure, renal failure and 
bleeding. (5) 
Clinically it is synonymously used with multiple terminologies including altered 
sensorium, altered mental status and change in mental status. 
It is important to understand normal mental status to identify patients with altered 
mental status. 





Figure 1 Domains of mental status 
Normal mental status is when the patient has normal level of consciousness and the 
content of consciousness is normal. 
Consciousness is the quality or state of being aware especially of something within 
oneself. 
The terms used to describe different level of consciousness are  
 
Normal or Alert 
Vigilant or Hyper alert 







Level of consciousness Content of consciousness 
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Normal mental status when impaired  is termed altered mental status which can be 
either an altered level of consciousness  ranging from being vigilant or hyper alert to 
being drowsy, stupor or comatose or an impairment in the content of the 
consciousness or a combination of both. 
ALTERED MENTAL STATUS (AMS) is used to describe different states of mental 
functioning that can vary between mild confusion to coma.(6) 
Different synonyms are used in the literature to describe this state such as, not acting 
right, confusion, altered behaviour, altered sensorium, lethargy, agitation, psychosis, 
disorientation, inappropriate behaviour, in attention. (7,4) 
The understanding of these terminologies will help us in identification of the problem 






MENINGITIS VERSUS ENCEPHALITIS 
An acute infection of the central nervous system is a very important problem because 
recognition of this problem early and rapid institution of therapy usually is lifesaving. 
Acute infection of the Central nervous system usually presents with one of these 
clinical syndromes 
1. Bacterial meningitis 
2. Viral meningitis or encephalitis 
3. Focal infection of brain- brain abscess or subdural empyema. 
Meningitis is when infection predominantly involves the arachnoid space. Nuchal 
rigidity is the pathognomonic sign for identifying meningeal involvement. However 
the sensitivity and specificity of the same is uncertain and it can be absent or reduced 
in patients with altered mental status, elderly, young and immunocompromised 
patients. 
The presence or absence of normal brain function is the significant differentiating 
feature between encephalitis and meningitis. The distinguishing feature between the 
both is frequently blurred since some patients may have both a parenchymal and 
meningeal process with clinical features of both. Meningoencephalitis is a common 
term used to describe this overlap. 
The importance of distinguishing between the two syndromes lies in the fact that the 





Encephalitis is an acute, diffuse inflammatory process affecting the brain.(8) 
The definition of acute encephalitis syndrome was introduced by the world health 
organisation to improve the surveillance for Japanese encephalitis which is the most 
common cause of encephalitis in tropical countries. Although this definition includes 
illnesses caused by both infectious and non-infectious aetiology most often acute 
encephalitic syndrome is considered to be due to a viral aetiology. With this definition 
even a basic health worker can identify a case which is defined as 
ACUTE ENCEPHALITIS SYNDROME 
“Clinically, a case of Acute Encephalitis Syndrome (AES) is defined as a person of 
any age, at any time of year with the acute onset of fever and at least one of: a) change 
in mental status (including symptoms such as confusion, disorientation, coma, or 
inability to talk); b) new onset of seizures (excluding simple febrile seizures1). Other 
early clinical findings may include an increase in irritability, somnolence or abnormal 










The true incidence of acute febrile encephalopathy (AFE) is difficult to determine 
because of the wide variety of aetiologies causing the syndrome. Broadly it can be 
classified as infectious and non-infectious. It is important to know the incidence, 
geographical distribution and the seasonal variations, so that it can aid in quicker 
diagnosis, prompt initiation of treatment, helps in devising preventive strategies and 
control measures. The incidence of infectious aetiology is particularly difficult to 
determine because many cases are unreported or the diagnosis may not be considered 
and specific viral aetiology is difficult to confirm. The non-infectious spectrum of 
acute febrile encephalopathy is not a notifiable disease and hence less public health 
awareness is present though it is very important to recognise particularly the heat 
stroke syndrome as it causes significant mortality and morbidity and the incidence of 
these are also not known. It is of paramount importance to know the incidence of acute 
encephalitic syndrome specifically those caused by different viruses since it can cause 
high morbidity and mortality. It affects peoples of all ages, however incidence is 
slightly higher in children. Male predominance was also shown in few studies. Some 
aetiology like herpes has a worldwide distribution while some like arbovirus-Japanese 
encephalitis are geographically restricted.(9) 







The estimated incidence of the acute encephalitis syndrome (AES worldwide is not 
clearly known. In US the estimated incidence is   ̴ 75000 per year for viral meningitis 
and   ̴ 20000 per year for the encephalitis. Worldwide there is no or underreporting of 
suspected acute encephalitic syndrome, so the actual incidence is expected to be much 
higher than is known. A list of incidence study on acute febrile encephalopathy (AFE) 
in the published literature in different regions of the world is shown in the table 1 
Analysis from the table revealed that tropical countries had an incidence rate of 
1.77(+/-0.32) where was western industrialised countries had an incidence rate of 
0.51-7.4. 









Kamei et al. (10) 2000 1989-1991 Japan 1.77 
Heinrich et al.(11) 2003 1993-1998 Thailand 6.34 
Akiba.(12) 1997 1997 Nepal 145-185 
Khetsuriani et al (13) 2007 1998-1997 USA 0.51-0.53 
Mailles et al (14) 2007 2000-2002 France 1.9 
Ponka et al (15) 1982 1980 Finland 3.5 
Klemola et al (16) 
Kaeaeriaeinen et al (17) 
1965 1945-1965 Finland 2-3 
Trevejo(18) 2004 1990-1999 USA 4.3 
Pedersen (19) 1956 1952-1954 Jutland 6.75-9.25 
Bhegi et al (20) 1984 1950-1981 USA 7.4 
Nicolosi(21) 1986 1950-1981 USA 7.4 




Few large nationwide studies done in different countries are as follows. 
A  nationwide survey done in Japan, to find the  aetiology of febrile encephalopathy  
reported 983 cases of encephalopathy with influenza virus as the most common cause 
followed by rota virus and human herpes virus.(22).The precise incidence of 
encephalitis is not known. The incidence of encephalitis in England was estimated  by 
linking hospitalisation data with a prospective study and using capture recapture 
model which estimated the  incidence of encephalitis as 5.23 cases/100000/year.(23). 
A systematic review by Granerod et al on the incidence of encephalitis in non-
outbreak situations estimated an annual incidence ranging from 0.07 cases to 12.6 
cases per 100000 population.(24) 
INDIAN SCENARIO 
The data available on the incidence of acute febrile encephalopathy in India is scarce. 
Most of the data that is available is only from the outbreak investigations, surveillance 
studies, case series and case reports. Three seventy five (375) million people in India 
are at risk of developing acute febrile encephalopathy(25). In India, surveillance done 
as part of the National vector borne disease control programme had reported almost 
50% of the AES cases from the states of Uttar Pradesh, West Bengal and Tripura. This 
may not reflect the prevalence of the disease in these regions, as much as better 
reporting practices in these states. The surveillance found  11586  AES cases with 
almost 10% mortality in 2015(26). 
The incidence rate  in India was estimated as 0.46 as compared to 5.6 in Nepal 




Figure 2 Distribution of Acute Febrile encephalopathy in India 
 
 
The etiology of Acute Encephalitic Syndrome  (AES) is often not identified due to 
non-availability of complete virus panel in most centres. An etiological agent is 
identified in 25% of cases of AES. A10 to 15 percent is caused by Japanese 
encephalitis and the remaining by other viruses such as enterovirus, mumps, rubella, 
measles, nipah virus, dengue, adenovirus, influenza, chikungunya and many 
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others.(25). AES in India were often attributed to Japanese encephalitis infection 
however recently new outbreaks caused by Nipah, Chandipura and enterovirus have 
been reported.(27–31)Japanese encephalitis is the most common cause of AES in Asia 
(32) with 10,000 deaths in about 50000 cases. Japanese Encephalitis was first reported  
by Carey et al from Christian Medical college hospital, Vellore in 1955(33) 
ETIOLOGY OF ACUTE FEBRILE ENCEPHALOPATHY 
 The aetiology of Acute Febrile Encephalopathy is broad including both infectious and 
non-infectious. Understanding the different aetiologies is important for the physicians 
in the emergency department as it can help in quicker diagnosis and early initiation of 
therapy. We will discuss the aetiology under two major heading the infectious and 
non-infectious. 
INFECTIOUS 
 Most of the literature on acute febrile encephalopathy has discussed mainly on the 
infectious aetiology(2,34–36). It is the most common cause to present with this 
neurological syndrome .The various aetiological agents known to cause this are 









ACUTE BACTERIAL MENINGITIS 
Acute bacterial meningitis constitutes a large number of patients who present with 
altered sensorium to the emergency department. It is a life threatening condition, more 
so in children than in adults. Thus, it is imperative to make a rapid clinical and 
microbiological diagnosis so that treatment can be initiated at the earliest. In the era 
before the use of antibiotics, the fatality due to acute bacterial meningitis was very 
high. However, after the advent of antibiotics, the mortality has drastically come 
down. However, a large number of patients are left with significant neurological 
sequelae causing significant morbidity. There have not been many studies which have 
been carried out in adults describing the epidemiology, risk factors and outcomes.(37) 
 
Infectious 








In adults the most common cause of acute bacterial meningitis is as follows –  
1. Streptococcus pneumoniae (56%) 
2. Neisseria meningitidis (20%) 
3. Group B Streptococci (15%) 
4. Listeria monocytogenes (6%) 
5. Haemophilusinfluenzae (5%) (38) 
RISK FACTORS  
There have been various risk factors identified in community acquired bacterial 
meningitis. The most common risks factors identified were a middle ear infection, 
sinusitis, an immunocompromised state, alcoholism and a co-existing pneumonia. 
Other risk factors identified were a recent head injury, CSF leak and those who have 
undergone recent neurosurgical procedures.(37) 
PATHOPHYSIOLOGY 
The basic pathology behind acute bacterial meningitis is an acute inflammation of the 
lepto-meninges with an exudate encasing the brain. This exudate tracks along the 
penetrating vessels and causes phlebitis or arteritis which in turn causes necrosis of 
surrounding vascular territory. This may sometimes lead to cerebral oedema and acute 





CLINICAL FEATURES  
Bacterial meningitis typically presents with the triad of fever, neck stiffness and 
altered mental status. Most patients present with short duration of high grade fever 
with associated severe holocranial headache and vomiting. On examination, there is 
almost always nuchal rigidity and an altered mental status with papilledema. Other 
findings to be looked for are a petechial rash which is highly specific for 
meningococcal meningitis. A small proportion of patients can present with seizures or 
a focal neurological deficit.(39) 
INVESTIGATIONS 
A lumbar puncture must be done as soon as possible in order to confirm the diagnosis. 
High opening pressures are always almost present and CSF analysis shows low 
glucose and elevated protein levels. It also shows a CSF pleocytosis (neutrophil 
predominant). A smear will occasionally show the organism of interest such as gram 
negative diplococci. 
TREATMENT 
Appropriate IV antibiotics must be given as soon as a diagnosis is made. If the results 
of CSF analysis are delayed and if clinical suspicion is high, empirical IV broad 
spectrum antibiotics must be started as soon as the lumbar puncture is performed. 






Overall mortality rates are around 25% for community acquired meningitis.  Three 
factors which were found to have higher association with mortality are age more than 
60 years, altered mental state on admission and seizures within 24 hours of 
admission.(39) 
SCRUB TYPHUS MENINGOENCEPHALITIS 
INTRODUCTION  
 Scrub typhus is caused by Orientiatsutsugamushi  (previously called Rickettsia 
tsutsugamushi)  .It usually presents as an undifferentiated febrile illness but a subset of 
then can present with the neurologic syndrome of acute febrile encephalopathy. 
EPIDEMIOLOGY  
  O. tsutsugamushi is found throughout the Asia Pacific region. Scrub typhus is 
endemic in India ,Taiwan ,Korea, China, , Japan, Pakistan, Thailand, ,Malaysia, and in 
the tropical Australia (40) 
INCUBATION PERIOD   
Infection commonly presents as an acute febrile illness seven to ten days after the bite 







Overview : Scrub typhus usually starts insidiously with anorexia, headache, and 
malaise, or sometimes begins abruptly with chills and fever. As the illness evolves, 
most patients develop the following symptoms: 
●Fever usually  lasts for long periods in untreated patients (median-14.4 days; 
range( 9-19) (42) 
● Generalized headache 
● Diffuse myalgias 
DIAGNOSIS  
 As with all rickettsial diseases, no lab test is diagnostically reliable in the early phases 
of scrub typhus. The disease is usually recognized when clinicians correlate the 
presence of compatible clinical signs, symptoms, and laboratory features, with 
epidemiologic clues (eg, recent exposure to environments in which chiggers are 
known or suspected to be present). 
Patients with scrub typhus may develop the following laboratory abnormalities: 
● Thrombocytopenia. 
● Elevations in liver enzymes, bilirubin, and creatinine. 
● Leukocytosis can occur or a normal white blood cell count. 
While these laboratory findings are relatively nonspecific, four methods can be used to 






o Polymerase chain reaction. 
SEROLOGY 
 The indirect fluorescent antibody (IFA)  is used in the serologic diagnosis. 
Biopsy of the generalized rash  or an eschar, reveals the pathological hallmark of 
scrub typhus, a lymphohistiocytic vasculitis. Damage to endothelial cells occurs early 
in infection, leading to widespread vascular dysfunction. This endothelial injury 
causes a loss of vascular integrity, egress of plasma and plasma proteins, and 
microscopic and macroscopic haemorrhages. Thus, the histologic changes in biopsies 
of eschars include focal areas of cutaneous necrosis surrounded by a zone of intense 
vasculitis, with perivascular collections of lymphocytes and macrophages. Thrombosis 
of small blood vessels can also occur. Demonstration of these typical vasculitic 
changes can be diagnostic, even when rickettsiae are not demonstrable by fluorescent 
antibody conjugates. 
POLYMERASE CHAIN REACTION — Polymerase chain reaction (PCR) 
technology done  in  scrub typhus patients can definitively establish the diagnosis, 






Doxycycline and Azithromycin are comparable in shortening clinical illness and 
reducing the incidence of relapse of infection.  
TUBERCULOSIS OF CENTRAL NERVOUS SYTEM 
INTRODUCTION — Tuberculosis (TB) of the Central nervous system (CNS) 
includes three clinical categories 
 Tuberculous meningitis 
 Intracranial tuberculoma 
 Spinal tuberculous arachnoiditis.  
All  of them are frequently encountered in the clinical practice where the incidence of 
tuberculosis is high and post-primary dissemination is commonly seen in  children and 
young adults(44) 
PATHOGENESIS  
During the hematogenous spread that follows a primary infection or reactivation 
tuberculosis (TB), scattered tuberculous foci (tubercles) are formed in the meninges 
and brain. The rupture of  sub-ependymal tubercle into the subarachnoid space is the 
critical event leading to the development of tuberculous meningitis.  
CLINICAL MANIFESTATIONS  
 Typically, patients with CNS tuberculosis  present with a subacute febrile illness that 
progresses through three discernible phases (45) 
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● The prodromal phase 
● The meningitic phase  
● The paralytic phase  
DIAGNOSIS  
 The diagnosis of CNS TB  is challenging and a high degree of suspicion is critical in 
order to initiate therapy promptly. Diagnostic tools consist of cerebrospinal fluid 
examination (including culture and nucleic acid testing) and radiography. 
SPINAL FLUID EXAMINATION  
 The cerebrospinal fluid examination is of critical importance to the early diagnosis of 
tuberculous meningitis. Typically, the CSF fluid shows elevated protein and lowered 
glucose concentrations with a mononuclear pleocytosis(46). CSF protein ranges from 
100 to 500 mg/dL in most patients. In patients where there is blockage of 
subarachnoid high levels in the range of 2 to 6 g/dL can be seen. In 80 percent of cases 
the CSF glucose is less than 45 mg/dL.  
RADIOGRAPHY  
Cerebral edema, basilar arachnoiditis, infarction, and hydrocephalus are seen in the 
imaging findings of patients with tuberculous meningitis 
TREATMENT  
Anti-tuberculous therapy (ATT)  should not be delayed for microbiological  proof. It 
should be initiated immediately if the clinical suspicion is high as the  clinical 
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outcome  varies  on the stage at which therapy is started .More harm results from 
delaying the therapy , even for a few days, than from inappropriate therapy .  
VIRAL MENINGOENCEPHALITIS 
As we discussed earlier the different viral infections of the central nervous system 
result in the clinical syndrome of aseptic meningitis or meningoencephalitis or 
encephalitis. More than 100 different viruses has been identified as causative agents of 
the infective aetiology of acute febrile encephalopathy such as herpes simplex, Epstein 
Barr, varicella zoster, adenovirus, enterovirus, mumps, measles, Japanese encephalitis 
and many more. The arthropod borne viruses causes epidemic encephalitis which is 
usually restricted to a geographical area and the frequency varies in different seasons 
of the same year.(47) 
PATHOPHYSIOLOGY 
Acute viral encephalitis is disease mainly involving the grey matter with parenchymal 
and perivascular infiltration of inflammatory cells.(47) Post infectious 
encephalomyelitis mainly involves the white matter with periventricular inflammation 
and demyelination.(47) 








HERPES  SIMPLEX ENCEPHALITIS 
INTRODUCTION  
Herpes simplex virus- 1 (HSV-1)  causes encephalitis  which is frequently the 
sporadic form and is fatal. 
PATHOGENESIS 
Routes of infection: HSV infection of the central nervous system (CNS) appears to 
arise via one of three routes, each accounting for approximately one-third of infections 
(48) 
● Direct CNS invasion via the trigeminal nerve or olfactory tract following an 
episode of primary HSV-1 of the oropharynx.Primary infection occurs in age 
group less than 18 years. 
●CNS invasion after an episode of recurrent HSV-1 infection, which is believed 
to represent viral reactivation with subsequent spread 
●CNS infection without primary or recurrent HSV-1 infection, which is felt to 
represent reactivation of latent HSV in situ within the CNS 
CLINICAL FEATURES 
Symptoms and signs: Focal neurologic findings may occur and are usually acute (<1 
week in duration) and include altered mental status and impairment of level of 
consciousness with focal cranial nerve deficits including aphasia, hemiparesis, 
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dysphasia, ataxia, or even focal seizures. About 90 percent of patients  have one of the 
above mentioned symptoms with fever (48) Other neurologic symptoms which can  
occur are fecal  and urinary incontinence, aseptic meningitis, localized dermatomal 
rashes, and even Guillain-Barré syndrome (49) 
Laboratory abnormalities: Cerebrospinal fluid examination  typically shows a 
lymphocytic pleocytosis,  increased erythrocyte count ( 84 percent of patients), and 
elevated protein. Normal cerebrospinal fluid (CSF)  can occur early in the disease. 
When the clinical suspicion is high a repeat testing is undertaken. If the  glucose is 
low, an alternative diagnosis should be considered (50) 
Imaging studies: Imaging in HSV encephalitis usually have temporal lobe 
abnormalities on brain imaging  .Temporal lobe abnormalities are unilateral  
associated  with or without mass effect (48) 
Electroencephalogram (EEG):  Focal electroencephalogram (EEG) findings occur in  
more than 80 percent of cases, typically showing  predominantly delta and theta waves 
Polymerase chain reaction: Polymerase chain reaction(PCR ) technology  is the gold 
standard for detecting herpes simplex virus DNA in the CSF .The test has a sensitivity 
of 98 percent and specificity of 94 to 100 percent. Treatment for HSV encephalitis 
should be initiated awaiting the results of PCR. HSV DNA is detectable  using the  
PCR analysis of the CSF for a minimum of two weeks and even  up to one month (51) 
TREATMENT  
As soon as HSV is suspected in the emergency department empirical therapy with 
intravenous acyclovir at the dose 10 mg/kg IV every 8 hours should be started. 
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Aggressive and early antiviral therapy prevents mortality and the limits the 
neurological sequelae such as cognitive and behavioral impairments.  
ADENOVIRUS ENCEPHALITIS 
Adenovirus is a common pathogen which affects the paediatric population in the form 
of respiratory, gastro-intestinal and renal infections. They have also in the recent past 
been found to cause neurological disorders such as aseptic meningitis, myelitis, 
subacute focal encephalitis and Reye-like syndrome. The most common presentation 
of patients with an adenovirus neuro-infection is a reversible encephalopathy.(52) 
ETIOLOGY 
Type 7 adeno virus has been most commonly associated with encephalitis in children. 
However, the other types (1,2,3,6 and 12) have been isolated from the CSF of patients 
with meningo-encephalitis.(53) Type 7 adeno virus has been known to be associated 
with a meningoencephalitis with a more severe course.(54)
 
RISK FACTORS 
There have been no specific risk factors identified. This entity is almost exclusively 
limited to children below the age of 10.(53)There has been one case report of a 
subacute adenovirus encephalitis in a 42 year old with malignant lymphoma on 
multiple immunosuppressants.(55) 
PATHOPHYSIOLOGY 
The pathophysiology of this disease is unknown, however, it has been postulated that 





Children presented with high grade intermittent fever which lasted for 5-7 days and 
progressive decline of sensorium. There were no symptoms or signs of raised 
intracranial pressure and no history of seizures. There is marked absence of nuchal 
rigidity and patients usually had a normal neurological examination.  Most children 
had concomitant respiratory, conjunctival or gastrointestinal symptoms.(54) 
INVESTIGATIONS 
Laboratory investigations are usually normal except for a minimal leucopenia. A 
lumbar puncture also yields normal results. CSF cultures and PCR’s are also negative. 
However, an EEG done shows diffuse background slowing which helps differentiate it 
from other forms of an aseptic meningitis. 
However, in case of an adenovirus meningoencephalitis, there is pleocytosis in the 
CSF along with presence of the organism in brain specimens. 




Treatment is conservative with no need for the use of antibiotics. There is gradual 




EPSTEIN BARR VIRAL ENCEPHALITIS 
EBV encephalitis is a rare (<1%) and self -limiting cause of encephalitis. It is disease 
entity which is almost always seen only in the paediatric age group.(56) It has also 
been reported to manifest as meningoencephalitis, cerebritis, transverse myelitis, 
neuropsychiatric syndrome and cranial nerve palsies. However, most neurological 
complications occur 1-3 weeks after the onset of illness. 
ETIOLOGY 
It is caused by the Epstein Bar virus (EBV) and EBV encephalitis can occur alone or 
in association with infectious mononucleosis. 
PATHOPHYSIOLOGY 
The pathophysiology of this disease is still under debate and has been postulated to be 
due to direct viral invasion or an autoimmune pathology. It has been shown to be a 
immune mediated process that result in multifocal demyelination of peri-venous white 
mater. 
CLINICAL FEATURES 
Patients were of the paediatric age group and presented with fever, seizures, headache, 
depressed sensorium and bizarre behaviour. On examination, they can have altered 
consciousness, meningeal signs, bulbar signs, cerebellar signs and cranial nerve 






Detection of virus in both CSF and blood is usually done with the help of PCR. MRI is 
the imaging of choice and shows peculiar distribution of reversible diffusion. There 
can also be changes in bilateral basal ganglia which accounts for the behavioural 
disturbances.(58,59) 
TREATMENT 
Acyclovir and corticosteroids have been tried in treatment of EBV encephalitis 
however their effectiveness is unknown.(60) 
OUTCOME 
Large enough studies have not been carried out to determine long term outcome and 
prognosis of these patients. However, it is usually associated with recovery in spite of 
severe disease which may require mechanical ventilation. 
DENGUE ENCEPHALITIS 
Dengue infection is a common infection worldwide and is a very common cause of 
febrile illness in the Indian sub-continent. Dengue ranges from dengue fever, dengue 
hemorrhagic syndrome and dengue shock syndrome. Some patients have also been 
reported to have neurological involvement in the form of an encephalopathy. Other 
manifestations such as transverse myelitis, Guillain- Barre syndrome, acute 
disseminated encephalomyelitis and myositis. However, these entities have been 





Dengue is a single stranded RNA virus of the flavivirus genus with 4 serotypes 1 to 4. 
The serotypes are heterogeneous and do not confer autoimmunity.  A secondary 
infection with a different serotype is almost always more severe. Few studies have 
shown that serotypes 2 and 3 are most likely to cause neurological complications. 
Secondary infection is also shown to have a higher incidence of neurological 
complications.(62) 
RISK FACTORS 
The lower socio-economic strata of society are more susceptible to dengue in view of 
poor living conditions. 
PATHOPHYSIOLOGY 
Once the virus enters the blood stream, it infects and replicates within the 
macrophages and monocytes. Host immune response plays an important role in the 
pathophysiology of this disease. Encephalopathy in dengue is very poorly understood. 
It is unknown if the virus is neurotropic or is mediated by direct infection of the 
nervous system. 
CLINICAL FEATURES 
A patient with dengue encephalitis usually presents with fever, decreased 
consciousness, headache and seizure. On examination, patients can have a focal 
neurological deficit, cranial nerve palsies and quadriparesis. Neurological symptoms 




Dengue is essentially a clinical diagnosis. Laboratory tests supplement the diagnosis 
such as the dengue RNA PCR which aid and can distinguish between different 
serotypes. Other tests available are the NS-1 antigen assay and the IgM antibody 
ELISA. 
For evaluation of neurological involvement, MRI of the brain is the imaging modality 
of choice. The findings which are usually seen are cerebral edema, white matter 
changes and necrosis and brain atrophy. Infarction and haemorrhage are also 
commonly seen.(61) 
TREATMENT 
Management of dengue includes careful monitoring and replacement of fluids with 
correction of electrolytes. In case of neurological involvement, airway must be secured 
and patient must be started on anti-epileptics if he/she has presented with seizures. If 
cerebral edema is suspected clinically or on imaging, anti edema measures must be 
initiated. There is no specific anti-viral therapy for the treatment of dengue 
encephalopathy, however many studies are underway for new treatment modalities. 
Since the pathogenesis is immune mediated, there may be a role for 
immunosuppression.(63) 
SEPSIS ASSOCIATED ENCEPHALOPATHY 
Septic encephalopathy is one of the most common causes of encephalopathy. The 
pathophysiology of septic encephalopathy is multifactorial including altered blood-brain 
barrier permeability, inflammatory cytokines, and increase in neurotransmitter octopine. In a 
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study done on 127 adult patients with AFE 12.7% was diagnosed as sepsis associated 
encephalopathy. (2)The common sources of community acquired sepsis in our institution are 
pyelonephritis particularly in diabetic patients and Community acquired pneumonia. 
NONINFECTIOUS 
Non-infectious can be due to variety of causes which includes metabolic 
derangements,  heat stroke, toxins and others.  
 
ACUTE TOXIC-METABOLIC ENCEPHALOPATHY 
Acute toxic-metabolic encephalopathy (TME) encompasses acute confusional state- 
an acute condition of global cerebral dysfunction in the absence of primary structural 
brain disease. 
PATHOPHYSIOLOGY  
All forms of acute toxic-metabolic encephalopathy (TME) interfere with the function 
of the ascending reticular activating system and/or its projections to the cerebral 
cortex, leading to impairment of arousal and/or awareness. Ultimately, the 
neurophysiologic mechanisms of TME include interruption of polysynaptic pathways 
Non-infectious 
Metabolic Toxic Others 
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and altered excitatory-inhibitory amino acid balance (64). The pathophysiology of 
TME varies according to the underlying etiology: 
●Cerebral edema contributes to acute fulminant hepatic encephalopathy and to 
hypo-osmolar encephalopathies. 
●Drug-induced delirium results from disruption of the normal integration of 
neurotransmitters, including dopamine, acetylcholine, glutamate, gamma-
aminobutyric acid (GABA), and/or serotonin(65). 
●Electrolyte derangements alter membrane excitability to produce TME. 
●Nutritional disorders disturb cellular energy metabolism and may result in 
neuronal death. 
●Exogenous toxins, including carbon monoxide and cyanide, cause impaired 
oxygen delivery and mitochondrial dysfunction. 
HEAT STROKE 
INTRODUCTION — Hyperthermia is defined as elevation of core body temperature 
above the normal diurnal range of 36 to 37.5ºC due to failure of thermoregulation. A 
temperature above 40ºC (or 104ºF) is generally considered to be consistent with severe 
hyperthermia. 
There are two types of heat stroke: 
●Classic (non-exertional) heat stroke – Classic heat stroke affects individuals 
(most often patients over 70 years) with underlying chronic medical conditions 
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that impair thermoregulation, prevent removal from a hot environment, or 
interfere with access to hydration or attempts at cooling (66). These conditions 
include cardiovascular disease, neurologic or psychiatric disorders, obesity, 
anhidrosis, physical disability, extremes of age, and the use of recreational drugs, 
such as alcohol or cocaine, and certain prescription drugs, such as anticholinergic 
agents or diuretics  
●Exertional heat stroke – Exertional heat stroke generally occurs in young, 
otherwise healthy individuals who engage in heavy exercise during periods of 
high ambient temperature and humidity. Typical patients are athletes and military 
recruits in basic training. In vitro muscle fiber testing, reveals evidence of 
susceptibility to malignant hyperthermia in some patients who present in this 
fashion (67).  
In addition to an elevated core body temperature, common vital sign abnormalities in 
heat stroke include sinus tachycardia, tachypnea, a widened pulse pressure, and 
hypotension (68). If they can respond coherently, patients with heat stroke may 
complain of weakness, lethargy, nausea, or dizziness. The presentation of elder adults 
with heat stroke may be subtle and nonspecific early in the course of the disease. 
Other physical findings may include flushing (cutaneous vasodilation), tachypnea, 
crackles due to non-cardiogenic pulmonary edema, excessive bleeding, and evidence 
of neurologic dysfunction, such as altered mentation, slurred speech, irritability, 
inappropriate behavior, agitation, ataxia and other signs of poor coordination, 
delirium, seizures, and coma (69). The skin may be moist or dry, depending upon 
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underlying medical conditions, the speed with which the heat stroke developed, and 
hydration status (68). Not all victims of heat stroke are volume-depleted. 
DIAGNOSIS  
The diagnosis of classic (non-exertional) heat stroke is made clinically based upon an 
elevated core body temperature (generally >40ºC [104ºF]), central nervous system 
dysfunction (eg, altered mental status), and exposure to severe environmental heat . 
Patients with classic heat stroke generally have increased susceptibility to the heat due 
to age or underlying medical conditions, manifest characteristic examination findings, 
and lack another explanation for their hyperthermia (eg, infection).  
MANAGEMENT 
Initial treatment and monitoring — The management of non-exertional (classic) heat 
stroke requires ensuring adequate airway protection, breathing, and circulation; rapid 
cooling; and treatment of complications. 
Cooling measures, that is evaporative cooling, is the method used most often to treat 
classic heat stroke because it is effective, noninvasive, easily performed, and does not 
interfere with other aspects of patient care. When used to treat elderly patients with 







From the literature review, it is evident that acute febrile encephalopathy is a common 
syndrome encountered by the emergency physicians. Not only is it  a common 
problem,  the challenges in diagnosis and the high mortality and morbidity associated 
with it  makes it an important subject to study. We also found from the literature that 
different geographical locations had different aetiologies causing the same syndrome. 
Most of the studies on acute febrile encephalopathy has been done in either central or 
North India. There was no data available on this syndrome from South India. We also 
find that all studies on acute febrile encephalopathy has only looked into the infectious 
spectrum but we find that even non-infectious aetiology can have similar presentation. 
Hence this study aims to study the entire clinical spectrum of patients with acute 
febrile encephalopathy including both infectious and non-infectious presenting to a 
tertiary centre in South India and also look at their outcome and the predictors for 















The study was conducted in Christian Medical College Hospital which is a tertiary 
care hospital located at Vellore in the state of Tamil Nadu, the Southernmost state of 
India. The hospital is a 2632 bedded hospital which caters to the need of people in 
various states including Tamil Nadu, Andhra Pradesh, West Bengal and many others. 
It has a department of Accident and Emergency medicine which tends to about 200 
patients per day including medical and surgical emergencies and trauma 
Period of Recruitment 
The study was conducted for a period of one year from June 2015 to May 2016 
Follow up 
The patients were followed up till discharge and 1 month after discharge through 
telephonic interview. 
Data collection 
The study was explained in detail to the participants and their close relatives and they 
were provided with an information sheet about the study (Annexure 1). Participants 
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were included after obtaining written consent either from the patient directly or from 
their close relative if the participant was otherwise indisposed (Annexure 2). For 
participants between the ages of 15 and 18 years, consent was obtained from the legal 
guardian and assent was taken from the participant. 
PARTICIPANTS 
All patients admitted in the adult emergency department with Acute Febrile 
Encephalopathy (AFE)  fulfilling the inclusion criteria were included in the study. 
Inclusion criteria  
1. Age > 16 years. 
2. Fever <14 days duration. 
3. Altered mental status+/-meningeal signs(headache, nuchal rigidity, 
photophobia) 
Exclusion Criteria 
1. Patients with acute cerebrovascular accident(hemorrhage/infarct) 
2. Patients with head injury /trauma 
Patients with HIV and pregnancy were not excluded from the study so as to study the 










Primary outcome  
Mortality 
Mortality at discharge 
Mortality at 1 month 
Functional Outcome 
Modified Rankin Score at  discharge 
Modified Rankin  score at 1month 
Secondary outcomes 
1. Seasonal distribution of the primary etiology 
2. Duration of hospital stay 
3. Duration of ICU stay 
4. Inotropic requirement 
5. Ventilator requirement 

















6. Ventilator free days 
7. Hospital acquired infection 
8. Other organ dysfunction 
Diagnostic criteria 
Acute viral meningoencephalitis with specific etiology  
Acute febrile encephalopathy +/- Meningitis with CSF pleocytosis of more than 5 
WBC/cumm in addition to the following criteria 
Absence of detectable bacterial pathogen on CSF smear/culture or blood culture 
AND/OR 
EEG/MRI/CT evidence of parenchymal disease AND/OR  
Positive CSF study for viral pathogen  
CSF serology or CSF viral Culture or multiplex PCR AND  
Negative for Tuberculous meningitis criteria. 
 
Acute viral meningoencephalitis (no specific etiology)- Unknown cause 
Acute febrile encephalopathy +/- Meningitis with CSF pleocytosis of more than 5 
WBC/cumm in addition to the following criteria 
Absence of detectable bacterial pathogen on CSF smear/culture or blood culture 
AND/OR 
EEG/MRI/CT evidence of parenchymal disease AND/OR  
Negative CSF study for viral pathogen 
CSF serology or CSF viral Culture or multiplex PCR AND  





Acute febrile illness with clinical features of meningitis and EITHER of the 
following 
Gram staining of CSF positive for meningitis causing bacteria  OR 
A CSF culture positive for a known bacterial pathogen  OR   
A blood culture positive for a known meningitis causing bacteria i.e. 
Streptococcus pneumoniae, Haemophilus influenzaetype b, Neisseria meningitides, 
Streptococcus suis, Staphylococcus aureus, Enterobacteriaceae spp etc.  
 
 
Scrub typhus meningitis/encephalitis 
Acute febrile illness with clinical features of meningitis or altered sensorium  
(AND) 









Acute febrile illness with clinical features of altered mental status+/- meningitis 
and: 
Ziehl-Neelsen stain of CSF positive for acid fast bacilli OR  
A CSF culture positive for tuberculous bacilli OR 
CSF Xpert-MTB RT-PCR analysis positive for TB OR 
Neuroimaging (CT/MRI scan) consistent with TB meningitis (hydrocephalus, 
basal meningeal enhancement etc.) OR  
Any other source positive for tuberculosis (lymph node biopsy / sputum smear / 
tissue biopsy / bone marrow biopsy / Chest x ray findings etc.)  AND/OR  
Clinician’s decision about the diagnosis 
 
Febrile Metabolic encephalopathy 
Acute febrile illness (differentiated /undifferentiated) with no acute CNS 
infection AND  any one of the following 
Hyponatremia ( Se Na < 125 meq) AND Correction of sodium reverses the 
altered sensorium OR 
Hypernatremia(Se Na > 145 meq) OR 
Hypoglycemia( Se Glucose < 40)  OR 
Hyperglycemia (DKA OR HHS) OR 
Hypercalcemia( Se calcium >10 ) AND No other etiology to explain the altered 
sensorium 
Hyperthermia ( Body Temperature- >105.1F/40.9C) HEAT STROKE 
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Febrile Toxic encephalopathy 
Acute febrile illness( differentiated /undifferentiated)  with no acute CNS 
infection AND 
History of Acute consumption of  Toxins (Alcohol) / Drug  followed by altered 
mental status 
 
Septic encephalopathy:  
Fever with altered mental status  AND  Features of sepsis include infection 
(documented or suspected)  and some of the following 
General variables 
 Temperature>38.3 or <36 
 HR >90 
 RR>20 
 Altered mental status 
 Significant edema 
 Hyperglycemia(plasma glucose 






 Normal WBC with >10% 
immature forms 
 Plasma  CRP >2 SD above normal 
value 




 Arterial hypotension(SBP<90 
mm Hg,MAP<70 mm Hg) 
Tissue perfusion variables 
 Hyperlactetemia(>1 mmol/L) 




Organ dysfunction variables 
 Arterial hypoxemia (PaO2/FiO2 <300) 
 Acute oliguria(<0.5ml/hr for >2 hours despite fluid resuscitation) 
 Creatinine increase>0.5 mg/dl 
 Coagulation abnormalities(INR>1.5 or aPTT>60 sec) 
 Ileus(absent bowel sounds) 
 Thrombocytopenia(platelet count<100000) 




Modified Rankin Scale 
0 No symptoms at all  
1 No significant disability despite symptoms; able to carry out all usual duties 
and activities 
2 Slight  disability;  unable  to  carry  out  all  previous  activities,  but  able  to  
look  after  own  affairs  without assistance 
3 Moderate disability; requiring some help, but able to walk without assistance 
4 Moderately severe disability; unable to walk without assistance and unable to 
attend to own bodily needs without assistance 





MEASUREMENT OF DATA 
Data was entered into a clinical research form(CRF) by the principal investigator. 
Data collection was done by the principal investigator at patient presentation to 
hospital followed by outcome assessment at discharge and 1 month through telephonic 
interview.  
The clinical data was documented in the CRF (Annexure 3) by the principal 
investigator. The following details were noted specifically 
1. Clinical features-Signs and symptoms 
2. Comorbidities 
3. Laboratory findings 
4. Hospital stay and ICU admission 
5. Outcomes –Mortality and functional outcome 
SAMPLE SIZE 
Sample size was based on the proportion expected to have modified Rankin scale 
(mRS) of more >3 at 1 month (mRS> 3 implies dependent functional status).  
From previous studies(1), this was assumed it to be 6% and with a 3% precision for 





Data was entered using Epidata version 3 and data analysis was done using 
Statistical Package for the Social Sciences (SPSS) software package (version 16). 
Continuous study variables were described using mean with standard deviation and 
discrete variables were summarized using frequencies with percentages. The 
diagnostic predictors for etiology and outcome predictors were identified using 
bivariate analysis and logistic regression analysis with odds ratio and 95 % confidence 
interval.  A P-value less than 0.05 was considered significant. 
 
FUNDING AND APPROVAL  
SOURCE OF FUNDING  
A FLUID research grant was approved from the institution for the purpose of this 
study.  
INSTITUTIONAL RESEARCH BOARD APPROPVAL AND ETHICAL 
CONSIDERATIONS  
The research proposal for Study was discussed by the Institutional Review Board in 
2015 and approval was obtained [IRB Min. No. 9450 dated 05.06.2015][ Annexure 4]. 









This prospective observational study was done in a tertiary hospital located in Tamil 
Nadu, the southernmost state of India. The study was conducted for one year duration 
from June 2015 to May 2016.All patients admitted in the emergency department were 
screened for the eligibility criteria and a total of 265 patients were included in the 
study. Presenting symptoms, signs, comorbidities, laboratory findings viz 
haematological, biochemical tests and CSF findings were obtained. They were further 
classified into infectious and non-infectious category based on the pre specified 
diagnostic criteria. The infectious causes accounted for majority of the aetiology 
(70.5%) while non-infectious aetiology contributed to (29.5 %). The infectious group 
was classified further based on whether it was a primary central nervous system 
(CNS) related infection or sepsis associated. The CNS infections have been classified 
based on the type of organism as bacterial, viral, fungal or protozoal infections. 
 The non-infectious causes were classified into metabolic, heat related and toxin 
related. The mortality and functional outcome were assessed at discharge and 1 month. 
All 265 patients were followed up till discharge and 247 patients were followed up at 
1 month. Eighteen (18) patients were lost to follow up at 1 month. 






























Figure 4 Strobe Figure 
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BASELINE CHARACTERISTICS OF THE STUDY POPULATION 
DEMOGRAPHIC CHARACTERISTICS 
The study cohort comprised of 265 patients. The 265 patients were classified into 
infectious and non-infectious category based on the primary aetiology according to the 
pre specified criteria. The demographic details of the cohort namely the age, sex, 
occupation and state of domicile are shown in Table 2 








Age    
15-29 58(31) 9(11.5) 67(25.3) 
30-44 43(23) 8(10.3) 51(19.3) 
45-59 37(19.8) 24(30.8) 61(23) 
60-74 40(21.4) 29(37.1) 69(26) 
>=75 9(4.8) 8(10.3) 17(6.4) 
Sex    
Male 111(59.4) 43(55.1) 154(58.1) 
Female 76(40.6) 35(44.9)) 111(41.9) 
State    
Tamil Nadu 129(69) 69(88.5) 198(74.7) 
Andhra Pradesh 50(26.7) 7(9) 57(21.5) 
West Bengal 3(1.6) 1(1.3) 4(1.5) 
Others 5(2.7) 1(1.3) 6(2.3) 
Occupation    
Housewife 68(36.4) 31(39.7) 99(37.4) 
Student 27(14.4) 5(6.4) 32(12.1) 
skilled 10(5.3) 3(3.8) 13(4.9) 
Unskilled 75(40.1) 37(47.4) 112(42.3) 
Others 7(3.7) 2(2.6) 9(3.4) 
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SEX WISE DISTRIBUTION 
The male : female ratio in the cohort were almost equal with male showing a slight 
preponderance as shown in the figure 5. The sex distribution within the  subcategory 
(Infectious and non-infectious)  also showed a similar pattern with men slightly 
predominant over the women 59.4% vs 40.6% in the infectious group and 55.1% vs 
44.9% in the non-infectious group.(figure 6) 
 
 
Figure 5 Sex wise distribution of the study population 
154, 58% 
111, 42% 






Figure 6 Sex distribution between the infectious and non-infectious group of the study population 
 
 
AGE WISE DISTRIBUTION 
The age distribution of the cohort ranged from 15-86.The Mean (SD) age of the cohort 
was 46.89 ( ±19.8). Infectious causes predominate among the younger age group with 
frequency decreasing with increasing age. The inverse is true of non-infectious causes 
for Acute febrile encephalopathy which is more common with advancing age. The 













Figure 7 Age distribution between infectious and non-infectious group of the study population 
 
STATE OF DOMICILE 
Majority of the patients in the cohort were from the two states of Tamil Nadu (74.7%) 
and Andhra Pradesh (21.5%) which is the catchment area of this hospital, however 
few patients also came from other states. (Figure 8) 
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OCCUPATION OF THE STUDY POPULATION 
Figure 9 represents the distribution of the occupation of the study cohort. Majority of 
the male patients were unskilled workers (N=112 42.3%) and among the female 
patients, majority were housewives(N=99,37.4%).  Majority were either house wives 
or unskilled workers as this is a common occupation given during registration in the 
hospital. Housewives, unskilled and skilled workers were equally distributed among 
both the infectious and non-infectious group. Most of the students were in the 
infectious group, probably related to age distribution of infectious etiology. 
 
 































CLINICAL CHARACTERISTICS OF THE STUDY POPULATION 
The clinical and laboratory characteristics of the study population is summarised in the 
table 3. 








Age—years No.(%)    
Mean ± SD 43.4(18.78) 55.27(17.63) 46.89(19.2) 
Median 40 59 48 
Range 15-86 16-85 15-86 
 Sex—No. (%)    
Male 111(59.4) 43(55.1) 154(58.1)) 
Female 76(40.6) 35(44.9) 111(41.9) 
Signs and Symptoms—No. (%)    
Altered sensorium 160(85.6) 77(98.7) 237(89.4) 
Head ache 106(56.7) 13(16.7) 119(44.9) 
Vomiting 91(48.7) 20(25.6) 111(41.9) 
Seizures 59(31.6) 20(25.6) 79(29.8) 
Nuchal rigidity 91(48.7) 9(11.5) 100(37.7) 
Papilledema 12(6.4) — 12(4.5) 
Cranial nerve palsy 5(2.7) — 5(1.9) 
Focal neurologic deficits 21(11.2) 3(3.8) 24(9.1) 
    
Vital Status — No. (%)    
Tachypnea(RR>20) 62(33.2) 10(12.8) 72(27.2) 
Tachycardia(HR>90) 66(35.3) 13(16.7) 79(29.8) 
Hypotension (MAP<70mHg) 20(10.7) 12(15.4) 32(12.1) 
SBP(<90mmHg) 15(8) 9(11.5) 24(9.1) 
Temperature(>104F) 7(4.2) 27(36.5) 34(14.1) 
Hypoxia (SpO2<92%) 23(12.7) 22(28.9) 45(17.5) 
    
GCS     
Median(Range) 13(2-15) 12(3-15) 13(2-15) 
Mean ± SD 12.03(3.11) 11.24(3.27) 11.8(3.17) 
Intubation at admission— 
No. (%) 
23(12.3) 12(15.4) 35(13.2) 
    
Comorbidities— (No.%)    
Diabetes mellitus 47(25.1) 33(42.3) 80(30.2) 
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Hypertension 34(18.2) 27(34.6) 61(23) 
Cerebrovascular accident 4(2.1) 6(7.7) 10(3.8) 
Chronic kidney disease 3(1.6) 1(1.3) 4(1.5) 
    
Laboratory findingsMean ± SD    
   
Total count cells/mm3  12966.4(5995.15) 13250(7021.8) 13050(6303) 
Platelets cells/mm3  2222820(12624) 192126(90700) 213778(117563) 
Creatinine mg/dl 1.23(1.08) 1.46(1.1) 1.29(1.1) 
Urea mg/dL 45.46(36.2) 46.43(37.9) 45.76(36.69) 
SGOT U/L 64.06(66.2) 344.16(1565) 147(860) 
SGPT U/L 40 38 78(450) 
Sodiumnmol/L 132.05(7.21) 125.65(12.25) 130.15(9.45) 
Lab abnormalitiesN(%)    
Abnormal WBC count(>12000 
or <4000)  
93(50) 41(52.6) 134(50.8) 
Neutrophilia(>75% on DC) 113(60.8) 55(70.5) 168(63.6) 
Thrombocytopenia(<50000) 14(7.7) 8(10.5) 22(8.5) 
Renal 
dysfunction(creat>1.2mg/dl) 
48(26.7) 34(44.2) 82(31.9) 
SGOT(>115U/L) 24(13.2) 14(18.2) 38(14.7) 
SGPT(>120U/L) 14(7.7) 7(9.1) 21(8.1) 
Uremia(>40mg/dl) 49(38) 24(41.4) 73(39) 
    
    
CSF Mean(±SD)    
Total Count (/cumm) 382.1(1166.59) 4.3(6.65) 312.03(1062) 
Glucose (mg/dL) 71.07(38.5) 93.8(44.01) 75.31(40.52) 
Protein (mg/dL) 161.7(170.58) 55.5(38.62) 141.84(160.04) 





Hospital stay- days — Mean ± SD 8.7(6.63) 8.99(8.62) 8.78(7.42) 
    
ICU admission —No.(%) 40(22.2) 14(17.9) 54(20.9) 
    
mRS pre admission  No.(%)    
<2 176(94.1) 68(87.2) 244(92.1) 
>=2 11(5.8) 10(12.8) 21(8) 
2-3 9(4.8) 6(7.7) 15(5.7) 
4-6 2(1) 4(5.1) 6(2.3) 




SYMPTOMS AT PRESENTATION 
 
The predominant signs and symptoms at presentation of the whole study population 
with subcategorization into infectious and non-infectious group is shown in figure 10 . 
We found that altered sensorium was present in almost all cases of non-infectious 
aetiology.(98.7% vs 85.6%).Headache was the predominant symptom in the infectious 
group (56.7% vs 16.7%).Seizures were present almost equally in the two groups. 
Features of meningism and increased intracranial pressures such as nuchal rigidity, 




























Altered sensorium Headache Vomiting Seizures Nuchal rigidity
Symptoms at presentation 
Infectious Non infectious Total
56 
 
VITAL STATUS AT ADMISSION 
The vital status of the cohort is shown in figure 11. We found that hypotension at 
presentation was seen more in the non-infectious group as compared to the infectious 
group (15.4 vs 10.).Features of SIRS such as tachycardia and tachypnea were more 
seen in the infectious group than non-infectious group 33.2 % and 35.3% vs 12.8% 
and 16.7% respectively. Very high temperature recording at admission of >104F at 
presentation was seen more commonly in the non-infectious group than infectious 
(36.5% vs 4.2%) due to heat related illness. Saturation at presentation was similar in 



























Tachypenia>20 Tachycardia>90 MAP<70 SBP<90 Temperature>104 SpO2<92




INTUBATION AT ADMISSION: 
Intubation rates among the infectious and non-infectious groups at admission were 
similar; 12.3% and 15.4% respectively (Figure 12) 
 
Figure 12 Intubation at admission 
 
COMORBIDITIES OF THE STUDY POPULATION 
Hypertension and Diabetes mellitus were the common comorbidities seen in the study 
population is shown in the figure 13. As expected, both diabetes and hypertension 
were more in the non-infectious group than the infectious group; 42.3 and 34.6% vs 
25.1% and 18.2% respectively. 
 














Comorbidities  of the study cohort  




The number of patients in the infectious and non-infectious group who required 
admission into intensive care were 22.2% and 17.9% respectively. This is depicted in 
the figure 14 
 
Figure 14 ICU admission 
 
BASE LINE MODIFIED RANKIN SCORE OF THE COHORT 
The baseline modified Rankin score of the study cohort is shown in the figure 15. 
Majority in the infectious and non-infectious group had a baseline mRS of less than 
two, however the number of patients with mRs>2  were more in the  non-infectious 









Figure 15 Baseline modified Rankin score between infectious and non-infectious group 
 
LABORATORY CHARACTERISTICS:  
The biochemical and clinical pathological tests findings were similar among the two 
groups, probably due to heterogeneity of the data, given the varying etiologies. 
However the cerebrospinal fluid assessment revealed higher white blood counts, lower 
glucose level and higher protein level among the infectious group compared to the 
non-infectious group. (Figure 16)
 
Figure 16 Cerebrospinal fluid findings 










Total CSF Count Glucose Protein
CSF tests 




The primary aetiology of all the patients in the study cohort as defined by the pre-
specified criteria is tabulated in the table 4 
Table 4 Primary aetiology of the study population 











 Herpes Simplex virus 3(1.6) 
 Dengue 5(2.6) 
 Varicella zoster virus 2(1) 
 Epstein bar virus 8(4.2) 
 Adeno virus 1(0.5) 
Total 18(9.6) 
Unknown aetiology 64(34.2) 
Fungal 2(1) 
Parasitic 2(1) 
Primary CNS infection 179 
  










Hepatic encephalopathy 1(1.3) 
Toxin 








INFECTIOUS VERSUS NON INFECTIOUS 
The proportion of infectious and non-infectious aetiology in the study cohort is shown 
in the figure 17.Infectious aetiology was the predominant cause for acute febrile 
encephalopathy accounting to 71%. 
 
Figure 17 Etiology-Infectious versus Non-infectious 
 
INFECTIOUS ETIOLOGY AMONG THE COHORT 
As shown in figure 18, among the infectious spectrum, aseptic/viral 
meningoencephalitis was the most common aetiology corresponding to 82 percent. 
Out of which a specific aetiology could be identified only in 18.8 %. The remaining 
was classified as aseptic meningitis of unknown aetiology. Among the bacterial 
causes, scrub meningitis was the most common followed by pyogenic meningitis. 
Leptospirosis and salmonella were seen in one case each. 
187, 71% 
78, 29% 





Tuberculous meningitis was diagnosed in 45 patients (45.24%)  Parasitic and fungal 
were also seen in 2 cases each. 
Sepsis associated encephalopathy was seen in (7.4% ) cases all of them were culture 
proven. 
 
Figure 18 Infectious etiology 
 
 
































SPECIFIC AETIOLOGY OF THE NON-INEFCTIOUS SPECTRUM 
The non-infectious spectrum was further classified as metabolic, toxin, drugs and 
others. The proportion in each category is shown in figure 20. 
 
Figure 20 Non-infectious aetiology 
 
Metabolic was the most common non- infectious aetiology of acute febrile 
encephalopathy. Among the non-infectious causes, hyperthermia (Heat stroke) formed 
the majority of the cases (62%).The remaining were as follows which is shown in 
figure 20.Alcohol was the most common toxin related aetiology. Others (n=6) 
included Auto-immune encephalitis (n=4), brain metastasis (n=1) and acute psychosis 

















The primary outcome namely the mortality at discharge, one month and modified 
Rankin score at discharge and one month is shown in the table 5 








Mortality at 1 month   30(16) 21(26.9) 51(20.1) 
    
Mortality at 
discharge 
16(8.5) 11(14.1) 27(10.2) 
    
Mortality between 
discharge and 1 
month 
14(7.5) 10(12.8) 24(9) 
    
mRS at 1month —No (%)    
>=2  49(28.7) 32(48.8) 81(32.7) 
0-1  124(71.2) 41(56.2) 166(67.2) 
2-3  15(8.6) 7(9.6) 22(8.9) 
4-6 35(20.1) 25(39.2) 59(23.8) 
mRS at discharge— No (%)    
>=2 70(37.6) 43(55.1)) 113(42.6) 
0-1  117(62.5) 35(44.9) 152(57.3) 
2-3  21(11.3) 14(17.9) 35(13.2) 
4-6  49(26.3) 29(37.2) 78(29.4) 
Figure 21, 22 depicts the modified Rankin score of the study cohort at baseline and the 




Figure 21 Modified Rankin sore at baseline, discharge and one month 
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MORTALITY AT DISCHARGE AND AT 1 MONTH : 
The mortality at discharge was 10.2%, and 20.1% at 1month. This is depicted in 
Figure 22. There was a significant number of death after discharge (10.2%).The 
mortality within the infectious and non-infectious group at discharge and one month is 
also shown in figure 23. One in five patients who presented with AFE were dead at 1 
month after admission.  
 
















Figure 22 Mortality at one month between infectious and non-infectious 
 
DIAGNOSTIC PREDICTORS 
SYMPTOMS AND DIAGNOSIS 
Differentiation between infectious and non-infectious etiology based on presenting 
symptoms is paramount for prompt initiation of appropriate management. Bivariate 
analyses of presenting symptoms were found to be significant in predicting infectious 
aetiology as shown in table 6. Head ache, vomiting, nuchal rigidity, focal deficits and 
cranial nerve palsies at presentation was found to be significant predictors of 
infectious cause of acute febrile encephalopathy. Presence of altered sensorium at 






























Altered mental status     
Yes 180 (67.5) 77 (32.5) 0.08(0.01-0.58) 0.001 
No 27 (96.4) 1 (36) 
 
 
Headache      
Yes 106 (89.1) 13 (10.9) 6.54(3.38-12.69) <0.001 
No 21 (95.5) 65 (44.5) 
 
 
Seizures     
Yes 59 (74.4) 20 (25.3) 1.34(0.74-2.62) 0.379 
No 128 (68.8) 58 (31.2)   
Vomiting     
Yes 91 (82) 20 (18) 2.75(1.53-4.93) 0.001 
No 96 (62.3) 58 (37.7) 
 
 
Nuchal Rigidity     
Yes 91 (96) 9 (9) 7.27(3.43-15.41) <0.001 
No 96 (58.2) 69 (41.8) 
 
 
Papilledema     
Yes 12 (100) 0 (0) 1.45(1.33-1.57) 0.021 





    
Yes 21 (87.5) 3 (12.5) 3.16(0.92-10.93) 0.062 
No 166 (68.9) 75 (31.1) 
 
 
Cranial Nerve palsy     
Yes 5 (100) 0 (0) 14.3(1.32-1.55) 0.326 
No 183 (70) 78 (30) 
 
 
Intubation     
Yes 23 (65.7) 12 (34.3) 0.77(0.36-1.64) 0.551 





SIGNS AND DIAGNOSIS 
Predictors of etiology based on clinical findings at presentation were analysed using 
bivariate analysis. Features of SIRS such as tachycardia, tachypnea and hypoxia 
(SpO2<92%) were found to be significant predictors of infectious cause of acute 
febrile encephalopathy as seen in table 7. High temperature >104F predicted a non -
infectious etiology.  











GCS     
<=8 30 (69.8) 13 (30.2) 0.96(0.47-1.93) 1 
>8 157 (20.7) 65 (29.3) 
 
 
Respiratory rate      
>20 62 (86.1) 10 (13.9) 3.37(1.63-7) 0.001 
<=20 125(64.8) 68 (35.2) 
 
 
Pulse rate     
>90 66 (83.5) 13 (16.5) 2.73(1.4-5.31) 0.003 
<=90 121(65.1) 65 (34.9)   
SBP     
<90 15 (62.5) 9 (37.5) 0.67(0.28-1.6) 0.357 
>=90 172 (71.4) 69 (28.6) 
 
 
MAP     
<70 20 (62.5) 12 (37.5) 0.66(0.31-1.42) 0.304 
<=70 167 (71.7) 66 (28.3) 
 
 
SpO2     
>92 158 (74.5) 54 (25.5) 2.79(1.44-5.42) 0.004 
<=92 23 (51.1) 22 (48.9) 
 
 
Temperature     
>=104 7 (20.6) 27 (79.4) 0.07(0.03-0.18) <0.001 
<104 160 (77.3) 47 (22.7)   
PaO2     
<60 76 (71.7) 30 (28.3) 1.69(0.55-5.16) 0.375 
>60 9 (60) 6 (40) 
 
 
P/F ratio     
<=200 46 (62.2) 28 (37.8) 0.44(0.13-1.45) 0.278 






COMORBIDITIES AND DIAGNOSIS 
Diabetes mellitus and hypertension were the common comorbidities in the study 
cohort. History of either of these comorbidities were found to be significant predictors 
of non- infectious cause of acute febrile encephalopathy. 
 











Diabetes Mellitus     
Yes 47 (58.8) 33 (41.3) 0.46(0.26-0.8) 0.008 
No 140 (75.7) 45 (24.3) 
 
 
Hypertension     
Yes 34 (55.7) 27 (44.3) 0.42(0.23-0.76) 0.006 





    
Yes 4 (40) 6 (60) 0.26(0.07-0.96) 0.069 
No 183 (71.8) 72 (28.2)   
Chronic Kidney 
disease 
    
Yes 3 (75) 1 (25) 1.26(0.13-12.26) 1 





LAB FINDINGS AND DIAGNOSIS 
Bivariate analysis of few lab findings were found to be significant in predicting 
infectious versus non-infectious aetiology as shown in table 9.Low 
sodium(<125nmol/L)  at presentation were found to be significant predictor of  non-
infectious cause of acute febrile encephalopathy, while high creatinine  (>1.2mg/dl) 















Leucocytosis     
               Yes 93 (69.4) 41 (30.6) 0.90(0.53-1.53) 0.787 
No 93 (71.5) 37 (28.5) 
 
 
Neutrophilia(>75%)     
Yes 73 (76) 23 (24) 1.55(0.88-2.73) 0.161 
No 113 (67.3) 55 (32.7) 
 
 
Platelet count(<50000)     
Yes 17 (89.5) 2 (10.5) 3.81(0.86-16.93) 0.069 
No 165 (69) 74 (31)   
SGOT(>115U/L)     
Yes 24 (63.2) 14 (36.8) 0.68(0.33-1.41) 0.338 
No 158 (71.5) 63 (28.5) 
 
 
SGPT(>120U/L)     
Yes 14 (66.7) 7 (33.3) 0.84(0.32-2.17) 0.804 
No 167 (70.5) 70 (29.5) 
 
 
Creatinine(1.2mg/dl)     
Yes 48 (58.5) 34 (41.5) 0.46(0.26-0.80) 0.008 
No 132 (75.4) 43 (24.6) 
 
 
Urea(>40mg/dl)     
Yes 49 (67.1) 24 (329.9) 1.15(0.61-0.80) 0.746 
No 164 (78.8) 44 (21.2) 
 
 
Sodium(<125nmol/L)     
Yes 20 (37) 34 (63) 6.34(3.28-12.08) <0.001 
No 





CSF FINDINGS AND DIAGNOSIS 
Bivariate analysis of cerebrospinal fluid analysis  were found to be significant in 
predicting infectious versus non-infectious aetiology as shown in table10.Eleveated 
CSF counts(>5 cells), elevated protein (45) and neutrophilia(>75%)  at presentation 
were  found to be significant predictors of  infectious cause of acute febrile 
encephalopathy. 
 











CSF Total count     
>5/cmm 140 (96.6) 5 (3.4) 0.46(0.26-0.8) 0.008 
<5/cmm 18 (36.7) 31.63.3) 
 
 
CSF Neutrophils     
>75% 34 (55.7) 27 (44.3) 0.42(0.23-0.76) 0.006 
<75% 153 (75) 51 (25) 
 
 
CSF Protein     
>45mg/dl 4 (40) 6 (60) 0.26(0.07-0.96) 0.069 
<45mg/dl 183 (71.8) 72 (28.2)   
CSF Glucose     
<45mg/dl 3 (75) 1 (25) 1.26(0.13-12.26) 1 








DEMOGRAPHY AND OUTCOME PREDICTION 
Bivariate analysis of age and sex was done to predict mortality at 1 month as shown in 
table11. Age greater than 40 was found to be significant predictor of mortality at 1 
month whereas sex did not have any role in predicting mortality. 






Unadjusted odds ratio 
(95% CI) 
P value 
Age     
<40 13(12.6) 90(87.4) 0.43(0.22-0.87) 0.01 
>40 35(25) 105(75) 
 
 
Sex     
Male 32(22.4) 111 (77.60 1.28(0.68-2.4) 0.525 




SYMPTOMS AND OUTCOME 
Presenting symptoms that could predict mortality at 1 month were analysed by 
bivariate analysis and presented in Table 12. Intubation at  admission was found to be 
predictor of  poor outcome of mortality at 1 month with an odds ratio of 4.32 whereas 
presence of headache and vomiting at presentation favours a good outcome with an 
odds ratio of 0.33 and 0.47 for mortality. The above finding could be due to the fact 















Altered mental status     
Yes 50 (22.7) 170 (77.3) 6.91(0.91-52.35) 0.035 
No 1 (3.8) 25 (96.2) 
 
 
Headache      
Yes 12 (10.9) 98 (89.1) 0.33(0.16-0.7) 0.002 
No 39 (28.7) 96 (71.3) 
 
 
Seizures     
Yes 15 (20) 60 (80) 0.84(0.41-1.65) 0.726 
No 36 (21.4) 135 (78.6)   
Vomiting     
Yes 15 (14.9) 86 (85.1) 0.47(0.24-0.95) 0.034 
No 36 (24.8) 109 (75.2)   
Nuchal Rigidity     
Yes 13 (14.3) 78 (85.7) 0.56(0.28-1.12) 0.133 
No 38 (24.5) 117 (75.5)   
Papilledema     
Yes 3 (37.5) 5 (62.5) 2.53(0.58-10.99) 0.195 
No 48 (20.2) 190 (79.8)   
Focal Neurologic 
deficits 
    
Yes 7 (30.4) 16 (69.6) 1.91(0.74-4.94) 0.177 
No 14 (19.7) 179 (81.3)   
Cranial Nerve palsy     
Yes 1 (20) 4 (80) 1.02(0.11-9.3) 1 
No 50 (20.7) 191 (79.3)   
Intubation     
Yes 15(46.9) 17 (53.1) 4.32(1.94-9.51) <0.001 





SIGNS AND OUTCOME 
The clinical findings at presentation that predicted mortality at 1 month were GCS<8, 
low systolic blood pressure (<90mmHg), low Mean arterial pressure of<70mmHg, 
temperature of >104F and saturation< 92% at  admission, with odds ratio of 6, 
4.19,2.8 , 2.7 and 3 respectively for mortality.  






Unadjusted odds ratio 
(95% CI) 
P value 
GCS     
<=8 21 (51.2) 20 (48.8) 6.012(2.97-12.64) <0.001 
>8 30 (14.6) 175 (85.4)   
Respiratory rate      
>20 10 (15.6) 54 (84.4) 0.64((0.239-1.36) 0.285 
<=20 41 (22.5) 141 (77.5)   
Pulse rate     
>90 12 (16.4) 61 (83.6) 0.68(0.33-1.38) 0.307 
<=90 39 (22.5) 134 (77.5)   
SBP     
<90 11(47.8) 12 (52.2) 4.19(1.73-10.18) 0.002 
>=90 40 (17.9) 183 (82.1)   
MAP     
<70 12 (38.7) 19 (61.3) 2.85(1.28-6.35) 0.016 
>=70 39 (18.1) 176 (81.9)   
SpO2     
<92 21 (47.7) 23 (52.3) 3.06(1.49-6.29) <0.001 
>=92 29 (14.9) 166 (85.1)   
Temperature     
>=104 12 (37.5) 20 (62.5) 2.70(1.21-6.05) 0.015 
`<104 35 (18.1) 158 (81.9)   
PaO2     
<60 27 (27.6) 71 (72.4) 0.76(0.24-2.43) 0.759 
>60 5 (33.3) 10 (66.7)   
P/F ratio     
<200 7 (38.9) 11 (61.1) 1.68(0.57-4.96) 0.392 






COMORBIDITIES AND OUTCOME 
Presence of diabetes mellitus as comorbidity were found to be a significant predictor 
of mortality at 1 month with odds ratio of 2.51(1.33-4.74) . 
 










Diabetes Mellitus     
Yes 24 (32) 51 (68) 2.51(1.33-4.74) 0.006 
No 27 (15.8) 144(84.2)   
Hypertension     
Yes 17(29.8) 40(70.2) 1.94(0.98-3.82) 0.063 
No 34(18) 155(80)   
Cerebrovascular 
accident 
    
Yes 4 (40) 6 (60) 2.68(0.73-9.89) 0.223 
No 47 (19.9) 189 (20.1)   
Chronic Kidney 
disease 
    
Yes 1(25) 3(75) 1.28(0.13-12.57) 1 






LAB FINDINGS AND OUTCOME 
Bivariate analysis of few lab findings were found to be significant in predicting dead 
versus alive at 1month as shown in table15.Abnormal white cell counts  
(leucocytosis/leukopenia), neutrophilia, abnormal renal function (elevated creatinine 
and urea), abnormal liver function ( elevated SGPT levels)  and low sodium  at  
admission were found to be significant predictors of  mortality at 1 month  . 
 






Unadjusted odds ratio 
(95% CI) 
P value 
Leucocytosis     
Yes 36 (28.8) 89 (71.2) 2.83(1.46-5.5) 0.003 
No 40 (18.3) 178 (81.7))   
Neutrophilia(>75%)     
Yes 39 (24.8) 118 (75.2) 2.09(1.03-4.25) 0.049 
No 12 (13.6) 76 (86.4)   
Platelet count(<50000)     
Yes 3 (17.6) 14 (82.4) 0.83(0.23-3) 1 
No 46 (20.5) 178 (79.5)   
SGOT(>115)     
Yes 10 (27) 27 (73) 1.61(0.72-3.6) 0.266 
No 38 (18.7) 165 (81.3)   
SGPT(>120)     
Yes 8 (38.1) 13 (61.9) 2.74(1.06-7.05) 0.044 
No 40 (18.3) 178 (81.7)   
Creatinine(>1.2)     
Yes 31 (39.2) 48 (60.8) 4.55(2.38-8.73) <0.001 
No 20 (12.4) 141 (87.6)   
Urea(>40)     
>40 24 (36.4) 42 (63.6) 3.06(1.49-6.29) 0.003 
No 17 (15.7) 91 (84.3)   
Sodium(<125)     
Yes 17 (33.3) 34 (66.7) 2.34(1.17-4-66) 0.020 
No 34 (17.6) 159 (82.4)   
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CSF FINDINGS AND OUTCOME 
Bivariate analysis of CSF to predict mortality at 1month as shown in table16. CSF 
findings at admission did not  predict  mortality at 1 month  which was statistically 
significant. 






Unadjusted odds ratio 
(95% CI) 
P value 
CSF Total count     
>5 19 (14.3) 114 (85.7) 0.43(0.19-0.97) 0.047 
<5 13(27.7) 34(72.3)   
CSF Neutrophils     
>75 7 (29.2) 17 (70.8) 2.16(0.81-5.74) 0.149 
<75 25 (16) 131 (84)   
CSF Protein     
>45 28 (19) 119 (81) 1.41(0.45-4.39) 0.790 
<45 4 (14.3) 24 (85.7)   
CSF Glucose     
<45 21 (15.9) 111 (84.1) 0.48(0.21-1.11) 0.102 
>45 11 (28.2) 28 (71.8)   
 
BASELINE MODIFIED RANKIN SCORE,ICU ADMISSION AND OUTCOME 
Univariate analysis of  baseline modified Rankin score (>2)  and requirement of 
intensive care unit(ICU)  admission were found to be significant in predicting 
mortality at 1month with odds ratio of 14.7 and 3.14 respectively as shown in table17.  







ratio (95% CI) 
P value 
mRS at admission     
>2 12 (75) 4 (25) 14.69 (4.50 - 47.95) <0.0001 
≤2 39 (17) 191 (83)   
ICU admission     
Yes 19(38) 31(62) 3.14(1.56-6.26) 0.002 







Multivariate analysis done to predict independent risk factors to predict diagnosis and 
outcome is shown in table 18. Only headache and nuchal rigidity were independent 
risk factors to predict infectious aetiology from non-infectious aetiology. 
Low GCS (<8), Intubation at admission, diabetes and mRS >=2 at admission were 
independent risk factors to predict mortality at one month. 
Table 18 Multivariate analysis of diagnostic and outcome predictors 




Diagnosis Prediction    
Headache 3.03 1.46-6.28 0.003 
Nuchal rigidity 4.67 2.08-10.46 <0.001 
    
Outcome prediction    
GCS(<8) 4.2 1.8-10.1 0.001 
Intubation 2.7 1.07-7.14 0.03 
mRS>=2 13.9 3.9-49 <0.001 














 Few of the infectious and non-infectious aetiologies were found to have seasonal 
variation. Figure25 shows the seasonal variation of infectious aetiology versus non-
infectious aetiology –heat stroke which was seen in large numbers in the month of 
April.  
 
Figure 23 Seasonal variation of various infections and heat stroke 
 
Figure 26 shows the seasonal trend of Epstein Barr virus( EBV) and scrub typhus 




















Figure 24 Seasonal variation of Scrub and EBV infection 
 
Figure 27shows that there was no seasonal variation in the tuberculous meningitis and 
aseptic meningitis of unknown aetiology which was seen throughout the year. 
 






























 Acute febrile encephalopathy (AFE) is a common problem encountered by the 
physicians in the emergency department. The wide spectrum of aetiology that can 
cause AFE makes this problem challenging for the physicians. Identifying the etiology 
early and initiating appropriate therapy prevents mortality and reduces the number of 
patients with long term neurological sequelae. 
This study was done primarily to look at the wide spectrum of etiologies that can 
present as AFE to the emergency department which included both the infectious and 
the non-infectious etiology. Most of the studies done before on AFE, have looked  at 
the infectious causes alone and have excluded the non-infectious 
causes(1,2,35,36,71).However few studies have mentioned the data on non-infectious 
aetiology (34). Our study attempted to look at both the spectrum infectious and non-
infectious to understand the proportion of infectious and non-infectious causes and we 
found that infectious etiology was the predominant cause for this syndrome 
corresponding to 70 percent. This can help the physicians in the emergency 
department to keep their differential diagnosis broad when they see patients presenting 
with this syndrome as 30 percent of them can be non-infectious. 
DEMOGRAPHIC DETAILS 
The study population included patients from all age group ranging from fifteen to 
eighty six (15-86). Infectious group were younger compared to the non-infectious 
group. Though the infectious aetiology can occur in all age group, the non- infectious 
cause that was predominantly seen in this study was heat stroke which was seen more 
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in the elderly group. There was no sex difference between the group, however there 
was slight male predominance which  was comparable with other studies  in the 
literature.(1,2,34).There was no significant association we could find between this 
syndrome and occupation. 
From the literature review, there are no previous published studies done on AFE in 
South India. Most of the studies done were from Central India and North India 
specifically Uttar Pradesh and Punjab. This is the first study from South India and the 
study population is predominantly from Tamil Nadu and Andhra Pradesh. 
PRIMARY ETIOLOGY. 
 The primary and the predominant aetiology  of acute febrile encephalopathy was 
infectious (70%).Among the infectious, our study found that primary central nervous 
system infection was the most common  cause which included acute bacterial 
meningitis (6.4%), scrub meningitis(17.6%), tubercular meningitis((24%), viral 
meningitis or meningoencephalitis(44%), fungal and protozoal meningitis. 
Previous studies in the literature had excluded non-infectious aetiology however most 
studies(1,2,35,36) have found that primary CNS infection was the most common 
aetiology.  Most studies have found  bacterial meningitis as the most common 
aetiology (1,34,35) however few studies have found viral meningitis more common 
than bacterial meningitis.(72) This could be attributed to the fact most of the cases of 
bacterial meningitis are treated at the primary level and only few cases came to our 
hospital which is a referral centre. Tuberculous meningitis commonly presents as 
either subacute or chronic meningitis, but we found that a proportion of our 
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patients(24%)  presenting with this syndrome had tuberculous aetiology which was 
less than 10 % in most other studies.(2,34,35,72) This could be attributed to this being 
a referral centre and the higher prevalence of tuberculosis in the community. 
Viral meningoencephalitis was the most common etiology in this study constituting 
about 45%(n=82). Majority of them had unknown etiology as compared with other 
studies(1,2,34,35).A specific etiology could be established only in 9.2%(n=18) and the 
remaining where unknown. All the patients with this syndrome did not undergo the 
PCR tests for herpes simplex virus, Adenovirus, Epstein Barr virus, Enterovirus or 
Varicella-zoster virus due to various reasons, however a major proportion of them had 
the tests done which could identify aetiology only in 18 patients. Epstein Barr virus 
was identified in the majority(n=8) which was seen as co infection in 5 patients , 3 
with tuberculous meningitis, 1 with scrub typhus and 1 with herpes simplex virus. 
Five patients had dengue virus encephalitis, 3 had Herpes simplex, 2 had Varicella 
zoster and 1 had adeno virus. 
Sepsis associated encephalopathy though is not a primary CNS infection presented 
with  this syndrome in 7.5 % of patients which was slightly less compared with a few 
studies which had mentioned sepsis associated encephalopathy as a 
aetiology(2,35).This could be because we included cases of sepsis associated 
encephalopathy who were blood culture proven. 
The non-infectious aetiology (n=78) was predominantly heat stroke which was seen in 
61%(n=48) of the patients in this group.  This was seen particularly in the summer 
season in the month of April and May. Other metabolic and toxin related contributed 




 In our study the mortality was 20.1% at the end of 1 month that is 1 in 5 of them 
presenting with syndrome die at the end of one month. This indicated the high 
mortality associated with acute febrile encephalopathy. Previous studies also show 
similar high mortality and morbidity associated with this syndrome.(1,2,34–36) 
The functional outcome assessed in our study show that a significant proportion of the 
patients have a poor functional outcome at the end of one month indicating a high 
morbidity caused by this which in turn will have a significant burden on the family 
and the society. 
DIAGNOSTIC PREDICTORS 
 In our study we also looked at various admission parameters including clinical 
symptoms, signs, comorbidities , vital status  and laboratory parameters both  
haematological ,biochemistry and CSF findings  would predict the diagnosis 
particularly infectious and non-infectious  as we know that early diagnosis and prompt 
treatment can prevent mortality and morbidity. We found in the bivariate analysis that 
presence of head ache, nuchal rigidity, and papilledema at admission would predict 
towards an infectious aetiology and similarly absence of altered sensorium in a patient 
with short duration fever with CNS dysfunction with meningeal signs or symptoms 
would point towards an infectious cause. Almost all patients in the non-infectious 
group had altered sensorium. Multivariate analysis done to look for independent 
factors predicting diagnosis as infectious and non-infectious we found head ache and 




In our study we also looked at various admission parameters including clinical 
symptoms, signs, comorbidities, vitals and laboratory parameters both haematological, 
biochemistry and CSF findings   and baseline modified Rankin score would predict 
the outcome. We found in our bivariate analysis presence of head ache had better 
outcome. This could be explained by the fact patients with head ache have a treatable 
infectious cause. ICU admission, low GCS(<8), requiring intubation at admission, 
poor modified Rankin score at admission (mRS>2 ) predicted poor outcome at one 
month. Presence of comorbidities specifically diabetes mellitus had a higher mortality 
at one month. Renal dysfunction and low sodium also predicted poor outcome 
Multivariate analysis done to look for independent factors predicting outcome at 
presentation we found low GCS, need for intubation at admission and presence of 
diabetes and a modified Rankin score of >2 at admission were independent risk factors 
for mortality at 1 month. 
SEASONAL TREND  
 We also found in our study a seasonal trend among few infections and non-infectious 
cases. Scrub meningitis was seen predominantly in the month of December and 
January. Heat stroke was predominantly seen during the summer months of April and 







There were few limitations to this study. Firstly all patients who were included in this 
study were the ones with access to healthcare at a tertiary medical centre or were 
referred to a tertiary centre which may lead to a referral bias. The findings of this 
study are therefore not representative of the prevalence of etiologies of AFE in the 
community.  Secondly Polymerase chain reaction (PCR) could not be done for all 
patients with suspected viral encephalitis as this was limited by cost. We also do not 
having tests for all virus causing encephalitis by PCR. Thirdly few patients about 10 




Acute febrile encephalopathy is a challenging clinical entity for the physicians in the 
emergency department because of the wide spectrum of aetiology causing it and the 
high mortality and morbidity associated with it.  In this study we attempted to look at 
the entire spectrum of patients presenting with AFE including both the infectious and 
non-infectious, identify the primary aetiology and their outcome which included 
mortality and functional outcome.  We found  that  the  demographic details of all the 
patients is of paramount importance because  locating their geographical location and 
considering aetiologies specific to that location will help in earlier diagnosis and 
initiating early empiric therapy that will prevent mortality and morbidity. Detailed 
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history taking and examination will help identify symptoms and signs that can predict 
diagnosis and outcome. In our study we found that head ache, papilledema and nuchal 
rigidity predicted towards an infectious aetiology and low GCS, requirement of 
intubation at admission, diabetes and a high modified Rankin score of >2 at admission 
were independent predictors of mortality at one month .It is therefore imperative for 
the clinician to keep the differentials broad when such a patient presents to the 
emergency department to initiate empiric therapy appropriately and look for predictors 
to assess diagnosis and outcome. We found that few infectious and non-infectious 
causes particularly scrub typhus and heat stroke had a seasonal trend and hence 
understanding them helps in early diagnosis. The high mortality and morbidity 
associated with this syndrome makes it more challenging and also warrants more 
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ANNEXURE 1 (PATIENT INFORMATION SHEET) 
PATIENT INFORMATION SHEET 
You have been hospitalized for evaluation of fever with changes in consciousness and 
hence have been requested to participate in this study. The sickness with which you 
are admitted is a very common cause of presentation to hospital in the emergency 
department. The usual causes are infection of the brain due to bacteria, virus or 
fungus. The other reasons are malaria, scrub typhus, dengue, leptospirosis, typhoid 
and many others. Identifying the cause early can help in starting treatment early so as 
to improve the outcome. 
.This study is aimed at identifying the cause of each disease so that we can diagnose 
disease and initiate treatment early. The information from this study will help other 
doctors in Vellore to make the right diagnosis and hence choose the correct treatment. 
In this study all patients presenting with short duration fever and altered sensorium 
will be managed as per the treating physician .The outcome of the disease will be 
assessed using a grading system by the investigator through a questionnaire. If you are 
willing to participate in this study, you may be asked to review 1 month  after your 
initial visit for a reassessment of your functional status otherwise you will be 
interviewed through the telephone. 
By participating in the study you will not be made to incur any added expenses apart 
from the routine initial investigations. There is no added risk or discomfort of any 
kind for you by participating in this study. Any personal information about you that is 
collected as part of this study will be maintained strictly confidential. Participation is 
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entirely voluntary and refusal to participate will not involve any loss of benefit or 
change in treatment that you receive.  
For trial related queries, the principal investigator Dr S.B Manoj Job to be contacted. 
Dr.S.B Manoj Job,                E mail: drmanojjob@gmail.com 























ANNEXURE 2 (CONSENT FORM) 
CONSENT FORM 
Study Number: ____________ 
Subject’s Initials: __________________ Subject’s Name: _________________________________________ 
Date of Birth / Age: ___________________________ 
 
(i)  I confirm that I have read and understood the information sheet dated ____________ for the 
above study and have had the opportunity to ask questions. [  ] 
(ii)  I understand that my participation in the study is voluntary and that I amfree to 
withdraw at any time, without giving any reason, without my medical care or legal rights 
being affected. [  ] 
(iii)  I understand that the Sponsor of the clinical trial, others working on the Sponsor’s 
behalf, the Ethics Committee and the regulatory authorities will not need my permission 
to look at my health records both in respect of the current study and any further 
research that may be conducted in relation to it, even if I withdraw from the trial. I agree 
to this access. However, I understand that my identity will not be revealed in any 
information released to third parties or published. [  ] 
(iv)  I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s).[  ] 
(v)  I agree to take part in the above study.[  ] 
 
Name of the study participant / signatory:________________________________________________ 
 






Date: _____/_____/______                                                                                  Date: _____/_____/______  
 
 
Name of witness: _________________________________________  







ANNEXURE 3 (CLINICAL RESEARCH FORM) 
CLINICAL RESEARCH FORM 
 
Clinical spectrum, diagnostic and outcome predictors of acute 
febrile encephalopathy in a tertiary hospital in south India 
 
 
Name: Age  
State TN AP WB  Sex Male Female 
Hospital No. 
Occupation 
Contact No.   
Symptoms and signs 
Fever Yes No Vomiting Yes No 
Altered Sensorium Yes No Nausea Yes No 
Lethargy Yes No Photophobia Yes No 
Extreme irritability Yes No Papilledema Yes No 
Change in behaviour Yes No Cranial nerve palsies Yes No 
Nuchal rigidity Yes No Ataxia Yes No 
Headache Yes No LOC Yes No 
Focal neurologic deficits Yes No  Yes No 
Seizures Yes No GCS E M V  
          Focal Yes No    
Generalised Yes No    
Intubation Yes No    
   Pedal edema Yes No 
Cough Yes No Respiratory crackles Yes No 
Chest pain Yes No Hepatomegaly Yes No 
Dyspnea Yes No Splenomegaly Yes  No 
      
Dysuria Yes No RR  Others specify 
Burning micturition Yes No PR  
Increased frequency Yes No BP  
Renal angle tenderness Yes No SpO2  
   Temp  
Comorbidites 
Diabetes Yes No HIV Yes No 
Hypertension Yes No Malignancy Yes No 
CKD Yes No CVA Yes No 
CLD Yes No CTD Yes No 
IHD Yes No    
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COUNTS  BIOCHEMISTRY  
TC  Sodium  
Neutrophil  Potassium  
Lymphocyte  Calcium  
Left shift  Phosphorus  
Platelets  Magnesium  
Malarial parasite Pos Neg Glucose  
TB DB SGOT SGPT ALK PHOS 
     
PT  Creatinine  
INR  Urea  
APTT  Lactate  
CRP  PaO2 FiO2 P/F 
Procalcitonin  PCO2  
HIV Pos Neg VDRL Pos Neg 
 
CSF Findings 
Total count  Opening pressure  
Neutrophil  CSF protein  
Lymphocyte  CSF gram stain  
CSF glucose  Blood glucose  
Multiplex PCR  
Culture  








Drug History Yes No 
  
  
Toxin exposure Yes No 
  
Alcohol Yes No 
  
Scrub Pos Neg  
Leptospirosis Pos Neg  
Dengue Pos Neg  
Blood culture Pos Neg  
Widal Pos Neg  
JE Pos Neg  
HSV Pos Neg  






CT brain  
USG  
MRI brain  
  
 
Admitted in ward Yes No Antibiotics Yes No 
 No of days  If yes,Name  
Admitted in ICU                         Yes No Duration  days 
No of days   Acyclovir Yes No 
Ionotropes used                  Yes No ATT Yes No 
No of days  Steroids Yes  No 
Invasive ventilation Yes No Anti epileptics Yes No 
No. of days    
Ventilator free  days    
Other organ dysfunction Yes  No HAI Yes No 






At discharge At 1 month 
mRS    
Vital status DAMA Alive Dead Alive  dead 
 
 
FINAL DIAGNOSIS: 1 
 












ANNEXURE 5 (DATA SHEET) 
Data sheet 
 
AGE STATE SEX OCCUP OCCUPATI PHONE FEVER SENSORILATHARGYIRRITABIBEHAVIOUNUCHAL HEADACHEFOCALNEUSEIZURESFOCAL GENERALIINTUBATICOUGH CHESTPAIDYSPNEADYSURIABURNINGFREQUENCRENAL VOMITING
23 1 1 2 student 9566536478 1 1 2 2 2 1 1 2 1 2 1 2 2 2 2 2 2 2 2 1
17 1 1 2 student . 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1
26 2 2 5 housewife 9492070830 1 1 2 2 2 2 1 2 1 2 1 2 2 2 2 2 2 2 2 1
55 1 2 5 housewife 9042391931 1 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 1
30 1 1 3 Manual labourer 9787423282 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1
73 2 1 0  . 1 1 2 2 2 1 1 2 2 2 2 1 2 2 2 2 2 2 2 1
76 1 1 3 Manual labour . 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
75 2 1 3 manual labourer 837489912 1 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
54 1 1 0  . 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
23 1 1 2 student . 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2
35 1 2 5 Housewife 9786187195 1 1 1 2 2 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2
29 1 2 5 housewife . 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1
24 1 2 5 housewife 9786957096 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
68 1 2 5 HOUSEWIFE . 1 1 2 2 2 1 1 2 2 2 2 2 1 2 2 2 2 2 2 1
60 1 1 3 labourer 7373992777 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
40 2 2 5 Housewife 8886102201 1 1 2 2 2 1 1 2 1 2 1 1 2 2 2 2 2 2 2 1
61 1 1 0  9944963172 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
55 1 1 0  . 1 1 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 1
40 2 1 3 Manual labourer 9704225191 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2
60 1 1 3 manual laboure 9940853402 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
70 1 2 5 housewife 9443478748 1 2 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2
23 1 2 5 housewife 9751096337 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2
32 1 1 3 manual labourer 9985917208 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1
22 1 1 2 student 9790281546 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2
45 1 2 5 housewife 9843088525 1 1 2 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2
38 1 1 3 manual labourer 9655824490 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2
73 1 1 3 Manual labourer 9443336736 1 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
17 1 2 2 student 9710753099 1 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 1
35 2 2 5 housewife 9966816427 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1
30 2 2 5 house wife 7730959695 1 2 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1
31 1 2 5 housewife 7730959695 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1
86 1 1 3 manual labourer 9585018298 1 1 2 2 2 2 1 2 1 2 1 2 2 2 2 2 2 2 2 2
23 2 1 2 student 9505517082 1 1 2 2 2 2 2 2 1 2 1 2 2 2 2 2 2 2 2 1
25 2 2 5 housewife 9944909859 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1
25 1 2 5 housewife 9944909859 1 2 1 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1
28 1 1 3 manual labourer 9944266815 1 1 2 2 2 1 1 2 1 2 1 2 2 2 2 2 2 2 2 1
52 2 1 3 Manual labourer 9848454270 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1
25 1 1 2 student 9789612586 1 1 2 2 2 1 1 2 1 3 1 1 2 2 2 2 2 2 2 1
25 2 1 2 student 988538692 1 1 1 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1
45 1 2 5 housewife 8.60484E+11 1 1 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2
68 1 2 5 housewife 9444030028 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2
26 2 2 5 housewife 8985757279 1 1 1 1 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2
72 1 1 3 Manual labourer 9003991299 1 1 2 2 2 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2
79 1 1 3 manual labourer 9440480008 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
71 1 1 3 manual labouer 9944446604 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
31 2 1 3 Manual labour 9581906365 1 1 2 2 2 1 1 2 1 2 1 2 2 2 2 2 2 2 2 1
50 2 1 0  9966340077 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2
46 2 1 3 manual labourer 9490725939 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
62 1 1 3 Manual labourer 9442412160 1 1 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1
25 2 2 5 housewife 8105850074 1 1 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1
78 1 2 5 housewife . 1 1 2 2 2 2 2 1 1 2 1 2 2 2 2 2 2 2 2 2
60 1 1 3 manual labourer 9626490937 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1
71 1 2 5 housewife . 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
52 1 2 5 housewife 8124900653 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
56 1 2 5 housewife . 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
55 1 1 8 BSNL officer 9790522733 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2
51 1 1 3 Manual labourer 9003492992 1 1 2 2 2 2 2 2 2 2 2 1 2 2 1 2 2 2 2 2
75 1 1 7 farmer 9994051947 1 1 2 2 2 2 2 2 1 2 1 1 2 2 2 2 2 2 2 2
62 1 2 0  9962987607 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
52 1 1 3 manual labourer 9940463977 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1
70 1 2 5 housewife . 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
67 1 1 3 manual labourer 9944804557 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
53 2 2 5 housewife 9177141090 1 1 2 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2
15 2 1 2 Student 9701234158 1 1 2 2 2 1 1 2 1 2 1 2 2 2 2 2 2 2 2 1
20 1 2 2 Student 8903687436 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2
51 1 1 5 housewife 7845407088 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
20 1 2 2 student 9585195039 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2
37 1 1 7 farmer 9943653932 1 1 2 2 1 2 2 2 1 2 1 1 2 2 2 2 2 2 2 1
59 1 1 3 manual labourer . 1 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
35 2 1 3 manual labourer 9849341483 1 1 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1
23 1 2 2 student 9443247989 1 1 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2
82 1 2 5 housewife 9362687881 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
16 2 1 2 student 8499923501 1 1 2 2 1 1 1 2 1 1 2 2 2 2 2 2 2 2 2 1
35 1 2 3 manual labourer 4162290457 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
32 1 1 9 Engineer 9962320234 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2
70 1 2 5 housewife 9486235794 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
57 1 1 3 manual labourer 8695132052 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1
53 1 2 5 house wife 9442317143 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 1
73 1 1 3 manual labourer 7845011832 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
25 1 1 3 Manual labourer-water supplier9894897953 1 1 2 2 2 2 1 2 1 2 1 2 2 2 2 2 2 2 2 2
26 1 2 2 student 9500340977 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1
45 1 2 5 housewife 9626123597 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
25 2 2 5 Housewife . 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2





NAUSEA PHOTOPHOPAPILLEDCRANIALATAXIA LOC GCSE GCSM GCSV TOTALGCSPEDAL CRACKLESHEPATOMESPLENOMERR PR BPSYS BPDIA SPO2 TEMP OTHERS1OTHERS2DIABETESHYPER CKD CLD IHD HIV
2 2 2 2 2 2 4 6 4 14 2 2 2 2 26 116 100 60 96 103.00 traumatic brain injury 2 2 2 2 2 2
2 2 1 2 2 2 4 6 4 14 2 2 2 2 20 126 120 60 96 95.50   2 2 2 2 2 2
2 2 2 2 2 2 2 5 2 9 2 2 2 2 24 76 100 60 100 97.80   2 2 2 2 2 2
2 2 2 2 2 2 2 5 2 9 2 2 2 2 20 118 120 80 94 98.00   1 1 2 2 2 2
2 2 1 2 2 2 4 6 5 15 2 2 2 2 18 72 110 60 98 96.60   2 2 2 2 2 1
2 2 2 2 2 2 1 3 1 5 2 2 2 2 32 124 150 80 93 .   1 1 2 2 2 2
2 2 2 2 2 2 4 6 4 14 2 1 2 2 58 100 190 100 94 104.00   1 1 2 2 2 2
2 2 2 2 2 2 4 5 4 13 2 2 2 2 28 118 100 60 93 100.80 Psychiatric illness 2 2 2 2 2 2
2 2 2 2 2 2 4 6 4 14 2 1 2 2 36 104 160 90 98 104.50   2 2 2 2 2 2
2 2 2 2 2 2 4 6 5 15 2 2 2 2 20 121 120 80 96 101.00 retroorbital pain 2 2 2 2 2 2
2 2 2 2 2 2 4 5 0 9 2 2 2 2 20 124 110 70 98 97.00   2 2 2 2 2 2
2 2 1 2 2 2 4 6 5 15 2 2 2 2 18 88 80 60 100 99.00   2 2 2 2 2 2
2 2 2 2 2 2 4 5 2 11 2 2 2 2 30 148 100 60 99 100.00   2 2 2 2 2 2
1 2 2 2 2 2 4 5 4 13 2 2 2 2 26 84 170 80 92 100.00   2 1 2 2 2 2
2 2 2 2 2 2 4 6 3 13 2 2 2 2 20 88 90 60 93 98.40   2 2 2 2 2 2
2 2 1 2 2 1 2 5 3 10 2 2 2 2 20 78 110 70 97 .   2 2 2 2 2 2
2 2 2 2 2 2 4 6 4 14 2 2 2 2 28 92 130 80 99 103.40 Seizure disorderPsychiatric illness1 2 2 2 2 2
2 2 2 2 2 2 3 4 1 8 2 2 2 2 46 126 120 80 90 . GRBS 332 1 2 2 2 2 2
2 2 2 2 2 2 4 6 5 15 2 2 2 2 36 82 100 80 96 98.90   2 2 2 2 2 2
2 2 2 2 2 2 4 6 4 14 2 2 2 2 34 134 100 60 92 97.60   2 2 2 2 2 2
2 2 2 2 2 2 4 5 0 9 2 2 2 2 22 108 120 80 99 99.00   2 1 2 2 2 2
2 2 2 2 2 2 3 6 5 14 2 2 2 2 20 102 130 90 99 97.00   2 2 2 2 2 2
2 2 2 2 2 2 4 6 5 15 2 2 2 2 24 105 120 70 97 96.50   2 2 2 2 2 2
2 2 2 2 2 2 1 5 2 8 2 2 2 2 44 154 100 70 80 98.00   2 2 2 2 2 2
2 2 2 2 2 2 4 6 4 14 2 2 2 2 36 981 100 70 99 98.60   1 1 2 2 2 2
2 2 2 2 2 2 4 5 4 13 1 1 1 1 34 102 130 80 89 99.00 jaundice eschar at left arm2 2 2 2 2 2
2 2 2 2 2 2 3 5 2 10 2 2 2 2 34 102 140 70 95 98.00   2 2 2 2 2 2
2 2 2 2 2 2 4 6 4 14 2 2 2 2 26 86 90 60 96 97.00   2 2 2 2 2 2
2 2 2 2 2 2 4 6 4 14 2 2 2 2 22 84 100 60 98 96.00 Eschar left back 2 2 2 2 2 2
2 2 2 2 2 2 4 6 5 15 2 2 2 2 24 130 100 60 97 100.60   2 2 2 2 2 2
2 2 2 2 2 2 4 6 5 15 2 2 2 2 24 130 100 60 97 100.60   2 2 2 2 2 2
2 2 2 2 2 2 4 5 3 12 2 1 2 2 20 88 110 70 94 101.00   2 2 2 2 2 2
2 2 2 2 2 2 1 5 2 8 2 2 2 2 28 104 100 70 94 101.00 skin lesions 2 2 2 2 2 2
2 2 2 2 2 2 4 6 5 15 2 2 2 2 22 90 100 60 100 99.40   2 2 2 2 2 2
1 2 2 2 2 2 4 6 5 15 2 2 2 2 22 100 100 60 100 .   2 2 2 2 2 2
2 2 2 2 2 2 4 6 5 15 2 2 2 2 20 102 90 60 98 100.00   2 2 2 2 2 2
2 2 2 2 2 2 3 5 2 10 2 2 2 2 34 142 160 100 98 103.40   2 2 2 2 2 2
2 2 2 2 2 2 4 5 1 10 2 1 2 2 34 136 140 80 94 103.00   2 2 2 2 2 2
2 2 2 2 2 2 3 5 3 11 2 2 2 2 30 142 140 60 95 103.20   2 2 2 2 2 2
2 2 2 2 2 2 4 6 4 14 2 2 2 2 20 88 120 80 98 99.00   2 2 2 2 2 2
2 2 2 2 2 2 4 6 4 14 2 2 2 2 22 126 90 50 95 100.40   1 2 2 2 2 2
2 2 2 2 2 2 2 5 2 9 2 2 2 2 24 78 100 80 98 100.00   2 2 2 2 2 2
2 2 2 2 2 2 4 5 3 12 2 2 2 2 24 120 120 80 79 99.00   2 2 2 2 2 2
2 2 2 2 2 2 4 6 4 14 2 2 2 2 32 124 110 70 97 99.00   1 1 2 2 2 2
2 2 2 2 2 2 4 6 4 14 2 2 2 2 26 130 90 60 93 100.00   1 1 2 2 2 2
2 2 2 2 2 2 4 6 4 14 2 2 2 2 24 98 100 60 96 .   2 2 2 2 2 2
2 2 2 2 2 2 4 6 4 14 2 2 2 2 30 126 90 60 98 103.00 Lower limb swellingE char left 2 2 2 2 2 2
2 2 2 2 2 2 1 5 2 8 2 2 2 2 40 114 128 80 84 101.00   2 2 2 2 2 2
2 2 2 2 2 2 3 6 3 12 2 2 2 2 24 104 120 70 95 98.30   1 2 2 2 1 2
2 2 2 2 2 2 4 6 5 15 2 2 2 2 24 72 110 70 99 100.00 Double vision 2 2 2 2 2 2
2 2 2 2 2 2 1 4 2 7 2 2 2 2 22 96 100 60 88 101.00   2 2 2 2 2 2
2 2 2 2 2 2 4 5 4 13 2 2 2 2 40 118 110 80 91 101.40 diarrhea  2 2 2 2 2 2
2 2 2 2 2 2 4 6 4 14 2 2 2 2 24 92 220 100 99 99.00   1 1 2 2 2 2
2 2 2 2 2 1 3 6 4 13 2 2 2 2 36 90 130 80 98 103.00 cpk - 2504 2 1 2 2 2 2
2 2 2 2 2 2 4 5 4 13 2 2 2 2 26 122 110 70 93 103.60 cpk- 1278 2 2 2 2 2 2
2 2 2 2 2 2 4 6 4 14 2 2 2 2 32 120 120 80 89 100.00   2 2 2 2 2 2
2 2 2 2 2 2 4 6 4 14 2 1 2 2 44 146 100 60 99 105.00   1 1 2 2 2 2
2 2 2 2 2 2 1 1 1 3 2 2 2 2 24 120 90 50 48 107.00   2 2 2 2 2 2
2 2 2 2 2 2 4 6 4 14 2 2 2 2 20 148 150 80 96 105.00 Tuberculosis 1 1 2 2 2 2
2 2 2 2 2 2 4 6 4 14 2 2 2 2 24 110 90 60 96 . anuria, abdominal pain 1 1 2 2 2 2
2 2 2 2 2 2 4 6 4 14 2 2 2 2 24 80 110 70 106 102.00 cpk - 2756 2 2 2 2 2 2
2 2 2 2 2 2 4 5 3 12 2 2 2 2 34 114 130 80 93 103.60   1 2 1 2 2 2
2 2 2 2 2 2 4 6 4 14 2 2 2 2 24 116 100 70 99 100.00   2 2 2 2 2 2
2 2 2 2 2 2 4 5 1 10 2 2 2 2 20 98 100 60 100 97.80   2 2 2 2 2 2
2 2 2 2 2 2 4 5 4 13 2 2 2 2 22 108 100 60 96 99.00   2 2 2 2 2 2
2 2 2 2 2 2 4 5 4 13 2 2 2 2 44 138 130 80 88 102.00   1 1 2 2 2 2
2 1 2 2 2 2 3 5 3 11 2 2 2 2 24 66 100 60 94 101.20   2 2 2 2 2 2
2 2 2 2 2 2 4 6 4 14 2 2 2 2 20 132 60 40 99 99.00   2 2 2 2 2 2
2 2 2 2 2 2 4 5 2 11 2 2 2 2 36 126 120 80 92 107.00 Parkinsons disease 1 1 2 2 2 2
2 2 2 1 2 2 4 6 4 14 2 2 2 2 20 721 140 80 97 100.20   2 2 2 2 2 2
2 2 2 2 2 2 4 6 4 14 2 2 2 2 20 84 130 80 90 100.20   2 2 2 2 2 2
2 2 2 2 2 2 3 5 3 11 2 2 2 2 30 120 90 50 91 101.20   1 1 2 2 1 2
2 2 2 2 2 2 4 6 4 14 2 2 2 2 24 132 90 60 99 102.60   2 2 2 2 2 2
2 2 2 2 2 2 4 2 2 8 2 2 2 2 34 130 100 60 93 104.40 Psychiatric illness 2 2 2 2 2 2
2 2 2 2 2 2 4 6 5 15 2 2 2 2 20 74 110 70 100 100.00   2 2 2 2 2 2
2 2 2 2 2 2 4 6 4 14 2 2 2 2 24 104 140 70 95 103.00   1 2 2 2 2 2
2 2 2 2 2 2 4 6 4 14 2 2 2 2 34 74 200 100 96 105.50   2 2 2 2 2 2
2 2 2 2 2 2 4 6 5 15 2 2 2 2 26 110 160 100 94 100.20   2 1 2 2 2 2
2 2 2 2 2 2 4 6 4 14 2 2 2 2 24 104 150 70 98 104.00   2 2 2 2 2 2
2 2 2 2 2 2 4 6 3 13 2 2 2 2 26 118 130 80 94 99.00   2 2 2 2 2 2
2 2 2 2 2 2 4 5 6 15 2 2 2 2 22 86 100 80 98 100.00   2 2 2 2 2 2
2 2 2 2 2 2 4 4 1 9 2 2 2 2 24 102 110 70 98 103.00 Psychiatric illnes 2 2 2 2 2 2
2 2 2 2 2 2 4 6 5 15 2 2 2 2 16 80 100 60 99 99.00   2 2 2 2 2 2




MALIG CVA CTD DRUG DRUGYESTOXIN TOXINYESALCOHOLSCRUB LEPTO DENGUEBLDCUL BCPOS WIDAL JE HSV MEASLESWBC URINECULURINEPOSTC NEUTROLYMPHO LEFTSHIFPLATELETMALARIALTB DB SGOT
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . 3  14,500 90 7 1 429,000 2 0.60 0.20 32
2 2 2 2  2  2 3 3 3 3  3 3 3 3 . .  29,900 93 4 1 252,000 2 0.70 0.30 19
2 2 2 2  2  2 2 3 2 2  3 3 3 3 . .  8,400 63 29 2 94,000 2 0.54 0.24 32
2 2 2 2  2  2 3 3 3 3  3 3 3 3 . .  11,500 66 17 2 300,000 3 0.70 0.20 35
2 2 2 2  2  2 3 3 3 3  3 3 3 3 . .  11,300 82 6 1 505,000 3 0.40 0.30 10
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . .  17,200 85 6 1 270,000 2 1.10 0.50 37
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . 2  9,600 89 3 1 124,000 3 0.90 0.40 17
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . .  10,800 77 14 2 . 3 1.40 0.10 115
2 2 2 2  2  2 3 3 3 3  3 3 3 3 . .  12,200 70 19 2 186,000 2 1.80 0.60 83
2 2 2 2  2  2 2 3 2 2  3 3 3 3 . .  13,100 77 10 2 333,000 2 0.50 0.10 19
2 2 2 2  2  2 3 3 3 3  3 3 3 3 . .  16,100 91 4 1 167,000 2 0.50 0.30 136
2 2 2 2  2  2 3 3 3 3  3 3 3 3 . .  7,700 66 23 2 204,000 3 0.29 0.10 22
2 2 2 2  2  2 2 2 2 2  3 3 3 3 . .  10,300 70 24 2 25,300 2 0.60 0.20 69
2 2 2 2  2  2 2 3 3 2  3 3 3 3 . .  14,900 77 16 2 196,000 2 1.00 0.20 45
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . .  10,000 69 23 2 217,000 2 0.25 0.10 34
2 2 2 2  2  2 2 3 3 2  3 3 3 3 . .  19,500 83 11 1 261,000 2 0.50 0.10 23
2 2 2 2  2  2 2 3 2 2  3 3 3 3 . .  7,600 81 10 2 111,000 2 0.40 0.20 43
2 2 2 2  2  2 3 3 3 1 ESBL 3 3 3 3 . .  1,300 21 4 2 8,000 2 3.20 1.50 62
2 2 2 2  2  2 1 3 2 2  3 3 3 3 . .  10,800 76 2 1 126,000 2 0.70 0.30 60
2 2 2 2  2  2 1 2 2 3  3 3 3 3 . .  15,500 77 17 2 103,000 2 0.98 0.50 205
2 2 2 2  2  2 3 3 3 3  3 3 3 3 . .  6,300 69 22 2 333,000 3 0.66 0.21 32
2 2 2 2  2  2 1 3 3 2  3 3 3 3 . .  9,800 79 18 2 236,000 2 0.80 0.30 75
2 2 2 2  2  2 1 2 3 3  3 3 3 3 . .  9,300 71 22 2 358,000 3 0.60 0.30 60
2 2 2 2  2  2 1 3 3 2  3 3 3 3 . .  12,100 74 21 2 145,000 2 2.80 2.50 129
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . .  5,700 77 17 2 111,000 3 0.90 0.10 23
2 2 2 2  2  2 1 2 3 3  3 3 3 3 . 3  10,800 61 35 2 26,000 2 6.35 5.42 160
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . .  11,000 85 6 1 169,000 2 1.20 0.30 27
2 2 2 2  2  2 3 3 3 3  3 3 3 3 . .  18,300 92 4 1 . 2 1.00 0.30 31
2 2 2 2  2  2 1 3 3 3  3 3 3 3 . .  4,700 68 23 2 166,000 2 0.60 0.20 21
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . 3  14,900 76 14 2 308,000 3 0.50 0.10 11
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . .  14,900 76 14 2 308,000 3 0.50 0.10 11
2 2 2 2  2  2 2 2 2 2  3 3 3 3 . .  7,600 91 5 1 104,000 2 . . 171
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . .  12,500 69 24 2 161,000 2 1.22 0.39 107
2 2 2 2  2  2 3 3 2 2  3 3 3 3 . .  10,000 27 66 2 232,000 2 0.20 0.10 49
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . .  10,000 27 66 2 232,000 2 0.20 0.10 99
2 2 2 2  2  2 1 3 2 2  3 3 3 3 . .  10,200 73 18 2 240,000 2 1.90 1.30 85
2 2 2 2  2  2 1 3 3 2  3 3 3 3 . .  14,100 80 17 2 31,000 2 1.00 0.30 139
2 2 2 2  2  2 1 3 1 2  3 3 3 3 . 3  10,200 73 18 1 240,000 2 1.90 1.30 85
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . 3  18,900 84 8 1 185,000 2 1.30 0.40 45
2 2 2 2  2  2 2 3 3 2  3 3 3 3 . .  7,900 60 27 2 273,000 2 0.80 0.10 18
2 2 2 2  2  2 1 3 3 2  3 3 3 3 . .  15,200 73 21 2 111,000 2 2.40 2.10 46
2 2 2 2  2  2 3 3 3 3  3 3 3 3 . .  7,800 69 21 2 201,000 2 1.00 0.50 36
2 2 2 2  2  2 3 3 3 3  3 3 3 3 . .  19,600 80 11 2 200,000 3 0.40 0.20 66
2 2 2 2  2  2 3 3 3 1  3 3 3 3 49 .  10,400 80 15 2 211,000 2 0.60 0.38 51
2 1 2 2  2  2 2 2 2 2  3 3 3 3 . .  16,000 70 22 2 136,000 3 0.90 0.37 111
2 2 2 2  2  2 1 3 3 2  3 3 3 3 . .  14,300 26 65 2 184,000 2 0.50 0.20 99
2 2 2 2  2  2 1 2 2 3  3 3 3 3 . .  8,300 71 21 2 5,000 2 0.60 0.40 151
2 2 2 2  2  2 1 3 3 2  3 3 3 3 . .  26,500 81 12 2 84,000 2 0.70 0.30 57
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . .  4,100 55 33 2 139,000 2 0.50 0.20 7
2 2 2 2  2  2 3 3 3 3  3 3 3 3 . .  10,100 89 7 1 492,000 2 0.60 0.22 12
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . 3  19,500 94 4 1 247,000 3 0.60 0.20 20
2 2 2 2  2  2 1 2 2 2  3 3 3 3 . .  12,300 69 28 2 102,000 2 2.60 2.40 93
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . .  11,300 80 13 2 346,000 3 0.40 0.10 22
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . .  14,900 89 7 1 277,000 3 0.80 0.30 38
2 2 2 2  2  2 2 3 3 2  3 3 3 3 . .  1,200 83 12 2 280,000 2 0.80 0.30 39
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . .  10,700 79 12 2 140,000 2 2.50 0.90 548
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . .  24,800 89 7 1 464,000 2 3.00 0.70 84
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . .  9,700 72 16 1 227,000 2 0.60 0.20 18
2 2 2 2  2  2 3 3 3 3  3 3 3 3 . .  7,300 75 18 2 131,000 3 1.00 0.30 96
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . 2  20,900 78 12 2 321,000 3 0.60 0.10 13
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . .  11,000 76 13 2 158,000 3 0.80 0.30 60
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . .  20,200 92 4 1 251,000 2 1.00 0.50 24
2 2 2 2  2  2 2 3 3 2  3 3 3 3 . .  10,500 78 17 2 17,400 2 1.00 0.60 42
2 2 2 2  2  2 1 3 3 2  3 3 3 3 . .  32,100 92 4 1 152,000 3 1.60 0.60 52
2 2 2 2  2  2 2 3 3 2  3 3 3 3 . .  8,600 74 18 2 220,000 3 0.40 0.10 25
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . .  13,300 84 6 1 169,000 3 1.00 0.40 195
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . .  19,300 73 16 2 322,000 2 . . .
2 2 2 2  2  1 3 3 3 2  3 3 3 3 . .  2,000 40 6 2 117,000 2 1.70 1.30 317
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . .  6,400 81 4 2 164,000 3 1.20 0.40 29
2 2 2 2  2  2 3 3 3 3  3 3 3 3 . .  12,000 82 10 1 300,000 2 1.40 0.40 23
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . .  19,200 77 17 2 345,000 3 0.30 0.10 19
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . .  24,400 90 7 1 16,100 2 0.60 0.30 22
2 2 2 2  2  2 3 3 3 1 ESBL 3 3 3 3 . .  5,000 59 25 2 168,000 3 0.50 0.20 28
2 2 2 1 Anti psychiatric medications2  2 3 3 3 2  3 3 3 3 . .  7,700 84 10 2 121,000 3 0.60 0.20 106
2 2 2 2  2  2 3 3 3 3  3 3 3 3 . .  12,200 92 6 1 235,000 2 1.14 0.20 46
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . 2  12,100 60 28 2 251,000 2 0.80 0.40 47
2 2 2 2  2  2 3 3 3 3  3 3 3 3 . .  8,800 78 13 2 217,000 3 1.50 0.60 118
2 2 2 2  2  2 3 3 3 3  3 3 3 3 . .  6,300 75 19 2 254,000 2 0.40 0.10 27
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . .  10,400 89 4 1 141,000 2 0.90 0.30 16
2 2 2 2  2  1 3 3 3 3  3 3 3 3 . .  9,200 57 29 2 264,000 2 0.85 0.30 95
2 2 2 2  2  2 3 3 3 3  3 3 3 3 . .  11,900 71 20 2 285,000 3 0.60 0.20 15
2 2 2 1 Anti psychiatic medications2  2 3 3 3 2  3 3 3 3 . .  14,100 82 11 2 193,000 3 0.50 0.10 21
2 2 2 2  2  2 3 3 3 2  3 3 3 3 . .  11,100 68 26 2 248,000 2 0.30 0.10 11




SGPT ALKPHOSPT INR APTT CRP PROCAL HIV1 SODIUM POTASSIUCALCIUMPHOSPHORMAGNESIUCREATINIUREA LACTATEPA02 FIO2 PF PC02 VDRL TOTAL NEUTROPHLYMPHOCYSFGLUCOTWOTHIRDGLUGLUCOSEGLU BLDGLUCO
62 123 . . . . . 3 128 4.60 . . . 0.53 13 0.90 115 21 548 20 . 8,000 90 10 2.00 75.33 113 -73.33 113
10 123 . . . . . 2 136 4.20 . . . 0.63 23 . . . . . 3 5,280 98 2 52.00 . . . .
32 110 . . . . . 2 134 4.20 . . . 0.58 . 1.10 . . . . . 5 15 85 88.00 102.00 153 -14.00 153
27 88 . . . . . 2 134 4.30 9.15 3.80 1.85 0.86 48 . . . . . 3 3 0 100 78.00 78.67 118 -0.67 118
8 389 . . . . . 1 129 4.10 . . . 1.50 92 . . . . . 3 60 34 60 21.00 70.67 106 -49.67 106
17 79 11.90 1.10 33.60 . . . 131 2.50 . . . 1.16 16 11.30 72 . . 11 . 2,100 96 2 29.00 198.00 297 -169.00 297
10 65 . . . . . . 122 3.50 . . . 2.05 57 1.70 67 21 319 28 . . . . . . . . 129
24 33 . . . . . 3 155 3.90 8.04 3.50 . 3.33 81 . . . . . 3 . . . . 77.33 116 . 116
37 58 . . . . . . 100 3.50 7.50 1.90 . 1.10 . 2.00 95 . . 18 . . . . . 106.00 159 . 159
20 90 . . . 4.31 . 2 138 3.40 9.38 3.70 . 0.94 . . . . . . . 80 3 97 56.00 . . . .
65 98 . . . . . . 136 2.90 . . . 1.02 26 . . . . . . 7 1 8 81.00 79.33 119 1.67 119
18 48 . . . . . 2 132 3.80 8.60 3.50 . 0.44 . . . . . . 2 . . . . . . . .
25 62 11.90 1.11 44.30 . . 2 155 3.50 . . . . . 1.10 . . . . 2 20 36 58 95.00 93.33 140 1.67 140
32 105 . . . . . 3 139 3.70 . . . 0.79 42 . . . . . 3 60 10 90 53.00 64.00 96 -11.00 96
7 188 . . . . . . 128 3.70 . . . 0.94 49 2.00 70 21 333 29 . 40 10 89 143.00 258.67 388 -115.67 388
9 109 11.30 1.05 30.60 . . 3 140 3.90 8.20 2.40 1.83 0.66 22 0.90 158 21 752 37 3 580 35 42 56.00 82.67 124 -26.67 124
13 44 . . . . . . 123 3.50 . . . 0.64 13 . . . . . . 15 8 68 72.00 . . . 122
45 110 11.40 1.06 26.40 . . . . . . . . . . . 86 100 86 17 . . . . . . . . 332
94 122 . . . . . 3 134 3.60 . . . 0.78 38 . . . . . 3 110 5 95 52.00 74.67 112 -22.67 112
87 42 . . . . . 2 131 4.00 7.10 2.30 . 1.29 89 . . . . . 3 8 22 64 37.00 90.67 136 -53.67 136
42 109 . . . . . 3 110 3.90 . . . 0.37 10 0.70 84 21 400 38 3 . . . . 85.33 128 . .
60 92 . . . . . 2 133 3.30 . . . 0.57 21 . . . . . 3 120 19 76 46.00 72.00 108 -26.00 108
87 295 . . . . . 2 132 3.90 . . . 0.58 . . . . . . . 30 2 98 65.00 66.67 100 -1.67 100
128 148 . . . . . 2 135 3.90 8.80 3.80 . 1.09 25 0.70 74 21 352 43 3 . . . . 113.33 170 . .
10 66 . . . . . 3 128 3.10 11.20 3.60 0.97 1.00 . 1.00 103 21 490 34 3 3 0 100 110.00 337.33 506 -227.33 250
68 220 11.40 1.05 41.50 . . 3 138 4.40 . . . 2.60 151 2.40 89 21 424 21 3 . . . . . . . .
11 51 . . . . . 2 138 4.10 8.52 2.70 . 1.58 51 . . . . . 3 10 44 48 65.00 43.33 65 21.67 65
9 71 . . . . . 3 130 3.80 . . . 0.63 . . . . . . 3 12 42 54 5.00 70.00 105 -65.00 105
11 59 . . . . . 2 133 3.90 . . . 0.68 13 . . . . . 3 190 5 92 11.00 54.67 82 -43.67 82
4 63 . . . 4.67 . 2 129 4.00 9.00 2.50 . 0.53 16 . . . . . 3 94 72 25 31.00 66.67 100 -35.67 100
4 63 . . . . . 2 129 4.00 . . . 0.53 16 . . . . . 3 94 72 35 31.00 146.67 220 -115.67 220
64 . . . . . . 3 138 4.30 7.54 5.00 2.57 4.46 193 1.70 82 21 . 30 3 . . . . 64.67 97 . 97
39 76 10.70 0.99 41.80 . . 2 133 4.70 7.50 2.10 1.72 0.89 . 1.30 300 40 750 35 3 . . . . 72.67 109 . 109
49 122 10.40 0.96 41.50 . . 3 136 3.90 . . . 0.63 11 . . . . . . . . . . . . . .
49 122 10.40 0.96 41.50 . . 2 132 4.10 . . . 0.54 . . . . . . 3 . . . . . . . .
116 122 12.10 1.12 34.00 . . 2 135 3.90 8.48 3.30 2.94 0.74 39 . . . . . . . . . . 75.33 113 . 113
39 34 14.10 1.30 63.80 . . 2 134 3.80 . 4.70 2.00 0.68 65 5.40 96 21 457 27 3 . . . . . . . .
116 122 12.10 1.12 34.00 . . 2 135 3.90 . . . 0.74 39 . . . . . 3 . . . . 134.67 202 . 202
12 117 . . . . . 2 131 3.60 . . 2.26 1.03 24 . . . . . 3 380 83 14 64.00 70.67 106 -6.67 106
18 61 . . . . . 2 135 3.70 8.10 3.60 1.64 . . . . . . . 3 3 30 60 73.00 102.00 153 -29.00 155
32 431 . . . . . 2 128 4.50 8.05 2.90 . 1.09 51 1.40 66 21 314 27 3 8 2 98 99.00 155.33 233 -56.33 233
37 73 . . . . . 2 137 38.00 . . . 0.50 15 . . . . . 3 60 10 85 55.00 67.33 101 -12.33 101
35 60 12.20 1.13 52.20 . . 3 135 4.60 . . . 2.10 54 2.10 73 45 162 28 3 3 0 100 151.00 146.00 219 5.00 219
22 102 12.90 . 34.10 . 3.80 3 137 4.40 . . 1.98 2.63 124 2.20 66 21 . 28 3 12 32 62 101.00 208.00 312 -107.00 312
61 44 . . . . . 3 142 4.00 . . . 2.50 75 2.20 64 21 305 27 3 . . . . 99.33 149 . .
98 135 . . . . . 2 133 4.00 . . . 1.33 44 . . . . . . 36 6 89 48.00 76.00 114 -28.00 114
30 192 14.10 1.30 62.50 . . 2 126 4.30 . . . 0.96 54 . . . . . . 6 60 30 33.00 . . . .
47 188 10.90 1.01 39.10 . . 2 128 4.10 . . . 0.73 44 1.10 79 21 376 31 3 100 5 93 75.00 77.33 116 -2.33 116
27 91 . . . . . 3 129 3.70 . . . 0.91 . . . . . . 3 1,750 2 78 54.00 100.00 150 -46.00 150
10 77 . . . . . . 125 3.90 . . . 0.47 20 . . . . . . 170 19 75 15.00 93.33 140 -78.33 140
10 34 . . . . . 3 102 3.00 7.93 2.10 2.04 0.63 85 4.70 . . . . . 250 1 91 29.00 100.00 150 -71.00 150
50 205 11.30 1.05 57.90 . . 2 136 4.30 . 6.40 2.32 3.51 147 0.70 100 45 222 18 3 10 18 82 79.00 42.67 64 36.33 64
18 98 . . . . . 2 125 4.60 9.64 1.60 . 0.63 24 0.90 61 100 61 29 1 200 29 69 52.00 . . . .
13 72 . . . . . 3 109 3.30 . . . 0.69 16 . . . . . . . . . . 94.00 141 . 141
11 65 . . . . . 3 117 4.10 . . . 0.93 . 0.90 66 21 314 22 . . . . . 93.33 140 . 140
251 45 11.90 1.10 29.70 . . 2 119 3.50 . . . 1.17 24 . . . . . 3 . . . . 99.33 149 . 149
49 52 11.40 1.05 36.00 . . 3 111 4.00 . . 1.78 1.08 17 12.80 143 100 143 17 3 . . . . 289.33 434 . 434
10 95 12.70 1.17 42.40 . . 2 127 4.60 7.17 3.50 1.48 2.16 . . . . . . . . . . . 133.33 200 . 200
28 60 10.50 0.97 33.60 . . . 135 3.80 . . . 1.07 47 . . . . . . . . . . 217.33 326 . 326
13 69 10.50 0.97 34.50 . . 2 136 8.30 . 4.70 1.81 9.48 127 11.70 141 21 671 12 . . . . . 38.67 58 . 58
19 31 . . . . . . 115 3.40 . . . 0.88 . 0.70 84 21 400 33 . . . . . 90.67 136 . 136
15 74 . . . . . 3 126 2.10 . . . 4.03 . . . . . . 3 5 5 85 53.00 102.00 153 -49.00 153
24 198 . . . . . 2 131 4.50 7.86 4.40 . 0.84 39 1.10 103 40 258 22 3 180 54 44 75.00 80.00 120 -5.00 120
15 68 . . . . . 2 144 4.50 9.30 3.40 2.29 0.78 36 . . . . . 3 3,400 80 17 30.00 83.33 125 -53.33 125
11 50 10.80 1.00 37.40 . . 2 135 3.60 8.80 3.70 1.36 0.59 . . . . . . 3 150 13 85 55.00 59.33 89 -4.33 89
53 67 11.20 1.04 40.20 . . 2 110 3.60 7.40 1.30 . 1.42 . 3.30 97 40 242 16 3 . . . . 196.67 295 . 295
. . . . . . . 3 134 3.70 7.54 2.90 1.91 0.79 . 2.00 145 40 363 22 3 30 6 94 100.00 . . . .
125 66 14.60 1.35 48.60 . . 2 132 3.00 . 5.00 1.88 2.06 . 6.00 69 21 329 23 . . . . . 94.00 141 . 141
13 62 . . . . . 3 116 3.70 7.40 2.60 1.84 1.33 . . . . . . 3 . . . . 181.33 272 . 272
8 84 11.10 1.03 27.80 . . 2 123 4.50 8.60 3.30 . 1.16 38 . . . . . . 80 8 84 54.00 104.67 157 -50.67 157
15 62 . . . . . 2 137 3.80 9.15 . 1.26 0.61 22 . . . . . 3 2 0 100 . 82.67 124 . 124
10 46 . . . . . 3 125 3.50 9.00 3.50 . 1.14 33 1.80 112 40 280 25 3 . . . . . . . .
8 84 . . . . . . 129 4.20 7.98 2.90 . 0.79 . . . . . . . 7 0 7 52.00 77.33 116 -25.33 116
49 149 . . . . . 3 133 38.00 . . . 1.28 . . . . . . 3 . . . . 161.33 242 . 242
56 106 . . . . . 2 129 4.20 . . . 0.95 30 . . . . . 3 150 28 70 59.00 . . . 142
42 36 11.60 1.07 31.70 . . 2 117 3.70 8.40 2.20 1.59 0.67 13 . . . . . . . . . . 106.00 159 . .
93 98 . . . . . 3 120 3.10 7.89 2.60 1.77 1.19 21 1.40 71 21 338 28 3 . . . . 134.67 202 . 202
13 93 . . . . . 2 130 3.60 9.10 3.40 . 1.44 14 . . . . . 2 80 12 88 83.00 . . . 169
17 67 10.90 1.01 40.20 . . 3 129 3.60 8.22 2.40 2.01 0.92 . . . . . . 3 . . . . 101.33 152 . 152
60 80 . . . . . 3 139 3.50 . . . 1.23 38 . . . . . 3 40 9 89 83.00 . . . 176
8 59 . . . . . 2 134 3.50 9.40 . . 0.63 36 . . . . . . 400 2 98 34.00 62.00 93 -28.00 93
17 66 . . . . . 3 134 3.30 . . . 2.09 72 . . . . . 3 1 0 100 78.00 108.67 163 -30.67 163
20 89 . . . . . 2 133 4.00 . . . 0.91 . . . . . . . 15 55 45 47.00 . . . .





PCR PCRPOSCULTUREOPENPRECSFPROTECSFGRAMCSFGRAMYXRAYDN XRAY CT CTBRAINUSGDN USG MRI MRIBRAINADMITWARDOA DOD MONTH HOSSTAYDAYSWARDA MITICUDAYSICUIONOTROPDAYSIONOVENTILATDAYSVENTVENTILFR
3  no growth. 700.00 1 negative 1 normal 1 old traumatic glosis2  2  1 12-Jan-2016 16-Jan-2016 1 4 4 . . 2 . 2 . .
2   . 316.00 2  1 normal 1 Multiple calcific foci,edema-left frontal2  2  1 22-Jan-2016 26-Jan-2016 1 4 4 2 . 2 . 2 . .
2   . 48.70 1 occ pus cells,no bacteria1 normal 2  2  1 HI L frontal oprcular ,raised ICT1 20-Jan-2016 02-Mar-2016 1 39 . 1 . 1 . 1 . .
3   . 52.90 2  1 Normal 1 hypodensity in the subcortical white matter2  2  1 09-Feb-2016 09-Feb-2016 2 1 1 2 . 2 . 2 . .
3   . 110.00 2  2  1 NORMAL 2  2  1 18-Feb-2016 04-Mar-2016 2 15 15 2 . 2 . 2 . .
.  Streptococcus pneumonia16 121.50 1 GPC .  1 Normal .  1 Normal 1 16-Mar-2016 30-Mar-2016 3 14 6 1 9 2 . 1 7 21
.   . . .  1 Normal .  .  .  1 22-Apr-2016 26-Apr-2016 4 4 4 2 . 2 . 2 . .
.   . . .  1 Normal 2  2  2  1 28-Apr-2016 05-May-2016 4 7 7 2 . 2 . 2 . .
.   . . .  1 Normal .  .  .  1 28-Apr-2016 06-May-2016 4 8 8 2 . 2 . 2 . .
2  no growth. 139.00 1 occasional pus 2  2  2  1 normal 1 02-Apr-2016 15-Apr-2016 4 13 13 2 . 2 . 2 . .
3  No growth. 29.90 1 No pus cells, no bacteria.  1 normal 2  2  1 07-Aug-2015 08-Aug-2015 8 1 1 2 . 2 . 2 . .
.   . . .  1 Right pleural effusion2  .  1 Subtle periventricular halo,FLAIR hi BRAINSTEM,Q1 01-Sep-2015 04- ep-2015 9 3 3 2 . 2 . 2 . .
2  No growth. 42.60 1 Occasional pus cells, no bacteria1 Normal 2  2  1 Splenial hyperintensity, cortical swelling rt temp1 04-Sep-2015 25-Sep-2015 9 21 21 2 . 2 . 2 . .
3  No growth. 143.00 1 Occasional pus cells, no bacteria1 NORMAL 1 Calcified granuloma2  2  1 03-Oct-2015 09-Oct-2015 10 6 6 2 . 2 . 2 . .
2   . 164.90 .  1 Normal 1 Normal 1 Normal 1 Normal 1 03-Oct-2015 10-Oct-2015 10 7 7 2 . 2 . 2 . .
2  no growth. 125.90 1 few pus cells, no bacteria1 Normal 2  2  1 FLAIR sulcal hyperintensities, GM swelling1 20-Oct-2015 26-Nov-2015 10 37 13 1 24 2 . 1 20 8
.   . 50.50 1 Occasional pus cells, no bacteria1 Normal .  .  .  1 28-Dec-2015 30-Dec-2015 12 2 2 2 . 2 . 2 . .
.   . . .  1 Normal 1 Normal 1  1 TO REVIEW - herpes encephalitis1 09-Dec-2015 25-Dec-2015 12 16 7 1 9 . . 1 9 .
2   . 52.20 2  1 NORMAL 1 NORMAL 2  2  1 07-Jan-2016 09-Jan-2016 1 2 2 2 . 2 . 2 . .
2   . 43.10 2  1 NORMAL 2  2  1 NORMAL 1 01-Jan-2016 05-Jan-2016 1 4 4 2 . 2 . 2 . .
.   . . .  1 NORMAL 1 Normal 2  2  1 16-Jan-2016 20-Jan-2016 1 4 4 2 . 2 . 2 . .
2  no growth. 144.10 1 moderate pus cells,no bacteria1 rmal 1 normal 2  2  1 10-Jan-2016 15-Jan-2016 1 5 5 2 . 2 . 2 . .
2  no growtgh. 72.60 1 occ pus cells  no bacteria1 norm l 2  2  1 Flair HI,increased grey white diffentiation1 27-Jan-2016 01-Feb-2016 1 5 5 2 . 2 . 2 . .
.   . . .  1 NORMAL 2  2  1 chronic granuloma left pareital region1 09-Jan-2016 15-Jan-2016 1 6 6 2 . 2 . 2 . .
2   . 73.90 2  1 Normal 2  2  1 Normal 1 09-Jan-2016 15-Jan-2016 1 6 6 2 . 2 . 2 . .
.   . . .  1 sugg of ARDS 2  2  1 normal 1 21-Jan-2016 27-Jan-2016 1 6 3 1 3 2 . 2 . .
2   . 66.80 2  1 Normal 2  2  2  1 23-Jan-2016 29-Jan-2016 1 6 6 2 . 2 . 2 . .
2  Streptococcus pneumonia. 392.50 2  1 Normal 1 Diffuse sulcal effacement2  1 Bilateral fronto paraeital leptomenineal enhanceme1 29-Jan-2016 05-Feb-2016 1 7 7 2 . 2 . 2 . .
3   . 469.00 2  2  2  2  1 Flair HI,leptomeningeal enhancement1 23-J -2016 31-Jan-2016 1 8 8 2 . 2 . 2 . .
2  no growth 16 110.00 1 few pus cells no bacteria1 no mal 1 normal 2  1 patchy area of FLAIR sulcal HI,dif dur thic, enhan1 31-Jan-2016 08-Feb-2016 1 8 8 2 . 2 . 2 . .
2  no growth. 110.00 1 few pus cells no acteria1 normal 2  2  1 flair sulcal HI ,dural thickening1 31-Jan-2016 08-Feb-2016 1 9 9 2 . 2 . 2 . .
.   . . .  1 normal 1 normal 2  2  1 23-Jan-2016 04-Feb-2016 1 12 12 2 . 2 . 2 . .
.   . . .  1 NORMAL 1 cerebral edema 2  2  1 21-Jan-2016 04-Feb-2016 1 14 10 1 4 2 . 1 4 24
.   . . .  1 NORMAL 2  2  1 Scattered Flair HI,aised ICT1 23-Jan-2016 06-Feb-2016 1 14 14 2 . 2 . 2 . .
.   . . .  1 normal 1 increased ICT 2  1 scattered flair HI,leptomeningeal enhancement1 23-Jan-2016 06-Feb-2016 1 14 14 2 . 2 . 2 . .
.   . . .  1 normal 1 features of raised ICT2  2  1 02-Jan-2016 16-Jan-2016 1 16 11 1 5 2 . 1 2 26
.   . . .  1 NORMAL 2  2  2  1 11-Jan-2016 30-Jan-2016 1 19 10 1 9 2 . 1 2 26
.   . . .  2  1 feature of raised ICT2  2  1 02-Jan-2016 26-Jan-2016 1 24 . 1 5 2 . 1 2 26
2   . 97.50 2  2  1 normal 2  1 subtle flair sulcal hyperintensity - frontal1 29-Feb-2016 02-Mar-2016 2 2 2 2 . 2 . 2 . .
3   . 35.10 2  1 nomal 1 normal 2  2  1 26-Feb-2016 01-Mar-2016 2 4 4 2 . 2 . 2 . .
3   . 71.50 2  1 normal 1 chonic infarct in left capsuloganglionic region2 2  1 21-Feb-2016 26-Feb-2016 2 5 5 2 . 2 . 2 . .
2   . 51.90 2  1 Normal 2  2  1 leptomeningeal enhancement,diffuse swelling HI1 21-Feb-2016 27-Feb-2016 2 6 6 2 . 2 . 2 . .
3   . 51.10 2  1 NOMAL 1 Cerebral and cerebellar atopy2  2  1 18-Feb-2016 25-Feb-2016 2 7 2 1 5 2 . 2 . .
2  no growth. 85.00 .  1 normal 2  2  2  1 21-Mar-2016 23-Mar-2016 3 3 1 2 2 1 2 2 . .
.   . . .  1 normal 2  2  2  1 26-Mar-2016 30-Mar-2016 3 4 4 2 . 2 . 2 . .
2   . 72.00 1 few pus cells, no bacteria1 Normal 1 Foramen magnum contents slightly crowded.  1 Meningeal inflammation, FLAIR HI1 03-Mar-2016 08-Mar-2016 3 5 5 2 . 2 . 2 . .
.   . 126.70 1 Negative 1 Normal 1 Normal .  .  1 05-Mar-2016 10-Mar-2016 3 5 5 2 . 2 . 2 . .
.   . 68.60 1 no pus 1 normal 1 normal 2  2  1 08-Mar-2016 13-Mar-2016 3 5 1 1 4 1 1 1 3 .
1 HSV,EBV . 239.40 2  1 Normal 1 Normal 2  1 subtle leptomenigeal enhancement,thickened tentori1 25-Mar-2016 30-Mar-2016 3 5 5 2 . 2 . 2 . .
.   . 162.50 1 Negative 1 Normal .  .  1 Meng enhnmnt, Nodular&ring enhng lesions1 23-Mar-2016 30-Mar-2016 3 7 . 2 . 2 . 2 . .
1 mycobacteium tuberculosis . 810.00 1 many pus cells 2  1 normal 2  2  1 26-Mar-2016 03-Apr-2016 3 8 8 2 . 2 . 2 . .
3   . 207.60 2  1 nomal 1 diffuse cerebral atropy2  2  1 20-Mar-2016 29-Mar-2016 3 9 2 1 7 2 . 1 5 23
2   . 262.50 .  .  1 Age related cerebral atrophy, prominent ventricles.  .  1 29-Mar-2016 14-Apr-2016 3 16 . 2 . 2 . 2 . .
.   . . .  2  2  2  2  1 25-Apr-2016 26-Apr-2016 4 1 1 2 . 2 . 2 . .
.   . . .  2  2  2  2  1 26-Apr-2016 28-Apr-2016 4 2 2 2 . 2 . 2 . .
.   . . .  1 Normal 2  2  2  1 21-Apr-2016 24-Apr-2016 4 3 3 2 . 2 . 2 . .
.   . . .  1 Bilateaal infiltates2  2  2  1 24-Apr-2016 27-Apr-2016 4 3 1 2 . 2 . 1 2 26
.   . . .  1 normal 1 normal 2  2  1 24-Apr-2016 28-Apr-2016 4 4 4 2 . 2 . 2 . .
.   . . .  1 Normal 1 Normal .  .  1 26-Apr-2016 01-May-2016 4 5 5 2 . 2 . 2 . .
.   . . .  1 normal 2  2  2  1 27-Apr-2016 02-May-2016 4 5 3 1 2 1 2 2 . .
.   . . .  1 normal 1 age related cortical volume loss2  2  1 16-Apr-2016 22-Apr-2016 4 6 6 2 . 2 . 2 . .
3   . 50.10 2  1 Normal 2  2  2  1 22-Apr-2016 28-Apr-2016 4 6 6 2 . 2 . 2 . .
2   . 85.60 2  1 NORMAL 2  2  2  1 01-Apr-2016 08-Apr-2016 4 7 7 2 . 2 . 2 . .
3   . . 2  1 normal 1 paucity of sulci over cerebal hemisphere2  1 l ptomenigeal enhancement1 08-Apr-2016 16-Apr-2016 4 8 8 2 . 2 . 2 . .
2   . 51.30 2  1 Normal 1 Normal 2  2  1 18-Apr-2016 26-Apr-2016 4 8 8 2 . 2 . 2 . .
.   . . .  1 NoRMAL 1 NORMAL 2  2  1 21-Apr-2016 29-Apr-2016 4 8 8 2 . 2 . 2 . .
2   . 38.50 2  1 Normal 2  2  2  1 23-Apr-2016 01-May-2016 4 8 8 2 . 2 . 2 . .
.   . . .  2  2  2  2  1 09-Apr-2016 18-Apr-2016 4 9 3 1 6 1 . 1 5 .
.   . . .  1 Normal 2  2  2  1 27-Apr-2016 06-May-2016 4 9 9 2 . 2 . 2 . .
.   . 52.70 .  2  2  1 PUJ obstruction 1 secondary vasculidis changes1 21-Apr-2016 01-May-2016 4 10 10 2 . 2 . 2 . .
3   . . 2  1 Normal 1 Increased ICT 2  1 Flair Sulcal leptomeningeal enhancement1 08-Apr-2016 20-Apr-2016 4 12 12 2 . 2 . 2 . .
.   . . .  1 Normal 1 Cerebal atropy,age elated2  2  1 15-Apr-2016 28-Apr-2016 4 13 13 2 . 2 . 2 . .
2   . 27.50 1 no pus cell 2  2  2  1 normal 1 20-Apr-2016 04-May-2016 4 14 14 2 . 2 . 2 . .
.   . . .  1 Normal 2  2  2  1 02-May-2016 03-May-2016 5 1 1 2 . 2 . 2 . .
3   20 196.70 1 occ pus cells,no bacteria1 normal 1 no significant abnormality2  2  1 19-May-2016 20-May-2016 5 1 2 2 . 2 . 2 . .
.   . . .  1 Normal 2  2  2  1 03-May-2016 06-May-2016 5 3 3 2 . 2 . 2 . .
.   . . .  1 Normal 1 Normal 2  2  1 04-May-2016 07-May-2016 5 3 3 2 . 2 . 2 . .
2  no growth 3 117.90 1 no pus cells ,no bacteria1 no mal 1 normal 2 not done 2 notdone 1 26-May-2016 30-May-2016 5 4 4 2 . 2 . 2 . .
.   . . .  1 Normal 2  2  2  1 10-May-2016 15-May-2016 5 5 5 2 . 2 . 2 . .
3   3 252.30 2 RBC was 68000 1 Normal 1 Normal 2  1 Normal 1 18-May-2016 23-May-2016 5 5 5 2 . 2 . 2 . .
3   . 109.50 1 mod pus cells 1 normal 2  2  2  1 14-May-2016 21-May-2016 5 7 7 2 . 2 . 2 . .
3   . 32.70 2  1 Normal 1 Normal 2  2  1 03-May-2016 11-May-2016 5 8 8 2 . 2 . 2 . .
3   . 66.20 1 occasional pus cell2  2  2  1 3mm calcified granulamo in L paietal1 05-May-2016 13-May-2016 5 8 8 2 . 2 . 2 . .




DYSFUNCTTYPESDYSANTIBIOTANTIYESANTIDURAZITH AZITHDAYDOXY DOXYDAYCFTRI CFTRIDAYPIPTA PIPTADAYMERO MERODAYPENCIL PENCILDACYCLOVIACYDRUATT STREOIDSANTIEPILHAI TYPEHAIMRSAD MRSDIS MRS1MNTHCONDDISCHAREDAMA DISCHARGAT1MONTHFIALDIAGFINALDIA
2  1  . 2 . 2 . 1 16 2 . 2 . 2 . 2 . 2 2 2 2  2 3 . 2 2 1 0 acute bacterial meningitis 
2  1  . 2 . 2 . 1 14 2 . 2 . 2 . 2 . 2 2 2 2  0 0 . 2 2 1 0 Pyogenic Meningitis 
2  2  . . . . . . . . . . . . . 1 14 2 2 2 2  0 4 . 1 1 1 0 autoimmune encephalitis 
2  2  . . . . . . . . . . . . . 2 . 2 2 2 2  0 0 . 1 1 1 0 viral encephlitis 
1 renal 2  . 2 . 2 . 2 . 2 . 2 . 2 . 2 . 2 2 2 2  0 0 . 2 2 1 0 Cryptococcal meningitis 
2  1 Ceftriaxone, ciprofloxacin. . . . . 1 8 . . . . . . 2 . 2 2 2 2  0 2 . 2 2 1 0 Pneumococcal meningitis 
1 Renal 2  . . . . . . . . . . . . . 2 . 2 2 2 2  0 0 . 2 2 1 0 Heat stroke 
2  2  . . . . . . . . . . . . . 2 . 2 2 2 2  3 3 . 2 2 1 0 heat stroke 
2  2  . . . . . . . . . . . . . 2 . 2 2 2 2  0 0 . 2 2 1 0 Heat stroke 
2  2  . . . . . . . . . . . . . 2 . 1 1 2 2  0 0 . 2 2 1 0 tuberculosis meningitisviral me ingooenephalitis
2  1 Ceftriaxone, Doxycycline2 2 . 1 2 1 2 2 . 2 . 2 . 2 . 2 2 2 2  0 5 . 1 1 1 0 Viral meningoencephalitisPartially tre ted bacterial meningitis
2  2  . . . . . . . . . . . . . 2 . 1 1 2 2  0 0 . 2 2 1 0 Probable Tuberculous meningitisviral meningoencephalitis
2  1 Ceftriaxone 14 2 . 2 . 1 14 2 . 2 . 2 . 1 14 2 2 2 2  0 4 . 2 2 1 0 Acute viral encephalitisHypernatremia (metabolic encephalopathy)
2  1  . 2 . 2 . 1 14 2 . 2 . 2 . 2 . 2 2 2 2  0 0 . 2 2 1 0 Viral meningitispar ally treated bacterial meningitis
2  1  . . . . . 1 14 . . . . . . 1 2 2 2 2 2  0 0 . 2 2 1 0 Partially treated bacterial meningitisViral meningitis
2  1 Ceftriaxone. 2 . 2 . 1 14 . . . . . . 1 14 2 2 1 1 VAP 0 5 . 2 2 1 0 Partially treated pyogenicViral meningoencephalitis
2  1  . . . . . 1 2 . . . . . . 2 . 2 2 2 2  2 2 . 2 2 1 0 Neuroleptic malignant syndrome 
2  1  . . . . . . . . . 1 14 . . 1 . 2 2 2 2  0 4 . 2 2 1 0 Sepsis associated encephalopathyESBL E.coli bacteremia
2  1  . 1 10 2 . 1 10 2 . 2 . 2 . 1 14 2 2 2 2  0 0 0 1 1 1 1 Scrub Meningitis 
2  1  . 1 5 1 7 2 . 2 . 2 . 2 . 2 . 2 2 2 2  0 0 0 2 2 1 1 Scrub Encephalitis 
2  2  . . . . . . . . . . . . . 2 . 2 2 2 2  0 0 0 2 2 1 1 Metabolic encephalopathyAcut  undiffentiated febrile illness- viral fever
2  1  . 1 5 2 . 2 . 2 . 2 . 2 . 2 . 2 2 2 2  0 0 0 2 2 1 1 Scrub encephalitis 
2  1  . 1 5 1 7 2 . 2 . 2 . 2 . 2 . 2 2 2 2  0 0 0 2 2 1 1 scrub encephalitis-cerebellitis 
2  1  . 1 4 1 7 1 4 2 . 2 . 2 . 1 4 2 2 2 2  0 0 0 2 2 1 1 Scrub encephalitis 
2  2  . . . . . . . . . . . . . 2 . 2 2 2 2  0 0 0 1 1 1 1 Metabolic encephalopathy- hyperglycemiaAcut  undiffeentiated febrile illness- viral fever
1 renal, hepatic 1  . 1 6 1 12 2 . 1 2 2 . 2 . 2 . 2 2 2 2  0 3 0 2 2 1 1 scrub submeningoencephalitis 
1 Renal 1  . 2 . 2 . 1 14 2 . 2 . 2 . 1 2 2 2 2 2  0 0 0 2 2 1 1 Partially treated bacterial meningitidViral meningitis
2  1  . 2 . 2 . 1 14 2 . 2 . 2 . 2 . 2 2 2 2  0 0 0 2 2 1 1 Pneumococcal meningitis 
2  1  . 1 5 2 . 2 . 2 . 2 . 2 . 2 . 1 1 2 2  0 0 0 2 2 1 1 TB meningitisScrub meningitis
2  1  . 2 . 2 . 1 11 2 . 2 . 2 . 1 2 1 1 2 2  0 0 0 2 2 1 1 tuberculous meningitisViral meningoencephalitis
2  1  . 2 . 2 . 1 9 2 . 2 . 2 . 1 2 1 1 2 2  0 0 0 2 2 1 1 Tuberculous meningitis 
1 renal 1  . 2 . 2 . 2 . 2 . 2 . 2 . 2 . 2 2 2 2  0 0 0 2 2 1 1 viral meningoencephalitis 
2  1  . 2 . 2 . 2 . 1 6 1 3 2 . 1 14 2 2 2 2  0 0 0 2 2 1 1 Varicella meningoencephalitisclinical
2  2  . . . . . . . . . . . . . 1 141 2 2 2 2  0 0 0 1 1 1 1 Asceptic meningitis- Viral 
2  1  . 2 . 2 . 1 14 2 . 2 . 2 . 1 14 2 2 2 2  0 0 0 2 2 1 1 Viral meningoenephaltisPartially treated bacterial
2  1  . 1 5 2 . 1 7 2 . 2 . 2 . 1 4 2 2 2 2  0 0 0 2 2 1 1 Scrub encephalitis 
1 RENAL 1  . 1 5 2 . 2 . 1 5 1 2 2 . 2 . 2 2 2 1 vap 0 0 0 2 2 1 1 Scrub meningoencephalitis 
2  1  . 1 15 . . 1 15 . . . . . . 1 15 2 2 1 2  0 0 0 2 2 1 1 Scrub meninoencephalitis 
2  1  . 2 . 2 . 1 14 2 . 2 . 2 . 2 . 2 2 2 2  0 0 0 2 2 1 1 partially treated pyogenic meningitisviral meningoencephalitis
2  2  . . . . . . . . . . . . . 2 . 2 2 2 2  0 0 0 1 1 1 1 Acute psychosisAcute febrile illness
2  1  . 1 5 2 . 2 . 2 . 1 10 2 . 2 . 2 2 2 2  0 2 0 2 2 1 1 Scrub encephalitis 
2  1  . 1 5 2 . 2 . 2 . 2 . 2 . 1 5 2 2 2 2  0 0 0 2 2 1 1 Viral meningoencephalitis 
1 RENAL 1  . 2 . 2 . 2 . 2 . 1 10 2 . 2 . 2 2 2 2  0 0 0 2 2 1 1 Sepsis related encephalopathy 
1 renal 1  . . . . . . . . . . . . . 2 . 2 2 2 2  0 0 0 2 2 1 1 Sepsis associated encephalopathy 
1 RENAL 1  . 1 3 2 . 2 . 1 4 2 . 2 . 2 . 2 2 2 2  0 0 0 2 2 1 1 heat stroke 
2  1  . 1 9 1 6 . . . . . . . . 1 3 2 2 2 2  0 0 0 2 2 1 1 MeningoencephalitisMumps, scrub
2  1  . 1 15 . . . . 1 6 . . . . 2 . 2 2 2 2  0 0 0 2 2 1 1 Scrub meningoencephalitis 
2  1  . 1 10 2 . 1 2 2 . 2 . 2 . 2 . 2 2 2 2  0 0 0 2 2 1 1 scrub meningoencephalitiscellutis, septic shock, encephalopathy
2  1  . 2 . 1 1 1 3 2 . 2 . 2 . 1 14 2 2 2 2  0 0 0 2 2 1 1 HSV MeningoencephalitisEBV meningoencephaliltis
2  2  . . . . . . . . . . . . . 2 . 1 1 2 2  0 3 0 2 2 1 1 tuberculous meningitis 
2  1  . 1 4 2 . 2 . 2 . 2 . 2 . 2 . 1 1 1 2  0 0 0 2 2 1 1 tuberculosis meningitis - culture proven 
1 renal 1  . 1 4 1 10 2 . 2 . 2 . 2 . 2 . 2 2 2 2  0 0 0 2 2 1 1 Scrub Meningoencephalitis 
2  2  . . . . . . . . . . . . . 1 10 2 2 2 2  0 0 0 2 2 1 1 Viral meningoencephalitis 
2  2  . . . . . . . . . . . . . 2 . 2 2 2 2  0 3 0 1 1 1 1 heat stroke 
2  2  . . . . . . . . . . . . . 2 . 2 2 2 2  0 0 0 2 2 1 1 Heat stroke 
2  2  . . . . . . . . . . . . . 2 . 2 2 2 2  0 0 0 2 2 1 1 Heat stroke 
2  1  . 1 51 2 . 2 . 2 . 2 . 2 . 2 . 2 2 2 2  0 0 0 2 2 1 1 Heat stroke 
2  2  . . . . . . . . . . . . . 2 . 2 2 2 2  0 0 0 2 2 1 1 heat stroke 
2  2  . . . . . . . . . . . . . 2 . 2 2 2 2  0 0 0 2 2 1 1 Heat stroke 
1 renal failure 1  . . . . . . . . . . . . . 2 . 2 2 2 2  0 0 0 2 2 1 1 heat stroke 
2  2  . . . . . . . . . . . . . 2 . 2 2 2 2  0 0 0 2 2 1 1 heat stroke 
1 Renal 1  . 2 . 2 . 2 . 1 3 1 4 2 . 2 . 2 2 2 2  0 3 0 2 2 1 1 Heat Stroke 
2  1  . 2 . 2 . 1 14 2 . 2 . 2 . 1 3 . . . .  0 3 0 2 2 1 1 patially teated bacterialviral meningoencephalitis
2  1  . 2 . 2 . 1 14 2 . 2 . 2 . 1 2 2 2 2 2  0 0 0 2 2 1 1 acute bacterail meningitiscrub eningitis
2  1  . 2 . 2 . 1 5 2 . 2 . 2 . 1 3 2 2 2 2  0 0 0 1 1 1 1 Viral meningoencephaltisPartially tre ted meningoencephalitia
1 renal 2  . . . . . . . . . . . . . 2 . 2 2 2 2  0 0 0 2 2 1 1 Heat Stroke 
2  1  . 2 . 2 . 1 14 2 . 2 . 2 . 2 . 2 2 2 2  0 0 0 2 2 1 1 Partially treated pyogenic meningitisviral meningoencephalit s
2  2  . . . . . . . . . . . . . 2 . 2 2 2 2  0 2 0 2 2 1 1 Toxic encephalopthy-Alcohol withdrawal syndrometoxic encephalopathy
2  2  . . . . . . . . . . . . . 2 . 2 2 2 2  0 0 0 2 2 1 1 Heat stroke 
2  2  . . . . . . . . . . . . . 2 . 1 1 2 2  0 0 0 2 2 1 1 tuberculosis meningitis 
2  1  . 2 . 2 . 1 14 2 . 2 . 2 . 1 14 2 2 2 2  0 0 0 2 2 1 1 Viral meningoencephalitis 
2  1  . 2 . 2 . 2 . 1 10 2 . 2 . 2 . 2 2 2 2  0 3 0 2 2 1 1 Heat stroke 
2  1  . 2 . 2 . 2 . 1 4 1 7 2 . 1 3 2 2 1 1 ESBL 0 2 0 2 2 1 1 autoimmune encepha;itis syndrome 
2  2  . . . . . . . . . . . . . 2 . 2 2 2 2  0 0 0 2 2 1 1 Heat stroke 
2  1  . 2 . 2 . 1 1 2 . 2 . 2 . 2 . 1 1 1 2  0 0 0 1 1 1 1 Tuberculous meningitis- probable 
2  2  . . . . . . . . . . . . . 2 . 2 2 2 2  0 0 0 2 2 1 1 Heat strokeDiabetes Mellitus
2  2  . . . . . . . . . . . . . 2 . 2 2 2 2  0 2 0 2 2 1 1 Heat stroke 
2  1  . 2 . 2 . 1 3 2 . 2 . 2 . 1 3 2 2 2 2  0 0 0 2 2 1 1 Viral meningoencephalitis?asceptic
2  2  . . . . . . . . . . . . . 2 . 2 2 2 2  0 1 0 2 2 1 1 Heat stroke 
2  2  . . . . . . . . . . . . . 2 . 2 2 2 2  0 0 0 2 2 1 1 Alcohol withdrawal syndromeViral meningoencephalitis
2  2  . . . . . . . . . . . . . 2 . 1 1 2 2  0 0 0 2 2 1 1 TB Meningitis 
2  2  . . . . . . . . . . . . . 2 . 2 2 2 2  0 0 0 2 2 1 1 Heat stroke 
2  1  . 2 . 2 . 1 4 2 . 2 . 2 . 1 2 1 1 2 2  0 0 0 2 2 1 1 Tuberculous meningitis 





52 2 1 3 Manual labourBiscuit factory worker9989258503 1 1 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2
31 1 1 3 manual labourer - chicken seller97864253332 1 1 2 2 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2
65 1 1 7 farmer 9884771830 1 1 2 2 2 1 2 2 1 2 1 2 2 2 2 2 2 2 2 2 1 2
31 2 2 5 house wife 9159256242 1 1 2 2 2 2 1 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2
70 1 2 5 house wife 9159495897 1 1 2 2 2 1 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2
22 2 1 2 student 9440808232 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
18 1 1 2 student 9894636680 1 1 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
60 1 1 3 Manual labourer-farmer 9956218906 1 1 2 2 2 2 2 1 1 2 1 1 2 2 2 2 2 2 2 2 2 2
34 1 1 3 manual labourer 9787463469 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
36 1 1 3 Manual labourer-Works in a hotel9944237525 1 1 2 2 1 2 2 2 1 2 1 1 2 2 2 2 2 2 2 1 2 2
85 2 2 5 Housewife 9885267122 1 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2
25 1 2 5 Housewife 9655341199 1 1 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 1 2
35 1 1 3 Manual labour 9751231959 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2
67 1 1 3 manual labourer 9677120970 1 1 2 1 1 2 2 2 1 2 1 2 2 2 2 2 2 2 2 1 2 2
20 1 1 2 Student 8678995979 1 1 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
70 2 2 5 Housewife 9849983189 1 1 2 2 2 2 1 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2
35 2 2 5 house wife 9550531267 1 2 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1 3 3
64 2 1 3 Manual labourer 9198859854 1 1 2 2 2 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2
55 3 1 3 manual labourer 9143226713 1 1 2 1 1 2 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2
40 2 2 5 housewife 9550688541 1 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
28 1 1 3 manual labourer 9597144315 1 1 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
40 3 1 3 manual labourer 9333830803 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
25 2 2 5 housewife 8897172235 1 1 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2
65 1 1 3 manual labourer 9443098444 1 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 1 2 2
71 2 1 8 Retired municipal officer 9492820227 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 1 1 2 1 2 2 2
46 1 1 3 manual labourer 9942416855 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
74 1 1 3 manual laboure 9751380303 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
27 1 1 6 Passport office employee 9994597745 1 1 1 2 2 2 1 2 1 1 1 2 2 2 2 2 2 2 2 1 2 2
53 1 2 5 house wife 9789402030 1 2 2 2 2 2 1 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2
24 1 2 5 housewifr 9787579113 1 1 2 2 2 1 1 2 1 2 1 2 2 2 2 1 2 2 2 2 2 2
65 3 2 5 housewife 9038386897 1 1 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 1 2
25 4 1 3 manual labourer 1725210120 1 1 2 2 2 1 1 2 1 2 1 1 2 2 2 2 2 2 2 1 2 2
17 2 1 2 student 9701104540 1 1 2 2 2 1 1 2 1 2 1 2 2 2 2 2 2 2 2 1 2 2
48 1 2 5 housewife 9944654657 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2
22 4 1 2 student 7736583788 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 1
40 1 2 5 housewife 9442132366 1 1 1 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2
53 1 1 8 teacher 988423312 1 1 1 2 1 1 1 1 1 2 1 2 2 2 2 2 2 2 2 2 2 2
61 1 2 5 Housewife 9940813212 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1 1 2
23 1 1 1 Completed degree 8695879952 1 1 1 1 2 2 1 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2
65 1 1 3 Manual labour 9367799032 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1
40 1 1 3 manual labourer 9585896776 1 1 2 2 1 2 1 2 1 2 1 2 2 2 2 2 2 2 2 1 2 2
57 1 2 5 Housewife 9787668794 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1
51 1 1 3 labourer . 1 1 2 2 1 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2
30 1 1 0  9092183644 1 1 1 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2
25 1 2 5 housewife 9585579210 1 1 2 2 2 2 1 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2
16 1 1 2 student 7200538853 1 1 2 2 2 2 1 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2
29 1 2 5 Hoousewife 9943141800 1 1 2 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2
60 1 2 5 housewife 9894231904 1 1 2 2 2 1 1 1 1 1 1 2 2 2 2 2 2 2 2 1 2 2
50 1 2 5 housewife 9159583017 1 1 2 1 2 1 2 2 2 . . 1 2 2 2 2 2 2 2 1 2 2
69 1 2 5 Housewife 7639473311 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
59 2 1 4 Telephone line worker 9494742144 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 1 1 2 2 1 1 2
28 1 1 0  9500958319 1 1 2 1 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
30 1 2 0  9952192554 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 1 2
61 1 1 3 manual labourer 9940778578 1 1 2 2 2 2 2 2 1 2 1 2 1 2 2 2 2 2 2 2 2 2
25 1 2 0  9786740388 1 2 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2
31 1 2 4 labourer- welder 8939398584 1 1 1 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 1 2 2
70 1 2 0  9751613501 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
65 1 2 0  9788302513 1 1 2 2 2 2 1 2 1 . 1 2 2 2 2 2 2 2 2 2 2 2
15 2 1 0  9603863544 1 1 2 2 2 1 1 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2
16 3 1 0  7766924885 1 1 2 2 2 1 1 2 1 2 1 2 2 2 2 2 2 2 2 1 2 2
45 1 1 0  9659928321 1 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 1 2 2
62 2 1 3 manual labourer 9494070744 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
50 1 1 8 Tuition teacher 9751557115 1 1 2 2 2 2 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2
23 2 1 2 student 9494745877 1 1 2 2 2 1 1 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2
85 1 2 5 housewwife 9843608811 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2
54 2 1 6 Electricity line manager 9490101220 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 1 1 2 2 1 2 2
70 1 1 3 labourer 9840290295 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2
65 2 1 3 manual labourer 8050819729 1 1 2 2 2 2 2 1 2 2 2 2 1 2 1 2 2 2 2 2 2 2
64 1 2 0  9597376591 1 1 2 1 2 2 2 2 1 . 1 2 2 2 2 2 2 2 2 1 2 2
16 1 2 2 Student . 1 1 2 2 2 2 2 2 2 2 2 1 1 2 1 2 2 2 2 1 2 2
31 1 2 4 carpentetr 9787459586 1 1 2 2 2 1 1 2 2 2 2 1 2 2 2 2 2 2 2 1 2 2
72 1 2 0  9894433574 1 1 1 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
51 1 1 3 manual labourer 9751193279 1 1 2 1 2 1 2 2 1 2 1 1 2 2 2 2 2 2 2 2 2 2
32 1 1 3 Lifts luggage at bus stand 9789920576 1 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2
36 1 1 0  . 1 2 1 2 2 2 1 2 2 2 2 2 2 2 1 2 2 2 2 1 1 2
55 1 1 0  8122095676 1 1 2 2 1 1 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2
59 1 1 0  7598401610 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
22 2 1 2 Student 8978239530 1 1 1 2 2 1 1 2 1 2 1 2 2 2 2 2 2 2 2 1 1 2
16 1 2 2 student 9788889600 1 1 2 1 2 1 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2
50 2 1 0  . 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2
50 1 1 0  9944336904 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
23 1 2 0  9790522476 1 1 2 1 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2
53 2 1 3 manual labourer 9500953217 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
59 1 2 5 housewife 9843516585 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2




2 2 2 2 4 6 4 14 2 2 2 2 26 104 120 80 97 99.00   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 20 72 110 80 98 99.00   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 2 12 2 2 2 2 24 102 150 90 89 99.00   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 5 15 2 2 2 2 22 86 120 80 98 98.20   2 2 2 2 2 2 2 2 2
2 2 2 2 3 5 2 10 2 2 2 2 35 114 180 100 86 99.00   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 24 94 100 60 98 96.00   2 2 2 2 2 2 2 2 2
2 2 2 2 4 5 2 11 2 2 2 2 20 102 100 60 92 100.00   2 2 2 2 2 2 2 2 2
2 2 2 2 2 5 1 8 2 2 2 2 22 61 140 80 99 99.00   1 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 20 80 180 100 99 99.80   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 5 15 2 2 2 2 36 130 160 90 95 102.00 Seizure disorder 2 1 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 28 90 130 80 99 103.00   1 2 2 2 2 2 2 2 2
2 2 2 2 4 6 5 15 2 2 2 2 20 80 90 60 99 98.60   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 24 72 90 60 96 96.60   2 2 2 2 2 2 2 2 2
2 2 2 2 4 5 4 13 2 2 2 2 20 104 160 100 96 100.00   2 1 2 2 2 2 2 2 2
2 2 2 2 4 6 5 15 2 2 2 2 20 96 100 60 97 96.70   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 20 72 148 74 99 99.40   2 1 2 2 2 2 2 1 2
1 2 2 2 4 6 5 15 2 2 2 2 22 118 110 80 99 98.00   2 2 2 2 2 2 2 2 1
2 2 2 2 1 2 2 5 2 2 2 2 24 100 160 70 99 99.00 RIGHT EYE CONJUNCTIVITIS 1 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 22 114 170 90 96 98.40   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 5 15 2 2 2 2 24 114 90 50 97 97.80   2 2 2 2 2 2 2 2 2
2 2 2 2 3 5 2 10 2 2 2 2 20 90 110 70 98 98.00   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 5 15 2 2 2 2 26 144 90 70 93 101.40 Rashes Eschar rt groin 2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 5 15 2 2 2 2 22 74 120 80 98 97.80   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 1 2 2 20 86 100 60 94 99.70   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 20 122 110 80 95 97.70 OA both knees 1 1 2 2 2 2 2 2 2
2 2 2 2 4 6 5 15 2 2 2 2 22 88 120 80 97 98.00   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 20 110 140 80 95 98.60   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 22 75 130 80 99 98.20   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 5 15 2 2 2 2 22 112 130 80 97 99.00   1 1 2 2 2 2 2 2 2
2 2 2 2 4 6 5 15 2 2 2 2 18 82 100 60 99 99.00   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 5 15 2 2 2 2 20 68 120 80 98 101.20 CSF rhinorrhoeaHypothyroidism 2 1 2 2 2 2 2 2 2
2 2 2 2 1 1 1 3 1 2 2 2 24 97 100 60 99 95.00 Nephrotic syndrome FSGS on steroids2 2 2 2 2 2 2 2 2
2 2 2 2 3 5 4 12 2 2 2 2 22 128 110 70 99 102.00   2 2 2 2 2 2 2 2 2
2 2 2 2 6 4 5 15 1 2 2 2 20 72 110 70 97 98.00 Eschar Hypothyroidism 2 1 2 2 2 2 2 2 2
2 2 2 2 4 6 5 15 2 2 2 2 20 94 140 100 . .   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 20 116 70 0 98 98.40   2 2 2 2 2 1 2 2 2
2 2 2 1 4 5 2 11 2 2 2 2 20 106 150 100 99 99.00   1 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 22 80 140 90 98 99.00   1 1 1 2 1 2 2 2 2
2 2 2 2 2 4 1 7 2 2 2 2 24 108 130 80 95 103.00   2 2 2 2 2 2 2 2 2
2 1 2 2 3 5 3 11 2 2 2 2 16 106 100 70 99 97.00   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 22 120 100 60 99 98.00   2 2 2 2 2 2 2 2 2
2 2 2 2 4 5 4 13 2 2 2 2 24 94 100 60 92 100.60   2 2 2 2 2 2 2 2 2
2 2 2 2 1 5 2 8 2 2 2 2 22 116 140 90 99 .   1 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 18 92 110 60 98 98.80   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 1 2 2 2 74 88 70 0 99 97.00   2 2 2 2 2 2 2 2 2
2 2 2 2 2 5 2 9 2 2 2 2 24 88 70 40 95 .   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 5 15 2 2 2 2 20 98 100 70 100 98.80   2 2 2 2 2 2 2 2 2
2 2 2 2 3 5 3 11 2 2 2 2 20 92 140 80 92 98.00   1 1 2 2 2 2 2 2 2
2 2 2 2 2 5 2 9 2 2 2 2 18 82 180 80 91 .   1 1 2 2 2 2 2 2 2
2 2 2 2 3 5 2 10 2 2 2 2 24 96 130 70 97 99.00   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 1 1 2 2 30 80 100 60 92 98.20   1 1 2 2 2 2 2 1 2
2 2 2 2 4 4 6 14 2 2 2 2 24 48 110 0 96 .   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 5 15 2 2 2 2 22 67 120 86 100 98.80   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 24 98 100 60 96 99.10   1 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 20 92 90 60 97 99.00   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 16 122 110 60 96 99.60 Loose stools 2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 26 168 110 80 95 99.00 Lt side axilla - Eschar 1 1 2 2 2 2 2 1 2
2 2 2 2 4 6 5 15 2 2 2 2 32 118 110 80 90 99.00   1 1 2 2 2 2 2 2 2
2 2 2 2 4 5 2 11 2 2 2 2 24 90 94 60 91 101.50   2 2 2 2 2 2 2 2 2
2 2 2 2 4 5 3 12 2 2 2 2 20 96 120 80 96 100.10   2 2 2 2 2 2 2 2 2
2 2 2 1 1 5 2 8 2 2 2 2 44 124 130 80 94 99.00   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 5 15 2 2 2 2 18 138 100 60 96 102.00   2 2 2 2 2 2 2 2 2
2 2 2 2 3 6 4 13 2 2 2 2 20 921 100 60 94 101.20 Rhinitis  2 2 2 2 2 2 2 2 2
2 2 2 2 4 3 1 8 2 2 2 2 29 90 130 80 99 .   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 24 82 120 80 94 99.00   2 1 2 2 2 2 2 2 2
2 2 2 2 4 6 5 15 2 2 2 2 32 112 150 80 96 104.00 Rash  1 1 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 1 2 2 2 30 110 110 70 . 104.00 Left lower limb swelling 1 2 2 2 1 2 2 2 2
2 2 2 1 2 5 3 10 2 1 2 2 24 62 80 60 98 99.00   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 5 15 2 2 2 2 24 92 90 50 95 98.20 Eschar noted in rt shoulder 2 2 2 2 2 2 2 2 2
2 2 2 2 2 5 2 9 2 2 2 2 32 150 120 80 . . Urine ketone +GRBS 311, Hb 2.42 2 2 2 2 2 2 2 2
1 2 2 2 1 5 1 7 2 2 2 2 40 110 110 80 99 102.00   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 24 84 140 90 96 .   1 1 2 2 2 2 2 2 2
2 2 2 2 2 2 5 9 2 2 2 2 20 100 130 90 66 99.00   2 2 2 2 2 2 2 2 2
2 2 2 2 4 5 3 12 2 2 1 2 20 122 80 60 97 97.20 Visual hallucination 2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 5 15 2 2 2 2 20 78 0 0 99 99.00 Abdominal pain 2 2 2 2 2 2 2 2 2
2 2 2 2 4 5 2 11 2 2 2 2 28 120 110 70 86 97.00   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 20 106 150 70 . 100.20 Psychiatric illness 1 1 2 2 2 2 2 2 2
2 2 2 2 2 5 2 9 2 2 2 2 20 60 120 80 100 98.60   2 2 2 2 2 2 2 2 2
2 2 2 2 3 5 2 10 2 2 2 2 44 138 100 80 97 . Vesicular eruptionsGRBS high 1 2 2 2 2 2 2 2 2
2 2 2 2 2 3 2 7 2 2 2 2 38 140 140 80 96 . Eschar over left anterior chest wall 2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 5 15 2 2 2 2 24 134 90 60 96 102.50 Hiccups  1 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 26 78 140 90 99 102.00   2 2 2 2 2 2 2 2 2
2 2 2 2 3 6 4 13 2 2 2 2 28 100 110 60 96 104.20   2 2 2 2 2 2 2 2 2
2 2 2 2 3 6 4 13 2 2 2 2 26 130 130 80 89 103.60   1 1 2 2 2 2 2 2 2




2  2  2 3 3 3 3  3 3 3 3 . .  16,100 90 7 1 205,000 2 0.60 0.20 76 20 88 . .
2  2  2 3 3 3 3  3 3 3 3 . .  7,800 98 8 1 229,000 2 0.70 0.20 31 18 63 . .
2  2  1 3 3 3 3  3 3 3 3 . .  5,400 86 6 1 166,000 2 0.49 0.10 34 11 90 . .
2  2  2 3 3 3 1 NFGNB 3 3 3 3 . .  15,500 90 3 1 178,000 2 0.21 0.10 36 24 77 . .
2  2  2 3 3 3 2  3 3 3 3 . .  13,800 63 31 2 241,000 2 1.20 0.90 26 19 153 12.50 1.13
2  2  2 3 3 3 3  3 3 3 3 . .  5,800 59 30 2 95,000 2 0.70 0.30 339 267 90 11.60 1.08
2  2  2 2 3 3 3  3 3 3 3 . .  12,600 57 30 2 181,000 2 0.76 0.30 49 13 124 . .
2  1 Native medicine 2 3 3 3 2  3 3 3 3 . .  11,400 80 11 2 194,000 2 1.20 0.40 37 22 126 10.80 1.01
2  2  1 2 3 3 2  3 3 3 3 . .  23,700 87 8 1 359,000 2 0.60 0.20 23 29 87 . .
2  2  1 2 3 3 3  3 3 3 3 . .  600 34 5 2 84,000 2 1.60 0.30 14 59 52 13.60 1.23
2  2  2 3 3 3 3  3 3 3 3 . .  5,100 90 8 1 101,000 2 0.40 0.20 52 12 69 . .
2  2  2 3 3 3 2  3 3 3 3 . .  5,800 83 12 2 . 2 0.50 0.20 16 9 26 . .
2  2  2 1 3 3 2  3 3 3 3 . .  14,600 55 41 2 153,000 2 1.19 0.80 236 267 296 . .
2  2  2 3 3 3 3  3 3 3 3 . .  . . . . 236,000 3 0.40 0.20 52 12 69 11.00 1.03
2  2  2 3 3 3 3  3 3 3 3 . .  8,200 92 6 1 321,000 2 0.50 0.20 36 18 56 . .
2  2  2 3 3 3 3  3 3 3 3 . .  10,000 80 15 2 237,000 3 0.70 0.20 46 14 67 10.60 0.99
2  2  2 2 3 3 2  3 3 3 3 . .  5,700 86 10 1 380,000 2 0.22 0.10 29 6 82 . .
2  2  2 3 3 3 2  3 3 3 3 . .  18,500 94 4 1 192,600 2 1.87 0.80 113 24 61 13.40 1.24
2  2  2 2 2 2 2  2 2 2 2 . .  10,500 59 28 2 93,000 2 0.78 0.40 19 10 257 11.60 1.08
2  2  2 3 3 3 3  3 3 3 3 . .  5,400 42 48 2 191,000 3 0.60 0.20 55 35 60 . .
2  2  2 3 3 3 2  3 3 3 3 . .  11,700 72 . . 302,000 2 0.50 0.20 23 14 82 . .
2  2  2 1 3 3 2  3 3 3 3 . .  6,900 66 32 2 86,000 2 0.70 0.20 120 71 60 11.60 1.08
2  2  2 3 3 3 2  3 3 3 3 . .  15,500 94 5 1 402,000 2 0.56 0.20 20 9 55 10.70 1.00
2  2  2 3 3 3 2  3 3 3 3 . .  13,200 86 7 1 135,000 3 0.70 0.10 83 20 46 . .
2  2  2 3 3 3 2  3 3 3 3 140 1 yeast 18,500 85 6 1 304,000 2 2.10 1.00 28 20 70 . .
2  2  2 2 3 3 2  3 3 3 3 . .  16,700 81 5 1 360,000 2 0.66 0.20 14 10 71 13.80 1.28
2  2  2 3 3 3 2  3 3 3 3 . .  10,500 50 40 2 175,000 2 0.74 0.30 72 43 102 . .
2  2  2 2 3 3 2  3 3 3 3 . .  11,200 74 15 2 171,000 2 1.05 0.40 25 23 64 . .
2  2  2 3 3 3 2  3 3 3 3 . .  8,900 63 29 2 360,000 3 0.60 0.20 20 11 89 . .
2  2  2 2 3 2 2  3 3 3 3 . .  1,900 68 26 2 232,000 2 0.20 0.10 26 6 70 . .
2  2  2 3 3 3 2  3 3 3 3 . .  20,700 93 5 1 328,000 2 0.50 0.20 83 74 146 . .
2  2  2 3 3 3 2  3 3 3 3 . .  24,400 96 2 1 210,000 2 0.20 0.10 42 21 175 14.20 1.31
2  2  2 3 3 3 3  3 3 3 3 . .  15,200 85 7 1 271,000 2 0.85 0.30 34 9 89 . .
2  2  2 1 3 3 2  3 3 3 3 . .  10,900 59 36 2 11,000 3 0.50 0.30 112 32 75 . .
2  2  2 2 3 3 2  3 3 3 3 . .  9,000 69 20 2 145,000 2 0.60 0.20 24 20 84 . .
2  2  2 3 3 3 3  3 3 3 3 . .  4,400 60 25 2 346,000 3 0.26 0.06 22 13 139 . .
2  2  1 1 3 3 2  3 3 3 3 . .  13,100 84 10 1 217,000 2 1.20 0.20 93 67 193 11.50 1.07
2  2  2 3 3 3 3  3 3 3 3 . .  13,800 79 13 2 222,000 3 0.50 0.20 12 8 73 10.70 1.00
2  1 Ayurvedic medicine2 3 3 3 2  3 3 3 3 . .  17,400 83 7 1 248,000 3 2.90 0.50 58 44 95 . .
2  2  2 2 3 2 3  3 3 3 3 . .  10,700 84 11 1 87,000 2 1.50 0.60 44 76 108 11.40 1.06
2  2  1 3 3 3 3  3 3 3 3 . .  5,700 72 19 2 172,000 2 1.10 0.30 84 12 37 . .
2  2  2 2 3 3 3  3 3 3 3 11 .  20,800 75 16 1 61,000 2 1.30 0.99 34 10 183 . .
2  1 Herbal medicine 1 3 3 3 3  3 3 3 3 . .  10,300 82 10 1 265,000 2 1.30 0.50 40 15 271 15.00 1.38
2  2  2 3 3 3 2  3 3 3 3 . .  18,000 85 10 1 276,000 2 1.42 0.33 18 22 76 . .
2  2  2 1 3 2 3  3 3 3 3 . .  6,400 76 21 2 30,000 2 0.23 0.12 43 18 44 10.70 1.00
2  2  2 1 3 3 2  3 3 3 3 . .  16,300 80 12 1 153,000 3 0.60 0.20 371 138 87 13.00 1.21
2  2  2 2 3 2 2  3 3 3 3 . .  10,300 88 6 1 242,000 2 1.41 0.45 24 8 86 . .
2  2  2 3 3 3 2  3 3 3 3 . .  8,400 78 11 2 169,000 2 0.80 0.30 39 22 51 . .
2  2  2 3 3 3 2  3 3 3 3 . .  25,500 90 6 1 287,000 2 0.50 0.20 22 7 117 11.10 1.04
2  2  2 2 3 2 3  3 3 3 3 . .  14,900 79 15 2 18,000 2 7.30 5.60 144 74 477 11.90 1.11
2  2  1 3 3 3 1 ESBL, E.coli 3 3 3 3 256 1 ESBL 18,600 90 3 1 86,000 2 0.99 0.83 34 44 323 12.00 1.12
2  2  1 2 3 3 3  3 3 3 3 . .  9,300 78 12 2 243,000 2 2.40 0.60 30 12 60 . .
2  2  2 3 3 3 2  3 3 3 3 . .  13,800 84 10 1 322,000 2 0.50 0.10 11 10 43 . .
2  2  2 3 3 3 3  3 3 3 3 . .  10,700 94 3 1 . 3 0.50 0.00 83 62 68 . .
2  2  2 3 3 3 2  3 3 3 3 . .  11,500 79 14 2 263,000 2 0.50 0.20 11 10 59 . .
2  2  2 1 3 2 1 Salmonella typhi 3 3 3 3 . .  3,500 67 27 2 68,000 2 1.10 0.30 361 155 117 . .
2  2  2 1 3 3 2  3 3 3 3 . .  9,700 86 8 1 104,000 2 0.80 0.20 91 50 89 11.30 1.05
2  2  2 1 3 3 2  3 3 3 3 . .  11,800 82 13 2 139,000 3 2.00 1.40 57 43 184 . .
2  2  2 2 3 2 2  3 3 3 3 . .  21,300 76 15 2 54,000 3 0.75 0.39 30 47 154 . .
2  2  2 3 3 3 2  3 3 3 3 . .  9,100 51 42 2 166,000 2 0.50 0.20 61 54 144 11.40 1.05
2  2  2 2 3 3 2  3 3 3 3 . .  21,100 96 2 1 237,000 2 1.80 0.40 32 15 54 . .
2  2  2 1 3 1 3  3 3 3 3 . .  8,500 54 35 . 121,000 2 0.74 0.37 44 57 . . .
2  2  2 3 3 3 2  3 3 3 3 . .  8,000 79 12 2 193,000 2 . . 19 10 . . .
2  2  2 3 3 3 2  3 3 3 3 . .  12,800 88 6 1 443,000 2 0.40 0.20 37 10 102 11.70 1.08
2  2  2 3 3 3 2  3 3 3 3 . .  18,000 92 4 1 265,000 3 0.90 0.30 63 40 92 . .
2  2  2 2 3 3 2  3 3 3 3 . .  10,700 86 9 1 331,000 2 0.80 0.40 29 20 42 . .
2  2  2 3 3 3 2  3 3 3 3 . .  23,000 82 14 1 275,000 2 1.40 0.40 36 . 66 . .
2  1 Antihypertensive medication2 3 3 3 3  3 3 3 3 . .  8,800 91 8 1 281,000 3 1.00 0.20 21 18 99 . .
2  2  2 1 2 2 3  3 3 3 3 . .  11,800 64 29 2 30,000 2 6.30 4.30 61 37 227 12.50 1.16
2  2  2 3 3 3 2  3 3 3 3 . .  5,700 93 2 1 50,000 2 0.40 0.20 21 8 123 21.40 1.95
2  2  2 3 3 3 1 Strep pneumonia3 3 3 3 . .  9,600 85 13 2 298,000 2 0.73 0.24 37 50 89 11.50 1.06
2  2  2 3 3 3 3  3 3 3 3 . .  13,100 71 21 2 412,000 3 0.36 0.15 21 8 68 . .
2  2  1 1 3 1 3  3 3 3 3 . .  11,400 77 20 2 39,000 3 2.96 2.86 163 79 292 12.70 1.18
2  2  1 3 2 2 1 GNB 3 3 3 3 . .  2,000 41 7 2 10,000 2 8.10 6.10 306 46 57 10.70 1.00
2  2  2 2 1 2 2  3 3 3 3 . .  4,700 83 10 2 26,000 2 2.51 2.46 79 22 165 11.30 1.05
2  2  2 2 3 2 3  3 3 3 3 . .  8,100 90 5 1 77,000 2 1.90 1.10 225 191 151 . .
2  2  2 3 3 3 3  3 3 3 3 . .  11,100 83 10 1 300,000 2 0.60 0.20 41 18 170 . .
2  2  2 3 3 3 3  3 3 3 3 . .  24,300 94 2 1 163,000 2 1.20 0.20 71 18 31 12.30 1.14
2  2  2 3 3 3 1 MSSA Staph aureus3 3 3 3 . .  20,600 88 5 . 244,000 3 0.30 0.10 14 27 113 11.00 1.03
2  2  2 1 3 3 2  3 3 3 3 . .  3,900 74 21 2 31,000 2 4.17 4.07 83 53 87 13.50 1.25
2  2  2 1 3 2 2  3 3 3 3 . .  10,900 75 12 2 168,000 2 0.54 0.33 145 128 90 . .
2  2  2 3 3 3 3  3 3 3 3 . .  13,600 87 6 1 358,000 2 0.50 0.19 13 8 80 . .
2  2  2 3 3 3 2  3 3 3 3 . .  10,800 86 7 1 208,000 2 1.20 0.40 87 59 26 . .
2  2  2 2 3 3 2  3 3 3 3 . .  8,200 76 18 2 186,000 2 1.10 0.40 37 11 30 . .




. . . 3 130 4.10 . . . 1.07 . 1.50 79 21 376 . 2 360 32 68 66.00 119.33 179 -53.33 179 2  No growth.
. . . . 140 4.70 . . . 0.77 . . . . . . 3 540 1 97 58.00 97.33 146 -39.33 146 1 VARICELLA ZOSTERNo growth.
. . . 3 129 4.10 . . . 2.10 48 1.40 44 21 210 35 3 3 0 70 108.00 115.33 173 -7.33 173 1 CMV PCR positiveNo growth.
. . . 2 139 3.80 9.97 2.60 1.70 0.51 . . . . . . 3 3 0 100 72.00 109.33 164 -37.33 164 2  no growth.
38.70 . . 2 130 4.50 9.50 4.50 1.50 1.19 28 . 31 20 155 31 3 1 0 100 170.00 410.00 615 -240.00 619 3  No growth.
29.80 . . 2 136 3.70 7.60 2.70 2.15 0.81 36 1.70 . . . . 3 3 0 100 84.00 76.67 115 7.33 115 2  no growth.
. . . 3 145 3.30 . . . 0.77 21 . . . . . 3 180 3 93 77.00 82.00 123 -5.00 123 2  no growth 18
35.50 . . 3 129 4.10 8.10 3.50 2.07 0.72 40 1.60 185 30 617 32 3 20 73 22 102.00 156.00 234 -54.00 234 2  No growth.
. . . 2 144 3.50 . . . 1.27 34 . . . . . 3 8 8 64 74.00 60.67 91 13.33 91 2  no growth.
. . . 2 129 3.00 8.30 1.50 2.26 1.19 147 . . . . . 3 3 0 100 85.00 . . . 147 3  No growth.
. . . 3 123 4.00 . . . 1.12 41 . . . . . 3 . . . . . . . 432 .   .
. . . 3 . . . . . 0.46 . . . . . . 3 300 1 92 39.00 60.67 91 -21.67 91 3  no growth.
. . . 3 138 3.30 . . . 0.85 . . . . . . 3 380 6 94 45.00 72.00 108 -27.00 108 3  No growth.
34.70 . . 2 137 4.20 . . . 1.80 63 1.80 73 21 348 . 3 30 77 20 68.00 74.00 111 -6.00 111 3  No growth.
. . . 2 133 4.30 . . . 0.61 . . . . . . 3 260 6 93 27.00 . . . . 3  Mycobacterium tuberculosis.
29.80 . . 3 134 3.90 8.11 2.20 . 0.68 19 . . . . . 3 20 85 12 67.00 104.00 156 -37.00 156 2  No growth.
. . . 2 130 4.20 . . . 0.67 . . . . . . 3 6 12 82 36.00 67.33 101 -31.33 101 3  No growth.
34.30 . 24.50 3 136 4.40 . . 1.98 0.93 . 1.80 74 100 74 26 3 15 36 56 183.00 243.33 365 -60.33 365 1 AdenovirusNo growth.
35.60 . . . 135 2.60 15.50 3.10 1.45 2.50 31 0.70 93 . . . . 1 100 0 74.00 . . . 110 3  No growth.
. . . 2 132 4.00 10.40 2.60 . 7.00 18 . . . . . 3 10 6 94 57.00 70.67 106 -13.67 107 3  No growth.
. . . 2 134 3.40 8.60 4.30 . 0.72 . . . . . . . 70 1 89 61.00 64.67 97 -3.67 97 2  No growth.
39.30 79.40 . 2 123 3.90 7.88 2.70 . 0.77 37 . . . . . 2 50 30 50 75.00 77.33 116 -2.33 116 3  No growth.
33.40 26.20 . 2 130 3.50 . . . 0.63 20 1.40 82 20 410 32 . 160 8 90 46.00 . . . . .   .
. . . 2 107 4.30 7.50 2.30 1.88 1.00 . 1.00 82 21 390 31 . 3 1 4 63.00 . . . 106 .   .
. . . 3 127 3.50 8.63 1.60 1.93 1.73 83 1.90 74 100 74 37 3 . . . . 97.33 146 . 146 .   .
35.50 19.90 . 2 132 4.50 9.05 4.00 . 0.66 . . . . . . 3 160 51 48 71.00 82.67 124 -11.67 124 2  No growth 27
. . . 2 128 4.10 8.48 3.60 1.96 0.77 33 0.90 72 24 300 32 3 540 15 55 41.00 64.67 97 -23.67 97 2  No growth.
. . . 2 118 4.10 8.90 4.60 . 0.87 36 . . . . . 3 80 51 44 13.00 80.00 120 -67.00 120 3  No growth.
. . 0.05 2 129 3.70 10.50 4.50 . 1.15 45 2.50 167 21 795 39 3 50 6 88 108.00 324.67 487 -216.67 487 1 HSV-1 No growth.
. . . 3 135 4.40 8.76 3.10 . 0.60 10 . . . . . 3 20 92 8 107.00 88.00 132 19.00 132 2  No growth.
. . . 3 129 3.20 . . . 0.66 17 . . . . . 3 1,900 94 4 48.00 90.00 135 -42.00 135 3  No growth.
52.70 72.04 . 2 . . 7.58 7.00 . 2.20 126 . 105 . . 30 3 4,000 82 6 96.00 84.67 127 11.33 127 3  Antigen detection positive for streptocoou.
. . . 3 134 3.80 . . . 1.16 30 1.80 49 . . 37 3 35 4 86 97.00 87.33 131 9.67 131 2  No growth.
. . . 3 126 4.40 . . . 1.09 . . . . . . . 10 0 99 64.00 227.33 341 -163.33 341 3  no growth.
. . . 2 135 3.40 . . . 1.11 27 . . . . . 3 7 15 85 62.00 78.67 118 -16.67 118 2  no growth.
. . . 1 133 . 7.89 3.70 . 0.52 28 . . . . . 3 95 20 76 49.00 94.00 141 -45.00 141 1 EBV No growth.
. . . 2 133 4.50 8.30 3.70 1.43 1.24 38 1.50 52 . . 42 2 190 7 91 147.00 135.33 203 11.67 203 2  no growth.
36.50 . . 3 128 . 4.60 . . 0.93 47 . . . . . 3 480 4 95 124.00 135.33 203 -11.33 203 2  no growth.
. . . . 106 3.10 7.91 2.80 1.93 0.54 14 0.90 136 21 648 25 3 3 0 . 70.00 104.00 156 -34.00 156 3   .
30.10 . . 2 122 4.00 . . . 2.80 197 3.30 76 21 362 26 . 1,500 10 83 89.00 296.00 444 -207.00 444 2   .
. . . 2 130 3.80 . . . 0.70 . . . . . . . 1 0 100 94.00 78.67 118 15.33 118 3  no growth.
. . . 2 136 4.20 . . . 0.74 . 1.30 72 . . 29 . 110 1 98 35.00 . . . 100 1 EBV no growth.
. . . 2 111 3.60 7.10 2.00 0.95 0.37 10 0.70 91 21 433 29 3 25 94 4 109.00 116.00 174 -7.00 174 2  no growth.
. . . 2 136 4.00 . . . 0.68 30 1.70 102 21 486 35 . 420 60 28 44.00 82.00 123 -38.00 123 .   .
29.50 . . 2 135 3.20 7.37 4.50 . . 20 0.90 89 21 424 29 . 3 1 9 72.00 150.00 225 -78.00 225 2  no growth.
40.50 . . 3 140 4.30 . 5.30 1.97 1.64 64 1.20 132 21 629 28 . 60 0 98 50.00 72.00 108 -22.00 108 1 EBV no growth.
. . . 2 136 3.90 8.50 2.90 2.19 0.84 16 . . . . . . 1 0 1 62.00 74.67 112 -12.67 112 2  no growth.
. . . 2 116 2.40 8.20 2.60 . 0.83 27 1.80 44 21 210 34 . 5 1 4 92.00 134.00 201 -42.00 201 2  no growth.
38.30 . 7.22 . 136 3.50 9.70 2.50 1.61 0.48 20 5.10 46 . . 48 . 6,400 92 8 62.00 117.33 176 -55.33 176 .  No growth.
61.40 . . 2 141 4.00 . 3.20 2.15 0.94 55 1.50 160 30 533 30 . 40 2 98 96.00 62.67 94 33.33 94 2   .
38.10 . . 2 127 4.40 9.30 . . 2.88 104 1.60 100 . . 15 . . . . . . . . . .   .
. . . 2 135 3.50 . . . 0.63 23 . . . . . . 140 51 47 44.00 68.00 102 -24.00 102 2   .
. . . 2 138 3.90 . . . 0.65 . . . . . . . 610 59 37 54.00 . . . 116 .   28
. . . . 145 3.40 8.50 1.80 2.69 1.59 47 . . . . . . 4 0 4 110.00 107.33 161 2.67 161 2   .
. 33.60 . . 137 3.60 . . . . . . . . . . . . . . . 64.67 97 . . .   .
. . . 2 121 2.70 . . . . . . . . . . . 7 3 21 48.00 . . . 111 .   .
35.00 . . . 127 4.00 8.20 2.20 . 1.27 48 1.00 70 . . 29 . 25 20 78 53.00 84.00 126 -31.00 126 .   .
. . . . 133 3.10 . . . 0.89 32 . . . . . . 300 48 39 163.00 . . . . .   .
. . . 2 135 4.40 . . . 0.57 27 . . . . . . 14 10 35 49.00 66.67 100 -17.67 100 2   .
28.60 . . 2 135 3.60 8.90 2.70 . 0.66 19 . . . . . . 240 3 7 58.00 125.33 188 -67.33 188 2  No growth.
. . . 2 133 3.40 . . . 1.23 . 1.90 77 . . 29 2 30 79 20 111.00 106.67 160 4.33 160 .   .
. . . 2 126 3.10 . . . 1.15 35 . . . . . . 40 20 78 62.00 76.67 115 -14.67 115 .   .
. . . 2 126 3.40 11.00 3.80 . 0.86 . . . . . . . 5 24 60 65.00 78.67 118 -13.67 118 .   .
51.60 . . 2 136 3.20 9.50 3.50 2.48 0.96 23 . . . . . 3 260 20 76 38.00 . . . . 1 EBV no growth.
. . . 2 104 2.90 . . . 0.48 26 . . . . . . 3 0 . 61.00 90.67 136 -29.67 136 2   .
. . . 2 126 4.10 . . . 0.98 23 . . . . . . 55 1 97 77.00 176.67 265 -99.67 265 2   .
. . . . 131 4.10 . . . 0.93 23 . . . . . . . . . . 124.67 187 . 187 .   .
. . . 2 133 3.90 . 1.80 1.77 0.90 28 1.70 334 60 557 35 . 3 1 4 96.00 102.00 153 -6.00 . .   .
42.40 . . . 137 3.80 . . . 0.67 . . . . . . . 130 8 88 72.00 62.67 94 9.33 94 2   .
73.00 . . 2 144 2.70 . . . 1.01 18 6.80 104 . . 14 . . . . . 207.33 311 . 311 .   .
34.50 . . 2 140 3.90 . . . 0.99 25 7.60 60 100 60 49 . . . . . 93.33 140 . 140 .   .
. 8.99 . . 122 4.10 8.50 3.30 . 0.82 . 1.10 84 . . 34 . 130 2 96 54.00 108.67 163 -54.67 163 2   .
44.30 . . . 128 4.70 . . 2.43 1.72 . 5.10 71 . . 39 . . . . . 335.33 503 . 503 .   .
50.90 . . 2 126 4.40 . 3.00 1.37 3.48 . 8.40 62 21 295 21 . . . . . . . . . .   .
32.60 . . . 138 4.20 . . . 4.87 131 2.90 86 . . 22 . . . . . 51.33 77 . 77 .   .
. . . . 136 4.00 . . . 0.88 28 . . . . . . 17 80 13 41.00 78.67 118 -37.67 118 .   .
. . . . 134 4.10 10.90 4.10 . 1.40 24 . . . . . . 6 1 21 147.00 246.00 369 -99.00 369 .   .
46.30 . . 2 136 3.80 10.10 3.40 . 1.23 . . . . . . . 2,500 88 10 56.00 170.67 256 -114.67 256 .  Steptococcal pneumonia.
34.10 . . . 116 5.20 6.80 0.70 1.45 0.77 74 0.60 . . . . . 4 40 60 274.00 400.00 600 -126.00 600 2   .
51.80 . . 2 138 4.60 . 4.30 2.37 1.61 . . . . . . . 13 2 98 60.00 66.00 99 -6.00 99 .   .
. . . . 111 4.20 . . . 0.77 33 1.30 80 21 381 25 . . . . . 183.33 275 . 275 .   .
. . . 2 119 3.90 . . . 0.48 . 2.70 88 21 419 33 . 280 12 86 19.00 95.33 143 -76.33 143 .   .
. . . 3 110 3.50 . . . 1.11 17 . . . . . 3 . . . . 174.00 261 . 261 .   .
. . . 3 118 2.70 . . . 0.90 22 1.10 68 21 324 24 3 2 0 80 80.00 . . . . 3   .





114.50 1 Few pus cells,no bacteria2 not done 1 normal 2  2  1 22-Jun-2015 27-Jun-2015 6 5 5 2 . 2 . 2 . . 2  1  
145.00 1 occ pus cells,no bacteria1 no mal 1 normal 2 NOT DONE 2 not done 1 08-Jun-2015 14-Jun-2015 6 6 6 2 . 2 . 2 . . 2  2 ceftriaxone
40.10 2  1 Normal 1 Normal 2  2  1 18-Jun-2015 26-Jun-2015 6 8 8 2 . 2 . 2 . . 2  2  
14.80 1 occ pus cells,no bacteria1 no mal 1 NORMAL 2 Not done 1 NORMAL 1 05-Jun-2015 14-Jun-2015 6 9 9 2 . 2 . 2 . . 2  1 piptaz later for catheter related blood stream inf
33.30 1 No pus cells ,no bacteria1 no mal 1 normal 2 NOT DINE 2 NOT DONE 1 22-Jun-2015 02-Jul-2015 6 10 10 2 . 2 . 2 . . 2  2 CEFTRIAXONE
33.40 2  1 Normal 1 normal 2 not doe 1 normal 1 08-Jul-2015 14-Jul-2015 7 6 6 2 . 2 . 2 . . 2  2 Ceftriaxone
74.00 2  1 Normal 1 bilareal globus pallidus calcification2 not done 2 not done 1 22-Jul-2015 28-Jul-2015 7 6 6 2 . 2 . 2 . . 2  1 ceftriaxone
45.40 1 many pus cells no bacteria1 NORMAL 2  2  1 Mild cortical edema,subcortical hypointesity-viral1 26-Jul-2015 05-Aug-2015 7 10 10 1 5 2 . 1 3 25 2  1 Piptaz
71.80 1 No pus cells no bacteria1 normal 1 HYPPDENSITY BILATERAL aca TERRITORY2 not done 1 diffuse leptomeningeal ehancement,aca ifarcts b/l1 26-Jul-2015 06-Aug-2015 7 11 11 2 . 2 . 2 . . 2  1 ceftriaxone
37.40 1 no pus cells ,no bacteria1 no mal 1 old calcified granuloma2 normal 2  1 03-Jul-2015 22-Jul-2015 7 19 12 1 7 2 . 1 3 25 1 renal,required dialysis1 Meropenam
. .  1 norml 2 Not done 2 Not done 2 Not done 2 30-Aug-2015 30-Aug-2015 8 1 1 2 . 2 . 2 . . 2  1 Piptaz
52.30 1 few pus cells no bacteria1 no mal 2 Solitary nodular enhancing lesion,rt parietal ?NCC2 Normal 2 Not done 1 02-Aug-2015 05-Aug-2015 8 3 3 2 . 2 . 2 . . 2  2  
227.40 1 No bacteria, occasional pus cells1  1 Old granuloma in left temporo occipital region2  2  1 14-Aug-2015 18-Aug-2015 8 4 4 2 . 2 . 2 . . 2  1 Ceftriaxone, Doxycycline
75.70 1 occ ous cells, no bacteria1  1 B/LMCA watershed,partial LtMCA subacute infarct2  2  1 26-Aug-2015 31-Aug-2015 8 5 5 2 . 2 . 2 . . 2  1 Ceftriaxone
251.30 1 Moderate pus cells, No bacteria1 Norm l 1 Meningitis, hydrocephalus1 Gall bladder sludge, ? cystitis2  1 28-Aug-2015 02-Sep-2015 8 5 5 2 . 2 . 2 . . 2  1 Ceftriaxone
84.00 1 no pus cells no bacteria1 Normal 1 Hypodense region noted in rt temporoparietal area2  1 Acu e to rly subacute infarct right MCA branch1 05-Aug-2015 11-Aug-2015 8 6 6 2 . 2 . 2 . . 2  1 Ceftriaxone
81.80 1 no pus cells no bacteria1 Normal 2  2 Not done 1 Normal 1 06-Aug-2015 14-Aug-2015 8 8 8 2 . 2 . 2 . . 2  1 Ceftriaxone
123.70 1 occ pus cells, no bacteria1  1 Age related cerebral atrophy2  1 No significant abnormality1 17-Aug-2015 28-Aug-2015 8 11 5 1 6 1 3 1 5 23 2  1  
52.40 1 no pus cells no bacteria1 Normal 1 Normal 2  2  1 29-Aug-2015 19-Sep-2015 8 21 21 2 . 2 . 2 . . 2  2  
45.70 1 No pus cells, no bacteria1 no mal 1 Few calcified granuloma2  2  1 12-Sep-2015 13-Sep-2015 9 1 . 2 . 2 . 2 . . 2  .  
57.80 1 Few pus cells, No bacteria1 Norm l 1 Normal 1 Normal 1 Normal 1 11-Sep-2015 14-Sep-2015 9 3 3 2 . 2 . 2 . . 2  2  
68.20 1 few pus cells no acteria1 Normal 1 Normal 2  2  1 26-Sep-2015 29-Sep-2015 9 3 3 2 . 2 . 2 . . 2  1 Doxycycline
68.60 1 Occasional pus cells, no bacteria1 Normal 1 Normal .  1 B/l frontal FLAIR sulcal hyperintensity1 23-S p-2015 27-Sep-2015 9 4 4 2 . 2 . 2 . . 2  1 Ceftriaxone
44.70 .  1 Rt MZ opacity 1 Normal .  1 lt frontal subdural collection1 12-Sep-2015 17-Sep-2015 9 5 5 2 . 2 . 2 . . 2  1 Piptaz
. .  1 Normal 1 Subacute/chronic infarct in Rt lentiform nucleus1 no mal kidneys 2 1 03-Sep-2015 09-Sep-2015 9 6 6 2 . 2 . 2 . . 1 renal 1 Meropenam
56.20 1 Few pus cells, no bacteria1 Cavity rt lower lobe2  1 Normal 1 Flair sulcal hyperintensity Lt occiput frontal rgn1 21-Sep-2015 27-Sep-2015 9 6 6 2 . 2 . 2 . . 2  2  
271.50 1 No pus cells, no bacteria1 No mal 1 Hypointensity b/l corona radiata, periventricular1 Normal 2  1 27-Sep-2015 03-Oct-2015 9 6 6 2 . 2 . 2 . . 2  1 Ceftriaxone
298.20 1 Occasional pus cells, no bacteria1 Normal 2  2  1 Leptomeningeal disease,Mild ventricular dilatation1 04-Sep-2015 15-Sep-2015 9 11 11 2 . 2 . 2 . . 2  1 Ceftriaxone
132.00 1 few pus cells no bacteria1 No mal 1 Confluent areas of hypodensity b/l periventricular2  1 Subcortical WM hypointensity, FLAIR hyperintensity1 14-Sep-2015 25-Sep-2015 9 11 11 2 . 2 . 2 . . 2  1 Ceftriaxone
216.00 1 Occasional pus cell, no bacteria1  1 Mild prominence of b/l temporal horn2  1 gyral edema, meningeal enhancement1 22-Sep-2015 07-Oct-2015 9 15 13 2 . 2 . 2 . . 2  1 Ceftriaxone
403.50 1 Few pus cells, no bacteria1 Norm l 2  2  1 Small defect in cribriform plate1 03-Sep-2015 19-Sep-2015 9 16 16 2 . 2 . 2 . . 2  1  
302.80 1 Occasional pus cells, no bacteria1 normal 1 Normal 2  1 Cavernous s thrombosis,infected material in vntrcl1 15-S p-2015 11-Oct-2015 9 26 18 1 8 2 . 1 8 20 1 Renal failure 1 Vancomycin, ceftriaxone
84.10 1 No pus, no bacteria1 Normal 1 Normal 2  2  1 08-Oct-2015 11-Oct-2015 10 3 3 2 . 2 . 2 . . 2  1  
80.60 1 Occasional pus cells, no bacteria1 normal 1 Normal 2  2  1 11-Oct-2015 14-Oct-2015 10 3 3 2 . 2 . 2 . . 2  1  
79.40 1 No pus cells, no bacteria1 No mal 1 Normal 2  1 Normal 1 18-Oct-2015 23-Oct-2015 10 5 5 2 . 2 . 2 . . 2  2  
75.30 2 occ pus cells, no bacteria1 Normal 2  2  2  1 31-Oct-2015 06-Nov-2015 10 6 6 2 . 1 1 2 . . 2  2  
189.60 1 few pus cells, no bacteria1 Normal 2  2  1 FLAIR hypeintensity within cortical sulci1 23-Oct-2015 31-Oct-2015 10 8 8 2 . 2 . 2 . . 2  1  
114.50 2  1 Normal 1 sulcal effeacement fronto pareital2  2  1 27-Oct-2015 06-Nov-2015 10 10 10 2 . 2 . 2 . . 2  1  
53.00 2  1 Normal 1 Normal 2  2  1 31-Oct-2015 25-Nov-2015 10 25 25 2 . 2 . 2 . . 2  2  
77.00 .  .  1 Normal .  .  1 27-Nov-2015 29-Nov-2015 11 2 2 2 . 2 . 2 . . 2  1  
34.20 1 No pus cells, no bacteria1 No mal .  .  .  1 11-Nov-2015 15-Nov-2015 11 4 4 2 . 2 . 2 . . 2  1  
115.70 1 Occasional pus cells, no bacteria1 Normal 1 Normal 2  2  1 21-Nov-2015 26-Nov-2015 11 5 5 2 . 2 . 2 . . 2  1  
129.00 1 No pus, no bacteria1 Normal 1 Normal 1 Normal 1 ? meningeal inflammation, age related atrophy1 24-Nov-2015 29-Nov-2015 11 5 5 2 . 2 . 2 . . 2  2  
214.60 1 Many pus cells, no bacteria.  1 Normal .  .  1 29-Nov-2015 04-Dec-2015 11 5 5 2 . 2 . 2 . . 2  1  
37.10 1 No pus cells, no bacteria1 No mal 1 Normal 1 Normal 1 Normal 1 11-Nov-2015 18-Nov-2015 11 7 4 1 3 1 1 2 . . 2  1  
144.00 1 Occasional pus cells, no bacteria1 normal 1 Normal 1 Normal 2  1 27-Nov-2015 04-Dec-2015 11 7 . 1 3 1 2 2 . . 1 Renal failure 1  
35.00 1 No pus cells, no bacteria.  1 Illdefined hypodensity lt frontal, WM edema.  1 Rt cysticercal granuloma1 10-Nov-2015 18-Nov-2015 11 8 8 2 . 2 . 2 . . 2  2  
61.00 1 No pus cells, no bacteria1 No mal 2  2  1 Chronic infact, WM hyperintensities, Vol loss1 16-Nov-2015 26-Nov-2015 11 10 10 2 . 2 . 2 . . 1 Renal 1  
511.90 1 Many pus cells, no bacteria1 Normal 1 Normal .  .  1 27-Nov-2015 08-Dec-2015 11 11 11 2 . 2 . 2 . . 2  1  
139.00 .  .  1 Normal .  .  1 01-Nov-2015 14-Nov-2015 11 13 4 1 9 . . 1 9 . 2  1  
. .  1 Normal .  1 Renal abscess.  1 08-Nov-2015 24-Nov-2015 11 16 16 2 . 2 . 2 . . 1 Renal failure 1  
463.40 1 Occasional pus cells, no bacteria1 Normal 1 Normal .  .  1 13-Dec-2015 14-Dec-2015 12 1 . 2 . 2 . 2 . . 2  1  
109.80 1 Moderate pus cells, no bacteria. 1 Mild prominence of temp horn, 2 calcified lesion.  .  1 04-Dec-2015 06-Dec-2015 12 2 2 2 . 2 . 2 . . 2  1  
78.00 1 Occasional pus cells, no bacteria1 Normal 1 Normal .  .  1 09-Dec-2015 11-Dec-2015 12 2 2 2 . 2 . 2 . . .  2  
. .  .  1 Diffuse cerebal edema.  .  1 13-Dec-2015 16-Dec-2015 12 3 3 2 . 2 . 2 . . 2  1  
29.30 1 Moderate pus cells, no bacteria1 N rm l .  .  1 Minimal vol loss,WM hyperintensities1 23-Dec-2015 26-Dec-2015 12 3 3 2 . 2 . 2 . . 2  1  
65.70 1 Occasional pus cells, no bacteria1 Normal 1 Normal .  1 Normal 1 24-Dec-2015 27-Dec-2015 12 3 3 2 . 2 . 2 . . 2  1  
195.00 1 Occasional pus cells, no bacteria1 Normal .  .  .  1 10-Dec-2015 14-Dec-2015 12 4 4 2 . 2 . 2 . . 2  1  
115.00 1 Occasional pus cells, no bacteria1 Normal 1 Normal .  .  1 24-Dec-2015 28-Dec-2015 12 4 4 2 . 2 . 2 . . 2  1  
277.20 1 No pus cells, no bacteria1 No mal 1 Normal .  1 Normal 1 26-Dec-2015 30-Dec-2015 12 4 4 . . . . . . . .  1  
73.90 1 No pus cells, no bacteria1 No mal 1 Normal .  1 Normal 1 27-Dec-2015 31-Dec-2015 12 4 . . . 2 . 2 . . 2  1  
57.00 1 No pus cells, no bacteria1 No mal 1 Normal .  .  1 31-Dec-2015 04-Jan-2016 12 4 . 2 . 2 . 2 . . 2  1  
57.70 1 No pus cells, no bacteria1 No mal 1 Normal .  .  1 12-Dec-2015 17-Dec-2015 12 5 5 2 . 2 . 2 . . 2  2  
592.60 1 Few pus cells, no bacteria1 Norm l 2  2  1 Leptomeningeal enhancement, T2 hypointensities1 28-D c-2015 02-Jan-2016 12 5 5 2 . 2 . 2 . . 2  1  
29.90 1 No pus cells, no bacteria1 No mal .  .  .  1 31-Dec-2015 05-Jan-2016 12 5 . 2 . 2 . 2 . . 2  2  
53.30 1 No pus cells, no bacteria1 No mal 1 Normal .  .  1 31-Dec-2015 05-Jan-2016 12 5 5 2 . 2 . 2 . . 2  1  
. .  .  1 Mild cerebral and cerebellar atrophy.  .  1 13-Dec-2015 19-Dec-2015 12 6 6 2 . 2 . 2 . . 2  1  
31.20 1 No pus cells, no bacteria.  .  .  1 Normal 1 23-Dec-2015 29-Dec-2015 12 6 6 2 . 2 . 1 2 . 2  1  
204.80 1 Moderate pus cells, no bacteria1 Diffuse inf ltrate.  .  1 Chronic infarct rt antr temp & rt frontal lobe1 10-Dec-2015 17-Dec-2015 12 7 7 2 . 2 . 2 . . 2  1  
. .  1 Infiltrate in lt lower zone.  1 B/l mild pleural effusion.  . 10-Dec-2015 18-Dec-2015 12 8 . 1 . . . 1 . . .  1  
. .  .  1 Increased ICT 2  1 Skull base osteomyelitis1 21-Dec-2015 29-Dec-2015 12 8 5 1 3 2 . 1 3 . 2  1  
348.00 1 Occasional pus cells, no bacteria1 Normal .  .  1 FLAI&WM hyprintnsity,diltd ventricl,WM hyprenhcnmt1 29-Dec-2015 06-Jan-2016 12 8 8 2 . 2 . 2 . . 2  1  
. .  .  1 Mild hydrcph,hypodensities lt frontal,parietal,tmp.  .  1 02-Dec-2015 11-Dec-2015 12 9 6 1 3 . . 1 2 . 2  1  
. .  1 Normal .  .  .  1 06-Dec-2015 17-Dec-2015 12 11 3 1 8 1 6 1 6 . 1 Renal 1  
. .  1 Normal .  1 Gr II renal parenchymal changes.  1 09-Dec-2015 20-Dec-2015 12 11 11 2 . 1 3 . . . 1 renal failure 1  
82.30 1 Occasional pus cells, no bacteria1 B/l infiltra s 1 Normal .  .  1 19-Dec-2015 31-Dec-2015 12 12 . 1 3 . . 1 2 . .  1  
82.70 1 No pus cells, no bacteria1 No mal .  .  1 Subtle aeas of GM swelling1 21-Dec-2015 03-Jan-2016 12 13 13 2 . 2 . 2 . . 2  1  
441.00 1 Gram positive cocci.  .  .  1 Acute lacunar infarct in frontal deep WM1 07-Dec-2015 22-Dec-2015 12 15 15 2 . 2 . 2 . . 2  1  
68.10 1 Occasional pus cells, no bacteria1 Normal 1 Normal .  .  1 10-Dec-2015 26-Dec-2015 12 16 10 1 6 2 . 2 . . 2  1  
65.30 1 Few pus cells, no bacteria1 Norm l 1 Normal 1 Normal .  . 21-Dec-2015 06-Jan-2016 12 16 11 1 5 . . 1 3 . 1 Lung 1  
. .  1 Normal .  1 Normal .  1 01-Dec-2015 05-Jan-2016 12 35 35 2 . 2 . 2 . . 2  1  
270.00 .  1 Normal 1 Normal .  .  1 30-Mar-2016 05-Apr-2016 3 6 . 2 . 2 . 2 . . 2  .  
. .  1 normal 2  2  2  1 24-Apr-2016 27-Apr-2016 4 3 3 2 . 2 . 2 . . 2  2  
48.50 2  1 Normal 1 Normal 2  2  1 16-Apr-2016 22-Apr-2016 4 6 6 2 . 2 . 2 . . 2  1  





. 2 . 2 . 1 10 2 . 2 . 2 . 1 3 2 2 2 2  0 0 0 2 2 1 1 Partially treated Bacterial meningitisViral meningoencephalitis
5 . . . . . . . . . . . . 1 14 2 2 2 2  0 0 0 2 2 1 1 Varizella zoster meningoencephaalitis 
. . . . . . . . . . . . . 1 3 2 2 1 2  0 0 0 2 2 1 1 Alcohol withdrwalIschiorectal abscess
14 2 . 2 . 2 . 1 14 2 . 2 . 1 3 2 2 1 2  0 0 0 2 2 1 1 viral meningoencephalitisAsc ptic meningoencephalitis
1 . . . . . . . . . . . . 2 . 2 2 2 2  0 0 0 1 1 1 1 Metabolic encephalopathy-HONK
5 . . . . . . . . . . . . 1 3 2 2 2 2  0 0 0 2 2 1 1 Probable dengue encephalopathy 
14 2 . 2 . 1 14 2 . 2 . 2 . 1 14 2 2 2 2  0 0 0 2 2 1 1 Viral meningoncephalitisPartially trea ed bacterial meningitis
7 2 . 2 . 2 . 1 7 2 . 2 . 1 5 2 2 1 2  0 3 0 2 2 1 1 Probable viral meningoencephalitis 
14 2 . 2 . 1 14 2 . 2 . 2 . 1 6 2 2 2 2  0 2 0 2 2 1 1 Viral meningoencephalitispartially tre ted bacterial meningitis
. 2 . 2 . 2 . 2 . 1 10 2 . 2 . 2 2 1 2  0 3 0 2 2 1 1 Metabolic encephaloptahy- WernickeHemaphagocytosis -macrophage activation syndrome
1 2 . 2 . 2 . 1 1 2 . 2 . 2 . 2 2 2 2  0 4 0 1 1 1 1 Metabolic encepholopathyViral meningioenephalitis
. . . . . . . . . . . . . 2 . 1 1 2 2  0 0 0 2 2 1 1 Tubercular meningitis 
. 2 . 1 7 1 4 2 . 2 . 2 . 2 . 2 2 1 2  0 0 0 2 2 1 1 Scrub meningoencephalitis 
5 2 . 2 . 1 2 2 . 2 . 2 . 2 . 2 2 2 2  0 3 0 1 1 1 1 Viral meningoencephlaitisPartially treated bacterial meningitis
5 2 . 2 . 1 5 2 . 2 . 2 . 2 . 1 1 2 2  0 0 0 2 2 1 1 Definite TB meningitis- culture proven 
. 2 . 2 . 1 14 2 . 2 . 2 . 1 14 2 2 2 2  0 0 0 2 2 1 1 Partially treated bacterial meningitisViral menigoencephalitis
14 2 . 2 . 1 14 2 . 2 . 2 . 2 . 2 2 2 2  0 0 0 1 1 1 1 Partially treated pyogenic meningitisViral meningoencephalitis
. 1 3 2 . 2 . 2 . 2 . 2 . 1 5 2 2 1 1 Ventilator associated pneumonia0 4 0 2 2 1 1 Adenovirus menigoencephalitis 
. . . . . . . . . . . . . 2 . 2 2 2 2  0 0 0 2 2 1 1 Metabolic encephalopathy secondary to hypervitaminosis D
. . . . . . . . . . . . . 1 5 2 2 2 2  0 0 0 2 2 1 1 Probable viral meningoencephalitispartially treat d pyogen c
. . . . . . . . . . . . . 1 14 2 2 2 2  0 0 0 2 2 1 1 Viral meningoencephalitis 
7 2 . 1 7 2 . 2 . 2 . 2 . 2 . 2 2 2 2  0 0 0 2 2 1 1 Scrub meningoencephalitis 
6 . . . . . . . . . . . . 2 . 1 1 2 2  0 0 0 2 2 1 1 Probable Tubberculous meningitisViral meningitis
10 2 . 2 . 2 . 1 10 2 . 2 . 2 . 2 2 2 2  0 0 0 1 1 1 1 Metabolic encephalopathy-hyponatremiaAspirartion pneumonia
14 2 . 2 . 2 . 2 . 1 14 2 . 2 . 2 2 2 2  0 0 0 2 2 1 1 Sepsis associated encephalopathy- pyelonephritismet bolic encephalopathy
. . . . . . . . . . . . . 2 . 2 2 2 2  0 0 0 2 2 1 1 Viral meninggoencephalitis 
7 2 . 2 . 1 7 2 . 2 . 2 . 1 7 1 1 2 2  0 0 0 2 2 1 1 Viral meningoencephalitisPartially tre ted bacterial
5 2 . 2 . 1 5 2 . 2 . 2 . 2 . 1 1 2 2  0 0 0 2 2 1 1 Tuberculous meningitis-MRC grade 3 
. 2 . 2 . 1 5 2 . 2 . 2 . 1 21 2 2 2 2  0 0 0 2 2 1 1 HSV meningoencephalitis 
14 2 . 2 . 1 14 2 . 2 . 2 . 2 . 2 2 1 2  0 0 0 2 2 1 1 Partially treated bacterial meningitisViral meningoenc phaliti
. 2 . 2 . 1 14 2 . 2 . 2 . 2 . 2 2 2 2  0 0 0 2 2 1 1 Acute bacterial meningitis 
14 2 . 2 . 1 14 2 . 2 . 2 . 2 . 2 2 2 1 Catheter related blood stream infection0 0 0 2 2 1 1 Pyogenic pneumococcal meningitisNephroti  syndrome
. 1 . . . 1 . . . . . . . 1 . 2 2 1 2  0 0 0 1 1 1 1 Viral meningoencephalitis 
. . . 1 7 . . . . . . . . 2 . 2 2 2 2  0 2 0 2 2 1 1 Scrub meningitits 
. . . . . . . . . . . . . 1 14 2 2 2 2  0 0 0 2 2 1 1 Probable viral meningitis 
. . . . . . . . . . . . . 1 14 1 1 2 2  0 0 0 2 2 1 1 EBV meningoencephalitisTub rculous meningitis
. 2 . 1 7 1 5 2 . 2 . 2 . 1 4 2 2 2 2  0 0 0 2 2 1 1 Scrub meningoencephalitis 
. 2 . 2 . 1 14 2 . 2 . 2 . 1 4 2 2 1 2  0 3 0 2 2 1 1 Partially treated bacterial meningitisviral meningitis
. . . . . . . . . . . . . 2 . 2 2 1 1 MSSA Skin infection0 0 0 2 2 1 1 Toxin related encephalopathy- auyrvedic medicine 
. . . . . 1 10 . . . . . . 1 . 1 1 2 2  0 0 0 2 2 1 1 TB meningitisv ral meningitis
. 1 5 . . . . . . . . . . 1 4 2 2 1 2  0 0 0 2 2 1 1 Alcohol related encephalopathyViral f ver
. . . 1 7 1 7 . . . . . . 1 . 2 2 2 2  0 0 0 2 2 1 1 Viral meningoencephalitis - EBV 
. . . . . . . . . . . . . 1 5 2 2 2 2  0 5 0 1 1 1 1 viral menigoencephalitispartially treated acterial
. . . . . 1 14 . . . . . . . . 1 1 . 2  0 0 0 2 2 1 1 TB meningitisv ral meningitis
. 1 . . . . . . . 1 . . . . . 2 2 2 2  0 0 0 2 2 1 1 Scrub meningoencephalitis 
. 1 5 . . . . . . . . . . 1 14 . 2 1 2  0 2 0 2 2 1 1 Scrub meningoencephalitisEBV
. . . . . . . . . . . . . 1 14 2 1 1 2  0 0 0 2 2 1 1 Neurocysticerosis 
. . . . . . . . . . . . . 1 14 2 2 2 2  0 0 0 2 2 1 1 Metabolic encephalopathy - hyponatremia
. . . . . 1 14 . . . . . . 2 . 2 2 2 2  0 0 0 2 2 1 1 Pyogenic meningitis 
. . . . . 1 10 . . . . . . 1 14 2 2 1 2  0 2 0 2 2 1 1 viral Meningoencephalitispartially tre ted bacterial
. . . . . . . . . 1 . . . 2 . 2 2 2 2  0 0 0 2 2 1 1 sepsis associoated encephalopathy-ecoli 
. . . . . 1 4 . . . . . . 1 4 1 1 1 2  0 0 0 2 2 1 1 Tuberculous meningitisviral me ingoencephalitis
. . . . . 1 4 . . . . . . 2 . 1 1 2 2  0 0 0 2 2 1 1 Tuberculous meningitis 
. . . . . . . . . . . . . . . 2 2 1 2  0 0 0 1 1 1 1 Acute viral meningoencephalitis 
. . . 1 7 . . . . . . . . 1 4 2 2 2 2  0 0 0 2 2 1 1 Viral meningitis 
. . . . . 1 14 . . . . . . 2 . 2 2 2 2  0 0 0 2 2 1 1 Enteric encephalopathy 
. 1 3 1 7 . . . . . . . . 2 . 2 2 2 2  0 0 0 2 2 1 1 Scrub meningoencephalitis 
. 1 . . . 1 . . . . . . . 2 . 2 2 1 2  0 0 0 2 2 1 1 Scrub typhus encephalitis 
. 1 . . . 1 5 . . . . . . 1 . 2 2 1 2  0 0 0 2 2 1 1 Acute viral meningoencephalitis 
. . . . . 1 14 . . . . . . 1 . . . . .  0 0 0 2 2 1 1 Viral meningoencephalitisPartially tre ted meningoencephalitis
. . . 1 7 . . . . . . . . 1 14 2 2 2 2  0 0 0 2 2 1 1 Viral meningoencephalitisPartial treated meningocephalitis
. 1 5 . . . . . . . . . . 1 . 2 2 2 2  0 0 0 2 2 1 1 Scrub meningoencephalitis 
. . . . . . . . . . . . . 1 14 2 2 2 2  0 0 0 2 2 1 1 Viral meningoencephalitis 
. . . . . 1 2 . . . . . . 1 1 1 1 1 2  0 0 0 2 2 1 1 Tuberculous meningitisEBV me ingoencephalitis
. . . . . . . . . . . . . 2 . 2 2 2 2  0 0 0 2 2 1 1 Metabolic encephalopathy (hyponatremia)Viral fever
. 1 11 . . 1 14 . . . . . . 2 . 2 2 2 2  0 0 0 2 2 1 1 Partially treated bacterial meningitisViral meningoenc phaliti
. . . . . . . 1 10 . . . . 2 . 2 2 2 2  0 0 0 2 2 1 1 Sepsis related encephalopathyLt lower limb cellulitis
. . . . . . . 1 10 . . . . . . 2 2 2 2  0 0 0 2 2 1 1 Toxic encephalopathy- antihypertensive relatedAspiration pneumonia
. 1 5 . . 1 . . . . . . . . . 2 2 1 2  0 0 0 2 2 1 1 Scrub typhus meningoencephalitis 
. 1 . . . . . 1 . 1 . . . 2 . 2 2 1 .  0 0 0 2 2 1 1 Metabolic encephalopathy-Diabetic ketoacidosisLRTI
. . . 1 . 1 . . . . . . . 1 . 2 2 2 2  0 0 0 2 2 1 1 Acute pyogenic meningitis, Strep pneumonia 
. . . . . 1 2 . . . . . . 1 4 1 1 . 2  0 2 0 1 1 1 1 Tuberculous meningitis 
. . . 1 . . . 1 . . . . . 2 . 2 2 . .  0 0 0 2 2 1 1 Probable scrub encephalitis 
. . . 1 . . . . . 1 . . . . . . . . 1 VAP 0 0 0 2 2 1 1 Sepsis asso. encephalopathy, GNB bacteremiaHepati  enceph lopathy
. . . . . . . . . . . 1 . 2 . 2 2 2 2  0 0 0 2 2 1 1 Leptospirosis related encephalopathy 
. 1 . . . . . . . 1 . . . 2 . 2 2 2 1 VAP 0 0 0 2 2 1 1 Acute meningoencephalitisARDS/ VAP
. . . . . . . 1 7 . . . . 1 10 2 2 2 2  0 0 0 2 2 1 1 Neuroleptic malignant syndrome 
. . . . . 1 14 . . . . . . 2 . 2 2 2 2  0 0 0 2 2 1 1 Acute pyogenic meningitis 
. . . . . . . . . . . . . . . 2 2 1 2  0 0 0 2 2 1 1 Metabolic enephalopathy-hyperglycemiaVaricella zoster infection with secondary MSSA bacteremia
. 1 . . . 1 14 . . . . . . 2 . 2 2 1 1 Pneumonia 0 0 0 2 2 1 1 Scrub typhus meningoencephalitis 
. 1 5 . . . . . . . . . . 2 . 2 2 2 2  0 0 0 2 2 1 1 Scrub typhus meningitisMetabolic encephalopathy (hyponatremia)
. . . . . . . . . . . . . . . 1 1 . 2  0 2 1 2 2 1 1 Tuberculous meningitisviral me ingitis
. . . . . . . . . . . . . 2 . 2 2 2 2  0 0 1 2 2 1 1 Heat stroke 
. 2 . 2 . 2 . 1 7 2 . 2 . 2 . 2 2 2 2  0 3 1 2 2 1 1 Heat stroke 




65 1 2 3 manual labourer 9524662246 1 1 2 2 2 2 2 2 1 2 1 2 2 1 1 2 2 2 2 1 1 2
27 1 2 5 housewife 7598152344 1 1 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2
44 2 2 5 housewife 9505110950 1 1 2 2 2 2 2 2 1 2 1 1 2 2 2 2 2 2 2 1 2 2
33 1 1 4 Barber 9943676723 1 1 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
37 1 1 3 manual labourer 9585672219 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2
25 2 1 3 Working in dairy farm 9676795114 1 1 2 2 2 1 1 2 1 2 1 2 1 2 2 2 2 2 2 1 2 2
51 1 1 0  9962676303 1 1 2 2 2 1 1 2 1 2 1 1 2 2 2 2 2 2 2 2 2 2
17 2 2 2 STUDENT 9160067644 1 1 2 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 1 2
24 1 2 5 house wife 7708361565 1 1 1 2 2 1 1 2 1 1 2 2 2 2 2 2 2 2 2 1 2 2
19 1 2 0  7708604944 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 1 2
46 1 1 3 manual labourer 9786861037 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2
56 1 2 5 housewife 7708232626 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
34 1 1 3 manual labourer 9443717262 1 1 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
70 1 1 7 farmer 9751380527 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
55 1 2 5 housewife 9597912220 1 1 2 2 2 1 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 1
19 2 2 2 student 9600435902 1 2 2 2 1 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2
40 1 2 5 housewife 9442132366 1 1 2 2 2 1 1 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2
18 2 1 2 student 9866393044 1 1 2 2 2 1 1 2 1 2 1 2 2 2 2 2 2 2 2 1 2 1
28 1 1 5 housewife 9842286697 1 1 2 2 2 1 1 1 1 . 1 2 2 2 2 2 2 2 2 1 2 2
48 1 1 3 Milkman . 1 2 2 2 2 1 1 1 2 2 2 2 2 2 2 2 2 2 2 1 2 1
48 1 1 0  9786449552 1 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
25 1 1 4 Tempo driver 7708341791 1 1 1 2 2 2 1 2 2 . . 1 2 2 2 2 2 2 2 1 2 2
35 2 1 4 Jewellery sales . 1 1 2 2 1 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2
70 1 1 3 vendor 9629671187 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
71 1 2 5 housewife 9025536733 1 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
37 1 1 3 Manual labourer tailor 9842855924 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
22 2 2 5 housewife 8886729100 1 1 2 2 2 1 2 2 1 1 2 1 2 2 2 2 2 2 2 2 2 2
21 1 2 4 works in shoe company 8526557021 1 1 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
35 1 2 5 housewife 9976227423 1 1 2 2 2 1 1 1 2 2 2 2 2 2 2 2 2 2 2 1 1 2
62 2 1 3 manual labourer 9701997355 1 1 2 2 2 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2
44 2 2 5 housewife 9573158101 1 1 2 1 2 1 1 2 2 . . 2 2 2 2 2 2 2 2 1 2 1
78 1 1 0  . 1 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2
55 1 1 3 manual labourer 4174249944 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
18 1 1 2 student . 1 1 2 2 2 1 1 1 1 2 1 2 2 2 2 2 2 2 2 1 2 2
65 1 1 7 farmer . 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
45 4 1 4 manual labourerhandloom worker9864498899 1 1 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
75 1 2 5 Housewife 9786540119 1 1 2 2 2 1 2 2 1 1 1 2 2 2 2 2 2 2 2 2 2 2
67 1 2 5 House wife 9600383834 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
50 1 2 5 housewife 9003333650 1 1 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 1 2 2
74 1 1 3 Manual labourer- Farmer 9940949609 1 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2
77 1 1 3 manual labourer 7299795955 1 2 2 1 2 1 1 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2
35 1 2 5 housewife 9442808870 1 1 2 1 2 2 1 2 2 2 2 1 2 2 2 2 2 2 2 1 1 2
50 1 1 3 manual labourer 9894246343 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
78 1 1 3 manual labourer 9843616420 1 1 2 2 2 2 2 2 1 2 1 1 2 2 2 2 2 2 2 2 2 2
36 1 2 5 house wife 9789682853 1 1 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
34 1 1 3 manual labourer 9943327511 1 1 1 2 2 2 1 2 1 2 1 2 2 2 2 2 2 2 2 1 2 2
62 1 1 7 farmer 9688345661 1 1 2 2 1 2 1 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2
47 1 1 5 housewife 9486946595 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 1 2 1 2 2 2 2
18 1 1 2 student 8489651825 1 1 2 2 2 2 2 2 1 1 2 1 2 2 2 2 2 2 2 2 2 2
72 1 2 0  7092967402 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
55 1 1 3 manual labourer 8122738624 1 1 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2
65 1 2 5 housewife 9551688931 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
72 1 1 3 manual labourer 9952226240 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2
68 1 2 5 housewife 9443540387 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2
66 1 2 5 House wife . 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2
65 1 2 5 Housewife 9962546696 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
77 1 1 3 manual labourer 9443491975 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
57 1 1 3 manual labourer 8682828142 1 1 2 2 2 2 2 2 1 2 1 2 2 2 2 2 2 2 2 1 2 2
68 1 1 7 farmer 9751893736 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
20 1 2 5 housewife 9585461046 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2
47 4 2 5 housewife 7022570199 1 1 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2
61 1 2 5 housewife 9362614738 1 1 2 2 2 2 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2
65 1 1 3 manual labourer 9842394835 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
55 1 1 3 manual labourer 9677675803 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
65 1 2 5 housewife 9003028128 1 1 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 1 2 2
64 1 1 3 manual labourer 8754497443 1 1 2 2 2 1 2 2 1 2 1 1 2 2 2 2 2 2 2 1 2 2
67 1 1 7 farmer 9894313838 1 1 1 2 2 2 2 2 2 2 2 1 1 2 1 2 2 2 2 2 2 2
43 1 2 0  9655746038 1 1 2 2 2 2 1 2 1 1 1 1 2 2 2 2 2 2 2 1 2 2
42 1 2 5 housewife 8122708079 1 1 1 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2
50 1 2 5 housewife 7639332747 1 1 2 2 2 2 2 2 1 2 1 1 2 2 2 2 2 2 2 2 2 2
29 4 1 3 Manual labourer-JCB worker9585329298 1 1 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 1 1 2
65 2 1 3 Manual labourer-farmer 9502217255 1 1 2 2 2 2 2 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2
30 2 1 3 manual labourer 9849871050 1 1 1 2 2 1 2 1 1 2 1 1 2 2 1 2 2 2 2 1 2 2
45 1 2 3 manual labourer 9442083271 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 1 1 1 1 2 2
72 1 1 3 manual labourer 9952406655 1 1 2 2 2 1 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2
63 1 2 5 Housewife 9994767071 1 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
70 1 1 1 Weaver, not working 9042610586 1 1 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2
34 2 1 3 Car parking 9866554007 1 1 1 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
79 1 1 7 Farmer 8903042665 1 1 1 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2
55 2 1 3 Manual labour 9442453678 1 1 2 2 2 2 2 2 1 2 1 2 2 2 1 2 2 2 2 2 2 2
50 1 1 3 manual labourer 9597943739 1 1 2 2 2 2 2 2 1 2 1 1 2 2 2 2 2 2 2 2 2 2
56 2 1 3 Manual labourer 9885594851 1 1 2 2 2 2 1 2 2 2 2 1 2 2 2 2 2 2 2 1 2 2
40 1 2 5 house wife 9344449181 1 1 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2
70 1 1 8 Headmaster 9944949195 1 1 2 1 2 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2
19 1 1 3 Shopkeeper 9500230477 1 1 2 2 2 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
57 1 1 3 Manual labourer 9442408782 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 1 2 2
82 1 1 3 labourere\ . 1 1 2 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2
65 1 1 3 Manual labourer 9789464481 1 1 1 2 2 1 2 2 2 2 2 2 1 2 1 2 2 2 2 2 2 2
37 2 2 5 housewife 7702443547 1 1 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2
34 1 1 6 CLERK 9790136268 1 1 2 1 2 2 1 1 1 2 1 2 2 2 2 2 2 2 2 2 2 2




2 2 2 2 4 5 1 10 2 2 2 2 20 94 110 80 94 99.00 Hiccups  2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 5 15 2 2 2 2 20 100 110 601 96 98.00 HERPETIC LESION OVER LIP 2 2 2 2 2 2 2 2 1
2 2 2 2 3 3 2 8 2 2 2 2 38 132 70 0 90 104.00   1 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 20 96 110 70 98 99.80   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 5 15 2 2 2 2 24 94 0 0 98 95.00   2 2 2 2 2 2 2 2 2
2 2 2 2 2 5 3 10 2 2 2 2 24 150 100 60 94 99.00   2 2 2 2 2 2 2 2 2
2 2 2 2 2 5 2 9 2 2 2 2 28 100 120 70 99 102.00   1 1 2 2 2 2 2 2 2
2 2 2 2 4 5 3 12 2 2 2 2 24 110 90 60 . 100.80   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 5 15 2 2 2 2 22 106 100 60 99 99.00   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 5 15 2 2 2 2 16 100 120 80 99 100.00   2 2 2 2 2 2 2 2 2
2 2 2 2 3 5 3 11 2 2 2 2 30 120 80 50 99 96.20   2 2 2 2 2 2 2 2 2
2 2 2 2 4 5 1 10 2 2 2 2 48 72 90 60 97 101.00 psychiatric illness 1 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 24 140 160 100 96 103.30   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 22 106 170 90 98 105.00   1 1 2 2 2 2 2 2 2
2 2 2 2 4 5 1 10 2 2 2 2 22 112 110 70 93 98.60   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 5 15 2 2 2 2 22 104 160 70 99 98.00   2 2 2 2 2 2 2 2 2
2 1 2 2 4 6 4 14 2 2 2 2 22 82 70 0 98 98.40   2 2 2 2 2 1 2 2 2
2 2 2 2 4 4 6 14 2 2 2 2 22 82 100 60 93 100.40   2 2 2 2 2 2 2 2 2
1 2 2 2 2 5 1 8 2 2 2 2 22 100 110 70 94 99.60   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 5 15 2 2 2 2 24 120 120 90 60 100.20   2 2 2 2 2 2 2 2 2
2 2 2 1 4 5 2 11 2 2 2 2 30 92 100 60 88 99.00 Giddiness 2 2 2 2 2 2 2 2 2
2 2 2 2 1 4 1 6 2 2 2 2 30 90 140 70 96 99.80   2 2 2 2 2 2 2 2 2
1 2 2 2 3 5 3 11 2 2 2 2 36 120 110 70 . .   2 2 2 2 2 1 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 22 120 120 80 96 104.00 parkinsons disease 1 1 2 2 2 2 2 2 2
2 2 2 2 4 4 1 9 2 2 2 2 26 76 100 50 100 101.20 parkinson disease 1 1 2 2 2 2 2 1 2
2 2 2 2 4 6 4 14 2 2 2 2 44 148 110 80 95 107.50   2 2 2 2 2 2 2 2 2
2 2 2 2 4 4 2 10 2 2 2 2 46 156 100 60 98 104.00   2 2 2 2 2 2 2 2 2
1 2 2 2 3 5 2 10 2 2 2 2 22 130 110 80 98 97.00   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 5 15 2 2 2 2 24 70 110 70 96 104.40   2 2 2 2 2 2 2 2 2
2 2 2 2 4 4 2 10 2 2 2 2 24 94 120 60 96 101.00   1 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 20 70 120 70 99 97.00   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 22 78 170 100 97 . Parkinson's disease 1 1 1 2 2 2 2 2 2
2 2 2 2 4 4 1 9 2 2 2 2 37 158 60 0 93 108.00 loose stoolspost taumatic bain injuy2 2 2 2 2 2 2 2 2
2 1 2 2 4 3 1 8 2 2 2 2 28 76 110 90 97 100.80   2 2 2 2 2 2 2 2 2
2 2 2 2 1 5 1 7 2 2 2 2 25 112 140 90 96 105.00 loose stool 1 1 2 2 2 2 1 1 2
2 2 2 2 4 6 4 14 2 2 2 2 20 74 130 70 99 98.00   2 2 2 2 2 2 2 2 2
2 2 2 1 4 6 0 10 2 2 2 2 20 102 160 90 95 .   1 1 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 50 140 220 100 86 104.70   1 2 2 2 2 2 2 2 2
2 2 2 2 2 4 3 9 2 2 2 2 40 150 150 50 97 108.80 loose stoolCPK - 2169 1 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 1 2 2 20 123 120 70 98 98.20   1 1 2 2 2 2 2 2 2
2 2 2 2 4 5 3 12 2 1 2 2 28 124 110 80 93 99.00 low back ache 1 1 2 2 2 2 2 2 2
2 2 2 2 4 5 3 12 2 2 2 2 16 153 0 0 90 104.20 skin lesions 2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 5 15 2 2 2 2 28 90 140 100 99 99.00   1 2 2 2 2 2 2 2 2
2 2 2 2 1 1 1 3 2 2 2 2 24 104 90 60 99 99.00   2 2 2 2 2 2 2 2 2
2 2 2 2 4 5 4 13 2 2 2 2 24 92 100 80 96 100.00   2 1 2 2 2 2 2 2 1
2 2 2 2 3 5 2 10 2 2 2 2 20 96 110 70 95 99.00   1 2 2 2 2 2 2 2 2
2 2 2 2 1 1 0 2 2 2 2 2 26 115 100 60 99 99.00   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 22 116 120 80 98 98.60   1 1 2 2 1 2 2 2 2
2 2 2 1 2 4 2 8 2 2 2 2 30 124 100 70 88 102.00   1 2 2 2 2 2 2 2 2
2 2 2 2 4 5 4 13 2 2 2 2 38 116 0 0 85 .   2 2 2 2 2 2 2 2 2
2 2 2 2 4 5 3 12 2 2 2 2 40 112 60 0 91 105.00   1 1 2 2 2 2 2 2 2
2 2 2 2 4 5 2 11 2 2 2 2 36 108 140 80 88 103.20   1 1 2 2 2 2 2 2 2
2 2 2 2 2 5 2 9 2 2 2 2 36 128 140 90 96 102.00 Parkinsons disease 2 1 2 2 2 2 2 2 2
2 2 2 2 4 5 3 12 2 1 2 2 42 132 220 110 92 103.00   1 1 2 2 1 2 2 2 2
2 2 2 1 1 5 2 8 2 1 2 2 40 126 60 30 88 104.50   1 2 2 2 1 2 2 1 2
2 2 2 2 3 5 3 11 2 2 2 2 32 140 120 80 42 105.40   2 2 2 2 2 2 2 2 2
2 2 2 2 3 5 2 10 2 2 2 2 26 96 170 80 95 100.00   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 38 162 100 70 88 105.00   2 2 2 2 2 2 2 2 2
2 2 2 2 3 5 3 11 2 2 2 2 24 102 126 80 96 102.00 hiccup  2 2 2 2 2 2 2 2 2
2 2 2 2 1 1 1 3 2 2 2 2 26 136 130 80 90 103.00   1 2 2 2 2 2 2 2 2
2 2 2 2 1 1 1 3 2 2 2 2 24 100 100 70 80 105.00 Parkinson disease 2 2 2 2 2 2 2 2 2
2 2 2 1 1 1 1 3 2 1 2 2 28 121 80 60 79 107.00   1 1 2 2 2 2 2 2 2
2 2 2 2 4 5 2 11 2 2 2 2 42 120 110 50 91 105.00   1 2 2 2 2 2 2 1 2
2 2 2 2 4 3 2 9 2 2 2 2 40 146 150 90 94 106.00   2 1 2 2 2 2 2 2 2
2 2 2 2 1 1 1 3 2 2 2 2 40 180 60 0 50 107.00   2 2 2 2 2 2 2 2 2
2 2 2 2 1 1 1 3 2 2 2 2 28 160 60 0 50 100.00   1 2 2 2 2 2 2 2 2
2 2 2 1 1 1 1 3 2 1 2 2 20 130 90 60 50 105.00 cpk -4457 2 1 2 2 2 2 2 1 2
2 2 2 2 3 3 1 7 2 2 2 2 20 82 100 60 98 .   2 2 2 2 2 2 2 2 2
1 2 2 2 4 5 2 11 2 2 2 2 22 86 90 50 100 102.50   2 2 2 2 2 2 2 2 2
2 2 2 2 3 3 1 7 2 2 2 2 40 140 60 0 66 99.00   2 2 2 2 2 2 2 2 2
2 2 2 2 1 5 1 7 2 2 2 2 12 80 90 60 99 98.00   2 2 2 2 2 2 2 2 2
2 2 2 2 2 5 2 9 2 2 2 2 12 90 160 80 98 104.00   2 1 2 2 2 2 2 2 2
2 2 2 2 4 5 3 12 2 1 2 2 48 160 110 70 74 99.00   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 3 13 1 2 2 2 28 11 100 60 98 99.60   1 2 2 2 2 2 2 2 2
2 2 2 2 2 5 1 8 2 1 2 2 38 100 70 50 77 99.00   1 1 2 2 2 2 2 2 2
1 2 2 2 1 4 2 7 2 1 2 2 18 93 94 60 93 99.00   1 2 2 2 2 1 2 2 2
2 2 2 2 4 6 4 14 2 2 2 2 24 78 50 0 93 98.80   2 1 2 2 2 2 2 2 2
2 2 2 2 2 5 1 8 2 2 2 2 22 82 110 60 99 97.80 TB Menigitis 2 2 2 2 2 1 2 1 2
2 2 2 2 2 4 2 8 2 2 2 2 20 90 100 60 98 101.20   2 1 2 2 2 2 2 2 2
2 2 2 2 3 6 4 13 1 1 2 2 30 174 140 90 92 99.00 Abdominal distensionPost MVR 2 1 1 2 2 2 2 2 2
2 2 2 2 1 1 1 3 2 1 2 2 28 110 120 80 73 100.50   1 2 2 2 2 2 2 2 2
2 2 2 2 4 5 4 13 2 2 2 2 20 70 160 80 97 97.00   1 1 2 2 1 2 2 2 2
2 2 2 2 3 5 3 11 2 2 2 2 28 134 110 50 92 103.20 Mental retardation, Retinitis pigmentosa, MELASBlindness, Dyslipidemia1 2 2 2 2 2 2 2 2
2 2 2 2 4 5 3 12 1 1 2 2 30 118 120 90 92 99.00   1 2 2 2 1 2 2 2 2
1 1 2 2 3 6 2 11 2 2 2 2 26 136 110 70 97 99.60   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 4 14 1 2 1 2 34 110 100 60 93 98.00 Abdominal pain 1 1 2 2 2 2 2 2 2
2 2 2 2 4 2 2 8 2 2 2 2 20 80 110 70 100 .   1 2 2 2 2 2 2 2 2
2 2 2 2 3 5 4 12 2 1 2 2 44 98 110 80 80 98.00   1 2 2 2 2 2 2 2 2
2 2 2 2 2 1 1 4 2 1 2 2 40 36 80 60 80 99.00   2 2 2 2 2 2 2 2 2
2 2 2 2 4 6 2 12 2 1 1 2 26 110 120 70 95 99.00   2 2 2 2 2 2 2 2 2




2  2  1 3 3 3 3  3 3 3 3 . .  25,500 71 6 . 211,000 2 1.08 0.40 271 34 87 11.00
2  2  2 3 3 3 2  3 3 3 3 . .  11,900 41 45 2 333,000 3 0.40 0.10 13 16 48 .
2  2  2 2 3 1 2  3 3 3 3 5 .  23,000 95 3 1 189,000 2 0.38 0.20 45 47 110 11.90
2  2  1 3 2 2 2  3 2 3 3 . .  14,800 70 24 2 399,000 2 0.90 0.30 182 48 82 .
2  2  2 2 3 2 2  3 3 3 3 . .  3,100 90 9 1 162,000 2 3.00 2.10 156 87 109 .
2  2  2 3 3 3 3  3 3 3 3 . .  7,400 69 27 2 219,000 2 0.49 0.23 92 64 98 11.10
2  2  2 1 3 2 2  3 3 3 3 . .  17,300 69 25 2 272,000 2 0.30 0.15 65 55 71 12.20
2  2  2 2 3 3 3  3 3 3 3 . .  6,600 69 21 . . 2 0.80 0.20 35 10 66 .
2  2  2 2 3 2 3  3 3 3 3 . .  11,500 69 25 2 267,000 2 1.50 0.20 21 10 64 .
2  2  2 2 3 2 2  3 3 3 3 . .  6,800 59 32 2 255,000 2 0.70 0.10 14 17 41 .
2  2  2 1 2 2 3  3 3 3 3 . .  17,500 90 8 1 16,000 2 1.00 0.70 192 43 203 12.90
1 Anti psychiatic mediationa2  2 2 3 3 2  3 3 3 3 . .  8,500 73 22 2 231,000 2 0.80 0.40 157 45 48 .
2  2  1 3 3 3 3  3 3 3 3 . .  21,800 87 4 1 193,000 2 2.20 1.60 132 105 75 10.30
2  2  2 3 3 2 2  3 3 3 3 . .  10,500 79 16 2 152,000 2 1.10 0.10 33 27 58 12.40
2  2  2 1 3 3 2  3 3 3 3 . .  4,900 60 38 2 131,000 2 0.50 0.30 120 39 142 12.60
2  2  2 2 3 2 2  3 3 3 3 . .  5,100 73 18 2 200,000 2 0.38 0.10 24 32 53 .
2  2  2 3 3 3 3  3 3 3 3 . .  4,400 60 25 2 346,000 3 0.40 0.20 20 15 154 .
2  2  2 3 3 1 2  3 3 3 3 . .  7,500 44 48 2 65,000 2 0.57 0.30 94 93 72 .
2  2  2 3 3 3 3  3 3 3 3 . .  11,100 76 10 2 270,000 2 0.72 0.25 20 13 60 .
2  2  2 3 3 3 2  3 3 3 3 . .  19,800 80 16 2 225,000 2 . . . . . .
2  2  2 2 3 3 2  3 3 3 3 . .  8,900 86 8 1 229,000 2 1.04 0.39 18 10 58 .
2  2  2 1 3 3 3  3 3 3 3 . .  17,700 61 28 . 446,000 3 0.33 0.17 72 104 77 10.90
2  2  2 3 3 3 3  3 3 3 3 . .  10,300 94 4 . 574,000 2 0.40 0.16 28 9 127 10.20
2  2  2 3 3 3 2  3 3 3 3 . .  13,200 78 16 2 306,000 2 0.60 0.20 42 17 61 12.00
2  2  2 3 3 3 2  3 3 3 3 91 3  15,100 82 9 1 174,000 3 0.80 0.40 55 7 65 .
2  2  2 3 3 3 2  3 3 3 3 . .  12,200 85 7 1 58,000 2 1.60 0.80 746 184 41 11.60
2  2  2 2 3 3 2  3 3 3 3 . .  11,000 87 9 1 134,000 2 0.70 0.30 200 133 45 12.40
2  2  2 3 3 3 3  3 3 3 3 . .  10,500 75 11 2 398,000 2 0.23 0.10 15 8 46 .
2  2  2 3 3 3 3  3 3 3 3 . .  11,400 77 14 2 165,000 2 0.90 0.20 15 12 36 10.60
2  2  2 3 3 3 2  3 3 3 3 . .  22,100 89 3 1 318,000 2 0.80 0.20 28 10 150 .
2  2  2 3 3 3 3  3 3 3 3 . .  6,700 66 27 2 384,000 3 0.24 0.10 19 13 79 10.10
2  2  2 3 3 3 3  3 3 3 3 . .  13,700 90 6 1 239,000 3 0.50 0.10 8 7 77 .
2  2  2 3 3 3 1 proteus miabilis 3 3 3 3 . .  10,200 86 2 1 158,000 3 1.10 0.20 102 20 38 .
2  2  2 3 3 3 2  3 3 3 3 . .  22,000 91 2 1 235,000 2 0.90 0.50 17 21 91 12.80
2  2  2 3 3 3 2  3 3 3 3 . .  10,000 70 20 2 220,000 3 0.80 0.10 19 15 68 .
2  2  2 3 3 3 3  3 3 3 3 . .  6,300 57 29 2 266,000 2 1.00 0.20 31 26 55 .
2  2  2 2 2 2 2  2 2 2 2 . .  20,900 87 7 1 366,000 2 0.54 0.18 32 18 107 .
2  2  2 3 3 3 2  3 3 3 3 . .  20,900 76 17 2 295,000 2 0.40 0.20 25 10 148 11.90
2  2  2 3 3 3 2  3 3 3 3 . .  20,200 88 5 1 122,000 2 0.90 0.40 161 90 26 .
2  2  1 3 3 3 1 Klebseilla 3 3 3 3 . .  15,600 83 8 1 338,000 3 . . . . . .
2  2  2 2 3 3 2  3 3 3 3 . .  15,200 94 1 1 181,000 2 1.90 1.30 70 21 58 11.40
2  2  2 2 2 1 2  3 3 3 3 . .  13,100 43 25 2 62,000 2 12.80 11.40 283 228 382 23.50
2  2  2 1 3 3 2  3 3 3 3 . .  10,700 60 32 2 182,000 2 1.10 0.60 207 142 216 10.70
2  2  2 3 3 3 2  3 3 3 3 . .  9,700 72 16 2 227,000 2 0.60 0.20 18 10 95 12.70
2  2  2 2 3 3 2  3 3 3 3 . 3  11,700 92 4 1 181,000 2 0.30 0.10 102 36 167 .
2  2  2 2 2 2 2  3 3 3 3 . .  17,100 86 10 2 90,000 2 3.94 3.35 9,780 6,280 207 22.90
2  2  2 2 3 3 2  3 3 3 3 . .  10,900 77 16 2 180,000 2 0.60 0.30 28 27 42 12.80
2  2  1 3 3 3 3  3 3 3 3 2 .  9,100 80 10 1 263,000 3 0.80 0.30 34 16 74 .
2  2  2 3 3 3 3  3 3 3 3 . 3  8,400 71 26 2 113,000 2 1.20 0.30 62 29 64 13.00
2  2  2 3 3 3 2  3 3 3 3 . .  15,500 88 8 1 94,000 3 0.80 0.30 58 54 126 .
2  2  2 3 3 3 2  3 3 3 3 . .  20,100 84 4 1 295,000 3 1.55 1.30 133 109 197 16.70
2  2  2 3 3 3 2  3 3 3 3 . .  14,400 91 1 1 130,000 3 2.70 2.20 320 206 50 .
2  2  2 3 3 3 2  3 3 3 3 . .  12,700 88 7 1 211,000 3 0.80 0.20 41 16 67 12.60
2  2  2 3 3 3 2  3 3 3 3 . .  14,300 84 7 1 514,000 2 1.10 0.30 15 12 288 .
2  2  2 3 3 3 2  3 3 3 3 . .  17,400 72 18 2 72,000 3 0.80 0.40 66 22 34 .
2  2  2 3 3 3 2  3 3 3 3 . .  20,800 87 6 1 346,000 3 0.80 0.30 9,898 3,660 97 14.50
2  2  2 3 3 3 2  3 3 3 3 . .  12,200 74 17 2 . 3 . . . . . .
2  2  2 2 2 2 2  3 3 3 3 . .  11,700 83 9 1 125,000 2 2.80 0.80 69 24 26 12.20
2  2  2 3 3 3 2  3 3 3 3 . 3  13,100 80 8 2 203,000 2 0.70 0.40 32 13 126 .
2  2  2 3 3 3 2  3 3 3 3 . .  14,700 76 19 2 299,000 2 1.30 0.60 101 65 61 16.40
2  2  2 3 3 3 2  3 3 3 3 . .  33,200 82 13 1 260,000 2 0.60 0.20 364 58 63 .
2  2  2 3 3 3 2  3 3 3 3 . .  15,300 58 36 2 272,000 2 0.50 0.30 61 20 93 13.30
2  2  2 3 3 3 2  3 3 3 3 . .  32,100 84 5 1 143,000 2 0.90 0.70 158 63 77 13.70
2  2  2 3 3 3 2  3 3 3 3 . .  11,800 87 6 1 102,000 3 1.50 0.20 112 54 29 .
2  2  2 3 3 3 3  3 3 3 3 . .  15,800 76 15 1 179,000 3 1.50 0.40 100 31 32 11.40
2  2  2 2 3 3 1 beta hemolytic streptococcus3 3 3 3 . .  25,000 80 15 1 94,000 2 2.00 1.80 78 71 369 11.70
2  2  2 3 3 3 2  3 3 3 3 . .  24,700 81 8 1 210,000 3 2.10 1.00 101 29 32 12.70
2  2  2 3 3 3 2  3 3 3 3 . .  5,500 74 18 2 188,000 2 0.50 0.30 135 92 121 11.20
2  2  2 3 3 3 2  3 3 3 3 . .  11,800 91 4 1 269,000 3 0.40 0.10 24 8 88 11.00
2  2  2 2 3 3 2  3 3 3 3 . .  11,300 60 25 2 12,500 3 0.20 0.10 80 50 86 10.30
2  2  2 2 2 3 3  3 3 3 3 . .  14,000 97 2 1 198,000 2 0.60 0.20 96 56 76 11.90
2  2  2 3 3 3 2  3 3 3 3 . .  14,600 83 8 2 325,000 2 0.60 0.30 36 30 192 .
2  2  2 3 3 3 2  3 3 3 3 . .  18,300 93 2 1 372,000 2 1.50 0.80 95 48 65 .
2  2  2 3 3 3 1 E coli 3 3 3 3 347 1 E coli 31,000 90 2 1 282,000 2 1.80 1.50 31 11 401 .
2  2  1 3 3 3 2  3 3 3 3 . .  12,300 88 3 2 52,000 2 2.44 1.30 78 134 134 11.90
2  2  2 3 3 3 3  3 3 3 3 431 1 E coli 11,500 77 14 1 20,000 3 . . . . . .
2  2  2 3 3 3 1 E coli 3 3 3 3 . .  11,600 70 6 1 . 2 0.30 0.20 175 54 71 .
2  2  2 2 2 2 2  2 2 2 2 15 .  3,900 71 9 . 118,000 3 1.51 0.70 32 111 90 10.90
2  2  2 3 3 3 2  3 3 3 3 . .  11,300 84 8 2 230,000 2 1.60 0.90 81 36 208 .
2  2  2 3 3 3 1 Pseudomonas 3 3 3 3 558 3  22,300 94 2 1 56,000 3 . . . . . 19.50
2  2  1 3 3 3 3  3 3 3 3 . .  17,800 86 9 1 175,000 3 0.50 0.10 25 11 88 .
2  2  2 3 3 3 3  3 3 3 3 . .  24,700 13 94 1 237,000 2 15.00 0.30 78 20 68 .
2  2  2 3 3 2 3 E coli 3 3 3 3 573 .  14,700 78 13 2 235,000 2 . . 25 19 . 13.00
2  2  2 3 3 3 3  3 3 3 3 . .  7,900 81 7 2 189,000 2 1.50 0.20 70 29 37 141.00
2  2  2 3 3 3 3  3 3 3 3 . .  12,400 86 7 1 457,000 2 0.85 0.40 34 17 35 .
2  2  2 3 3 3 1 E coli 3 3 3 3 881 2  26,500 84 4 1 198,000 3 1.20 1.00 25 16 257 .
2  2  2 2 3 1 2  3 3 3 3 . .  17,200 88 6 1 34,000 2 3.10 2.10 99 45 275 14.20
2  2  2 3 3 3 2  3 3 3 3 . .  26,300 95 2 1 561,000 3 1.28 0.46 14 9 87 .
2  2  2 1 3 3 2  3 3 3 3 . .  17,160 82 14 1 315,000 2 0.60 0.30 55 14 278 13.00
2  2  1 3 3 3 1 nfgnb 2 2 2 2 . .  38,200 80 10 1 260,000 2 0.50 0.30 59 72 191 11.40




1.03 32.50 . . 3 112 4.00 7.50 2.30 1.45 1.08 20 . . . . . . . . . . 85.33 128 . . .   
. . . . 2 135 4.30 . . . 0.78 22 . . . . . 3 40 1 95 77.00 150.67 226 -73.67 226 2  no growth
1.11 380.00 . . 2 115 7.10 . . 1.15 2.30 68 5.30 114 100 114 16 . 5 52 48 165.00 204.67 307 -39.67 307 2   
. . . . 2 136 3.30 . . . 0.95 52 1.00 88 21 419 32 . 5 0 100 67.00 72.00 108 -5.00 108 2  no growth
. . . . 3 135 3.40 . . . 2.05 . 1.20 72 21 343 33 . 5 0 . 80.00 90.67 136 -10.67 136 3  no growth
1.04 37.70 . . 2 134 40.00 8.76 3.10 . 0.84 . 3.90 84 21 400 28 3 40 11 86 77.00 96.67 145 -19.67 145 2  No growth
1.13 28.60 . . 2 134 4.20 8.20 4.20 . 1.84 43 10.00 123 21 586 25 3 690 15 85 149.00 133.33 200 15.67 200 1 EBV No growth
. . . . 2 140 5.00 7.30 1.80 2.35 0.63 61 . 76 21 362 37 . 20 39 9 72.00 81.33 122 -9.33 122 2   
. . . . 2 137 3.70 8.20 2.50 . . 14 0.80 90 21 429 38 3 70 12 78 64.00 95.33 143 -31.33 143 2  No growth
. . . . 2 137 3.50 . . . 0.57 . . . . . . . 180 0 95 57.00 . . . . 2   
1.19 27.50 . . 2 139 4.80 . . . 2.42 . 2.50 93 21 443 22 3 30 35 64 44.00 139.33 209 -95.33 209 3   
. . . . 3 131 2.60 . . . 0.75 12 8.80 90 40 225 10 3 . . . . . . . . .   
0.94 33.20 . . 2 139 2.70 . . . 0.87 13 . . . . . 3 2 0 100 37.00 90.67 136 -53.67 136 3   
1.15 25.30 . . 3 112 3.70 . . . 1.19 39 . . . . . . . . . . . . . . .   
1.17 27.10 . . 2 139 4.00 . . 2.00 0.57 29 1.60 61 24 254 29 . 3 8 88 84.00 . . . 138 2  No growth
. . . . 2 135 4.40 8.63 3.00 1.91 0.74 . . . . . . 2 2 0 . 63.00 66.00 99 -3.00 99 2   
. . . . 1 128 . 7.89 3.70 . . . . . . . . 3 130 34 55 45.00 58.00 87 -13.00 87 1 EBV  
. . . . 2 133 4.00 8.30 4.20 . 0.64 . 0.80 76 21 362 35 . 40 5 95 61.00 76.00 114 -15.00 114 2   
. . . . 2 137 4.20 8.49 3.10 . 1.08 . . . . . . . 90 20 78 28.00 60.00 90 -32.00 90 .  No growth
. . . . 2 127 3.60 . . . 0.79 29 . . . . . . 320 3 93 55.00 60.67 91 -5.67 91 3  No growth
. . . . . 132 3.20 8.62 2.30 . 0.84 . 1.10 53 . . 33 . 35 69 30 89.00 103.33 155 -14.33 153 2   
1.02 37.00 . . 2 137 4.10 9.38 4.60 2.40 0.89 15 1.00 81 . . 37 . 410 3 97 57.00 . . . . 2  Nil
0.94 34.00 . . 1 129 3.60 . 2.70 . 0.60 15 3.40 34 . . . . 30 1 97 66.00 104.67 157 -38.67 157 2  Mycobacterium tuberculosis
1.11 31.20 . . 2 126 4.10 8.39 1.50 . 0.75 19 . . . . . . . . . . . . . . .   
. . . . . 143 4.70 9.04 4.00 1.02 1.64 108 . . . . . 3 3 30 70 70.00 . . . 171 3  no growth
1.07 30.60 . . 3 132 3.40 7.00 1.50 1.97 1.66 33 . . . . . 3 . . . . . . . . .   
1.15 27.60 . . 2 143 3.60 11.60 . 1.98 2.72 . 2.20 92 60 153 15 3 7 0 100 117.00 107.33 161 9.67 161 2   
. . . . 2 140 3.10 . . . 0.59 26 . . . . . 3 450 5 87 13.00 62.67 94 -49.67 94 2  occasional pus cells,no bacteria
0.96 29.70 . . 2 138 2.30 . . 1.87 0.57 . . . . . . 3 280 65 35 7.00 102.00 153 -95.00 153 1 XPERT TBmYCOBACTERIUM TUBERCULOSIS- MDR TB
. . . . 2 130 2.80 . . . 0.94 89 3.20 78 21 371 35 3 70 30 45 236.00 451.33 677 -215.33 677 2  No growth
0.95 29.00 19.30 . 2 137 4.50 9.44 4.10 . 0.64 . . . . . . . 230 1 97 45.00 97.33 146 -52.33 146 .   
. . . . . 135 3.30 7.62 29.00 . 1.11 . 2.30 66 100 66 33 . 50 96 4 60.00 66.00 99 -6.00 99 .   
. . . . 3 140 3.60 . . . 1.86 60 2.70 . . . . 3 . . . . 100.67 151 . 151 .   
1.18 . 203.00 . 2 143 3.60 8.00 3.30 . 0.67 28 . . . . . . 135 74 24 72.00 100.00 150 -28.00 . .   
. . . . 3 133 3.60 7.20 2.60 . 1.25 29 . . . . . . 1 0 100 69.00 200.67 301 -131.67 301 3   
. . . . 2 132 4.10 9.52 2.90 . 0.82 23 . . . . . 3 30 3 94 66.00 69.33 104 -3.33 104 2  no growth
. . . . . 124 4.00 . . . 0.86 41 . . . . . . 30 87 13 136.00 196.67 295 -60.67 290 .   
1.10 39.40 . . 2 129 4.50 . . . 1.09 31 . . . . . . 3 40 60 167.00 266.00 399 -99.00 399 .   
. . . . 3 130 1.90 . 2.70 2.12 0.62 16 2.90 32 21 152 35 . . . . . 258.67 388 . 388 .   
1.28 42.80 . . 2 126 4.10 9.10 3.60 1.35 0.56 . . . . . . 3 . . . . 153.33 230 . 230 .   
1.05 . . . 2 127 3.20 8.41 1.90 . 2.00 129 1.10 85 21 405 26 3 40 46 54 73.00 180.00 270 -107.00 270 2   
2.16 55.30 . 0.80 2 136 4.70 . . . 0.74 39 1.30 103 21 . 24 3 5 0 88 76.00 75.33 113 0.67 113 2  no growth
0.99 38.10 . . 2 127 5.20 8.72 4.90 1.97 1.11 . 1.40 . . . . 3 70 4 88 137.00 91.33 137 45.67 . 2  no growth
1.17 42.40 . . 2 126 4.60 7.17 3.50 1.48 2.16 31 . . . . . 3 . . . . 133.33 200 . . .   
. . . . 2 135 3.90 8.75 4.10 1.82 3.60 97 3.50 64 21 305 . 3 160 59 41 64.00 189.33 284 -125.33 284 2   
2.10 62.00 . . 2 135 3.00 9.60 6.60 3.05 2.15 66 11.20 83 21 . 34 3 . . . . 99.33 149 . 149 .   
1.18 30.20 . . 3 132 3.30 3.30 . . 0.79 . 1.10 48 100 48 29 3 60 3 95 72.00 78.67 118 -6.67 118 2  no growth
. . . . 2 117 3.40 8.00 3.00 2.01 0.70 11 . . . . . . 450 29 71 18.00 104.67 157 -86.67 157 .  Mycobacterium tuberculosis
1.20 29.20 . 1.27 2 132 4.50 8.60 2.40 0.98 0.83 36 0.86 336 100 336 73 2 2 50 50 108.00 151.33 227 -43.33 227 .   
. . . . . 148 4.40 8.14 5.00 . 1.86 216 . 97 21 462 27 . 3 60 40 78.00 110.00 165 -32.00 . .   
1.54 44.80 . . 2 115 3.00 . . . 2.63 41 3.10 97 21 462 20 3 . . . . 110.00 165 . . .   
. . . . 3 112 2.40 . . . 2.41 45 0.90 . . . . 3 . . . . 279.33 419 . 419 .   
1.16 35.50 . . 3 159 3.90 . . . 1.32 94 1.50 94 40 235 25 3 . . . . 99.33 149 . . .   
. . . . 3 108 38.00 . . . 0.67 20 . . . . . 3 . . . . 192.00 288 . 288 .   
. . . . 3 140 3.80 7.80 . 1.32 1.38 123 1.70 56 21 267 35 3 . . . . . . . . .   
1.34 32.80 . . 2 136 5.40 . . . 1.13 . 2.60 53 21 252 76 . . . . . . . . . .   
. . . . 3 113 3.60 . . . 1.08 . . . . . . 3 2 0 100 121.00 92.67 139 28.33 139 3   
1.13 32.50 . . 2 109 4.30 6.90 3.70 1.60 1.31 24 3.80 172 40 430 28 3 . . . . 188.00 282 . 282 .   
. . . . 2 131 3.70 . . . 1.65 75 . . . . . . 156 5 95 127.00 88.00 132 39.00 132 2   
1.51 34.10 . . 2 111 3.50 . 1.60 1.09 1.50 34 11.30 . . . . 3 1 0 100 138.00 364.00 546 -226.00 546 3   
. . . . 2 132 3.40 . . . 1.87 55 2.10 226 100 226 25 3 . . . . 131.33 197 . 197 .   
1.23 35.80 . . 3 127 4.60 . 2.80 1.69 1.08 29 8.30 118 100 118 35 . 2 0 100 86.00 252.67 379 -166.67 379 2   
1.27 34.60 . . 3 123 3.40 6.00 2.40 . 2.21 55 1.90 121 40 303 23 3 . . . . 261.33 392 . 392 .   
. . . . 3 106 3.50 8.20 2.70 . 1.33 . 4.50 124 40 310 19 3 . . . . 124.67 187 . 167 .   
1.05 37.40 . . 3 123 3.30 . . 2.80 2.06 44 5.00 80 21 381 20 3 1 0 100 101.00 95.33 143 5.67 143 3   
1.08 31.00 . . 2 143 3.60 . . . 1.91 93 15.70 119 100 119 92 3 30 96 4 106.00 273.33 410 -167.33 410 3   
1.17 34.40 . . 3 124 3.40 . 1.50 1.58 2.91 93 2.50 . . . . . 8 4 78 108.00 117.33 176 -9.33 176 3  no growth
1.04 34.10 . . 2 137 3.20 7.50 2.90 1.85 1.29 . . . . . . . 5 0 100 108.00 142.00 213 -34.00 213 2   
1.02 38.50 . . 2 133 3.70 8.50 2.60 . 0.94 31 . . . . . 3 . . . . 74.00 111 . 111 .   
0.95 22.10 . . 2 143 4.00 . 1.80 2.08 1.78 39 7.10 . . . . 3 2 0 100 107.00 176.00 264 -69.00 264 2   
1.08 37.60 . . . 146 3.70 . . 2.93 1.52 35 . 184 40 460 29 3 . . . . 91.33 137 . 137 .   
. . . . 2 125 3.50 . . . 1.02 39 . . . . . 3 24 77 33 154.00 209.33 314 -55.33 314 2  No growth
. 39.20 . . 2 129 4.70 . . 2.47 0.56 48 3.90 99 50 198 31 3 5 10 84 61.00 78.67 118 -17.67 118 1 Xpert TB mycobacterium tuberculosis
. . . . 3 109 3.70 6.50 1.90 . 3.30 108 . . . . . 3 6 30 60 46.00 . . . 131 3  no growth
1.11 40.40 . . 3 136 3.90 8.20 4.60 . 2.00 . 9.10 77 50 154 48 3 1 0 100 66.00 70.67 106 -4.67 106 3  No growth
. . . . 1 137 3.00 . . . 1.99 65 . . . . . 3 20 82 18 128.00 90.67 136 37.33 136 3  No growth
. . . . 3 135 6.10 . . . 6.27 120 . . . . . 3 3 0 100 65.00 60.00 90 5.00 90 3  no growth
1.02 27.30 . . 1 129 3.80 . . . 0.38 18 1.90 89 . . . . . . . . . . . . .   
. . . . 3 115 3.50 . . . 1.24 41 0.80 . . . . 3 . . . . . . . . .   
1.78 59.60 . . 2 132 5.10 . . . 5.54 98 5.40 131 . . . 3 8 98 2 135.00 119.33 179 15.67 179 3  no growth
. . . . 3 120 4.30 . . . 1.18 32 6.80 67 100 67 28 3 30 2 98 120.00 76.67 115 43.33 115 2  No growth
. . . . 3 120 3.50 . . 2.72 0.73 . 1.80 67 21 319 29 3 . . . . 216.67 325 . . .   
1.21 41.60 . . 2 124 4.80 8.24 4.70 . 2.64 78 5.20 . . . . 3 10 77 13 101.00 35.33 53 65.67 . 3  No growth
1.30 31.20 . . 3 137 4.00 8.75 3.10 . 1.05 . 1.70 60 21 286 32 3 12 20 80 80.00 98.67 148 -18.67 148 2  No growth
. . . . 2 133 3.10 . . . 6.38 43 1.10 94 21 448 36 3 12 4 96 50.00 86.67 130 -36.67 130 3  No growth
. . . . 3 125 4.50 . . . 1.42 71 6.00 157 31 506 41 3 . . . . 339.33 509 . . .   
1.31 58.80 . . 2 136 4.40 . . . 3.61 . 2.20 67 . . 31 3 12 87 6 72.00 56.67 85 15.33 85 3  no growth
. . . . 2 119 4.80 . . . 0.87 58 . 46 21 219 17 3 70 3 95 135.00 288.00 432 -153.00 432 3   
1.21 50.10 . 0.65 2 136 5.50 . 7.50 2.47 0.80 24 3.00 38 100 38 55 3 280 83 11 24.00 58.67 88 -34.67 88 2  No growth
1.06 34.20 . . 2 129 4.00 8.90 4.80 . 0.81 33 . . . . . 2 2 0 100 40.00 85.33 128 -45.33 128 2  no growth




. . .  .  1 Acute on chronic ischemic WM changes.  .  1 25-Aug-2015 30-Aug-2015 8 5 5 2 . 2 . 2 . . 2  2
. 70.40 2  1 normal 2  2  1 Outside -normal 1 21-Oct-2015 28-Oct-2015 10 7 7 2 . 2 . 2 . . 2  1
. 45.20 1 no pus cells, no bacteria1 Normal 2  2  1 WM swelling hyperintensities - parieto occipital1 21-Oct 2015 05-Nov-2015 10 15 1 1 14 2 . 1 10 . 1 Renal 2
. 33.60 1 No pus cells, no bacteria1 No mal 1 Normal 1 Grade II fatty liver1 Normal 1 25-Oct-2015 11-Nov-2015 10 17 17 2 . 2 . 2 . . 2  2
. 42.00 1 Occasional pus cells, no bacteria.  1 Normal .  1 Healed granuloma lt parasagittal precentral area1 26-Nov-2015 01-Dec-2015 11 5 5 2 . 2 . 2 . . 1 Renal failure 1
. 108.00 1 Occasional pus cells, no bacteria1 Normal 1 Normal .  1 Few swollen gyri&FLAIRhyperint,SulcalFLAIRhyperint1 11-Nov-2015 21-Nov-2015 11 10 10 2 . 2 . 2 . . 2  1
. 177.00 1 Occasional pus cells, no bacteria.  .  .  1 L&Pmeningeal enhnmnt,diffuseFLAIR sulcal hyperint1 11-Nov-2015 21-Nov-2015 11 10 6 1 4 1 1 1 3 . 2  1
. 18.70 1 No pus cells, no bacteria1 No mal .  .  1 Lepto & pachymeningeal disease1 08-Nov-2015 19-Nov-2015 11 11 11 2 . 2 . 2 . . 2  .
. 70.30 1 No pus cells, no bacteria1 No mal .  2  1 Rt Cerebellar swg, Tentorial enhnmt-restrd diffusn1 23-Nov-2015 08-Dec-2015 11 15 15 2 . 2 . 2 . . 2  2
23 117.00 1 No pus cells, no bacteria1 No mal .  1 Normal 1 Incr ICT, Leptomeningeal enhancement1 07-Dec-2015 12-Dec-2015 12 5 . . . 2 . 2 . . 2  2
. 71.40 2  1 Normal 1 Normal 2  2  1 24-Jan-2016 04-Feb-2016 1 11 11 2 . 2 . 2 . . 1 RENAL 1
. . .  1 Normal 2  2  2  1 25-Apr-2016 07-May-2016 4 12 12 2 . 2 . 2 . . 2  1
. 51.80 2  1 NORMAL 2  2  1 BOTH OPTIC NEVE TOETUOUS RAISED ict1 10-Apr-2016 25-Apr-2016 4 15 15 2 . 2 . 2 . . 2  2
. . .  1 normal 2  2  2  1 03-May-2016 07-May-2016 5 4 . 2 . 2 . 2 . . 2  2
. 545.00 1 Occasional pus cells, no bacteria1 Normal 1 Chronic infarcts frontal lobes b/l2  1 leukoencephalopathy1 23-Sep-2015 02-Oct-2015 9 9 9 2 . 2 . 2 . . 2  1
. 56.20 .  .  1 Lt parietal WM edema.  1 Normal 1 06-Oct-2015 28-Oct-2015 10 22 22 2 . 2 . 2 . . 2  2
13 245.00 1 Occasional pus cells, no bacteria1 Normal .  .  .  1 01-Nov-2015 06-Nov-2015 11 5 5 . . 1 1 2 . . 2  .
. 77.60 1 No pus cells, no bacteria.  1 Illdefined hypodensities in b/l cerebellum.  .  1 06-Nov-2015 11-Nov-2015 11 5 2 1 3 2 . 2 . . 2  1
. 99.50 1 No pus cells, no bacteria1 No mal 1 Normal 1 Normal 1 Lepto&pachymeningitis,IncredICT,rt PCA&ACA infrct1 11-Nov-2015 30-Nov-2015 11 19 19 2 . 2 . 2 . . 2  1
. 136.00 1 Few pus cells, no bacteria1 Norm l 1 Normal .  1 Diffuse meningeal enhancement1 23-Dec-2015 02-Jan-2016 12 10 . 2 . 2 . 2 . . 2  1
. 135.00 1 No pus cells, no bacteria1 No mal 1 Multiple calcification in brain.  1 Lt frontal 1 01-Dec-2015 12-Dec-2015 12 11 11 2 . 2 . 2 . . 2  1
. 82.50 . Nil .  1 Diffuse cerebral edema, slit like lat ventricles.  1 Cortical,deepWM&GM swlng,diffuse meningoencephalt1 02-Dec-2015 29-Dec-2015 12 27 16 1 11 . . 1 28 . .  1
. 112.00 1 Occasional pus cells.  .  .  1 TO REVIEW - Meningitis1 23-Dec-2015 29-Jan-2016 12 37 25 1 12 2 . 1 12 . 2  1
. . .  2  1 atropic changes, lacunar infarcts in rt basalgang2  2  1 24-Apr-2016 28-Apr-2016 4 4 4 2 . 2 . 2 . . 2  2
. 52.30 1 no pus cells no bacteria2  2  2  2  1 19-Apr-2016 28-Apr-2016 4 9 9 2 . 2 . 2 . . 2  1
. . .  1 normal 2  2  2  1 27-Apr-2016 07-May-2016 4 10 10 2 . 2 . 2 . . 1 renal 1
. 90.10 2  1 Normal 1 Normal 2  2  1 01-May-2016 04-Jun-2016 5 34 15 1 19 2 . 1 18 10 1 Renal 1
. 900.00 1 occ pus cells no bacteria1 Right side upper lobe infiltrates1 normal 2  1 Hyperintensity in the right side pons,lower midbra1 01-Jun-2015 05-Jun-2015 6 4 4 2 . 2 . 2 . . 2  2
. 124.30 1 few pus cells,no bacteria1 no mal 1  2 NOT DONE 1 Leptomeningeal enhancement,acute infarcts -left fr1 02-Ju -2015 13-Jun-2015 6 11 11 2 . 2 . 2 . . 2  2
. 993.00 1 Occasional pus cells, no bacteria1 normal 1 B/l subdural ? empyema2  1 Focal long T2 hyperintensity Lt parietal lobe1 09-Sep-2015 16-Sep-2015 9 7 7 2 . 2 . 2 . . 2  1
. 121.50 1 Few pus cells, no bacteria.  1 Normal .  1 Infective spondylodiscitis D9 - 101 04-Nov-2 15 11-Nov-2015 11 7 . . . 2 . 2 . . 2  1
. 109.10 1 Occasional pus cells, no bacteria.  1 Diffuse cerebral atrophy.  .  1 11-Dec-2015 29-Dec-2015 12 18 18 2 . 2 . 2 . . 2  1
. . .  1 NOrmal 2  2  2  1 24-Apr-2016 04-May-2016 4 10 10 2 . 1 2 2 . . 1 Renal 1
. 102.70 . 150 2  2  2  1 sugg of meningoencephalitis1 06-Apr-2016 23-Apr-2016 4 17 17 2 . 2 . 2 . . 2  1
. 41.50 .  1 Normal 1 Cerebral atropic changes2  2  1 07-May-2016 18-May-2016 5 11 11 2 . 2 . 2 . . 2  1
. 139.00 1 occ pus cells no bacteria1 no mal 1 norml 2 not doe 2 s/o viral menigitis/long tr hyperintensity1 07-Jul-2015 24-Jul-2015 7 17 17 2 . 2 . 2 . . 2  1
. 23.80 1 No pus cells, no bacteria1 No mal .  .  1 B/l smallvessel isch changes, age related atrophy1 18-Nov-2015 10-Dec-2015 11 22 22 2 . 2 . 2 . . 2  1
. 30.00 1 Occasional pus cells, no bacteria1 Normal .  .  .  1 23-Apr-2016 28-Apr-2016 4 5 5 2 . 2 . 2 . . 2  1
. . .  1 normal 2  2  1 normal 1 27-Apr-2016 04-Jun-2016 4 38 23 1 15 1 . 1 . . 2  1
. . .  1 Infiltrates lower zone1 Small vessel ischemic changes,age related cerebral2 Not do e 2 Not don 1 14-Jun-2015 25-Jun-2015 6 11 11 2 . 2 . 2 . . 1 Renal 1
. 98.60 2  1 normal 1 hypodense areas cotical and subcortical2  2  1 31-Jan-2016 02-Feb-2016 1 2 2 2 . 2 . 2 . . 1 Renal 1
. 32.90 1 oc pus cells,no bacteria1 normal 2  2  1 Flair Sulcal HI 1 26-Jan-2016 29-Jan-2016 1 3 0 1 3 1 3 1 3 . 2  1
. 186.90 1 few pus cells no bacteria1 no mal 2  2  1 flair sulcal HI 1 08-Jan-2016 26-Jan-2016 1 18 . . . . . . . . .  .
. . .  2  1 normal 2  2  1 19-Feb-2016 20-Feb-2016 2 1 1 2 . 2 . 2 . . 1 renal 2
. 258.00 1  2  1 normal 2  2  1 09-Feb-2016 17-Feb-2016 2 8 1 1 7 1 . 1 7 21 1 kidney failure 1
. . .  1 normal 1 normal 2  2  1 02-Feb-2016 16-Feb-2016 2 14 0 1 14 2 . 1 8 6 1 renal,hepatic 1
. 71.40 1 occasional pus cell1  2  2  1 Flair HI right hippocampus,leptomeningeal enhancem1 20-Mar-2016 27-Mar-2016 3 7 0 1 7 1 3 1 7 . 2  1
. 447.60 .  .  1 Normal .  1 Communicating hydrocephalus,subtle LM enhancement1 09-Mar-2016 18-Mar-2016 3 9 9 2 . 2 . 1 1 . 2  1
. 56.10 .  2  2  2  2  1 13-Mar-2016 22-Mar-2016 3 9 4 1 5 2 . 1 . . 2  1
. 46.00 1 No pus cells, no bacteria1 No mal 1 Normal .  .  1 20-Mar-2016 30-Mar-2016 3 10 . 2 . 1 2 2 . . 1 Renal .
. . .  1 Normal 2  2  2  1 23-Apr-2016 24-Apr-2016 4 1 1 2 . 1 1 2 . . 1 Renal 1
. . .  1 NORMAL 2  2  2  1 27-Apr-2016 28-Apr-2016 4 1 1 2 . 2 . 2 . . 1 RENAL 1
. . .  1 Normal 1 Age elated volume loss2  2  1 28-Apr-2016 29-Apr-2016 4 1 1 2 . 2 . 2 . . 2  1
. . .  1 Normal 2  2  2  1 23-Apr-2016 25-Apr-2016 4 2 2 2 . 2 . 2 . . 2  1
. . .  1 NORMAL 2  2  2  1 26-Apr-2016 30-Apr-2016 4 4 4 2 . 2 . 2 . . 1 renal 1
. . .  1 normal 2  2  2  1 26-Apr-2016 30-Apr-2016 4 4 4 2 . 2 . 2 . . 1 renal 1
. 73.90 2  1 Normal 2  2  2  1 19-Apr-2016 24-Apr-2016 4 5 5 2 . 2 . 2 . . 2  1
. . .  1 Normal 1 Normal 2  2  1 21-Apr-2016 26-Apr-2016 4 5 5 2 . 2 . 1 2 26 2  1
. 119.70 2  1 normal 2  2  1 sugg of viral meningitis1 13-Apr-2016 19-Apr-2016 4 6 6 2 . 2 . 2 . . 2  1
. 105.30 2  1 NORMAL 1 cerebral edema 2  1 diffuse flair HI 1 16-Apr-2016 23-Apr-2016 4 7 . 1 7 2 . 1 7 . 1 renal 2
. . .  1 NOrmal 2  2  1 MSA p 1 29-Apr-2016 10-May-2016 4 11 11 2 . 2 . 2 . . 1 RENAL 2
. 57.10 1 negative 2  1 normal 2  2  1 17-Apr-2016 30-Apr-2016 4 13 . 1 13 1 . 1 14 . 2  1
. . .  1 Nomal 1 hypodense lesions left pons2  2  1 24-Apr-2016 07-May-2016 4 13 13 2 . 2 . 2 . . 1 RENAL 1
. . .  1 NORMAL 1 rIGHT VENTICULAR IC BLEED2  2  1 29-Apr-2016 12-May-2016 4 13 13 2 . 2 . 2 . . 2  2
. 22.80 2  1 normal 2  2  1 flair sulcal HI 1 20-Apr-2016 04-May-2016 4 14 7 1 7 1 5 1 5 23 1 RENAL 1
. 838.00 1 few GPC in pairs 1 normal 2  2  1 DR in r cerebellar hemisphere1 06-Apr-2016 26-Apr-2016 4 20 22 1 22 1 2 1 22 6 1 renal 1
. 50.90 .  2  2  2  1 acute infarcts in pons and cerebellum1 23-Apr-2016 20-Jun-2016 4 58 40 1 18 1 10 1 . 0 1 renal 1
. 69.70 1 No pus cells, no bacteria.  1 Normal .  .  1 03-May-2016 12-May-2016 5 9 9 1 9 1 . 1 9 . 1 Renal 1
. . .  1 Normal 1 illdefined hypodensity left thalamus2  1 basal meningitis 1 09-May-2016 23-May-2016 5 14 14 2 . 2 . 2 . . 2  2
. 98.00 2  1 Normal 1 Normal 2  1 diffuse dural thickening1 06-May-2016 24-May-2016 5 18 2 1 16 1 6 1 . . 1 renal 1
. . .  1 Normal 2 normal 2  1 Cerebral edema,Bilateral medial temporal lobe1 28-Jun-2015 30-Jun-2015 6 2 2 1 1 2 . 1 2 26 1 LIVER,renal 1
. 94.30 1 Occ pus cells,no bacteria1 normal 1 bilateral multiple cortical infarcts2 not do e 2 not done 1 22-Jun-2015 27-Jun-2015 6 5 5 2 . 2 . 2 . . 2  1
. 46.30 2 occ pus cells,no bacteria1 RETICULONODULAR SHADOWS1 Commuinicating hydrocephalous2 NOt done 2 Commuicating hydrocephalous,multiple infarcts1 24-Jun-2015 01-Jul-2015 6 7 0 1 7 2 . 1 7 22 2  2
. 105.90 1 occ pus cells,no bacteria1 No mal 1 Normal 1 emphysematous pyelonephritis2  1 11-Jul-2015 18-Jul-2015 7 7 4 1 3 2 . 2 . . 1 Renal,hepatic 1
. 52.60 1 No pus, no bacteria1 Normal 1 Normal 2  2  1 18-Aug-2015 19-Aug-2015 8 1 1 2 . 1 1 2 . . 2  1
. 140.70 1 no pus cells no bacteria1 Normal 2  2  1 Diffuse pachymeningeal&leptomeningeal enhancement2 25-Aug-2015 25-Aug-2015 8 1 1 2 . 2 . 2 . . 1 Renal 2
. 44.70 2 no pus cells,no bacteris1 normal 1 Age related cerebral atrophy2  2  2 23-Aug-2015 25-Aug-2015 8 2 2 2 . 2 . 2 . . 1 renal 1
. . .  .  1 Moderate communicating hydrocephalus.  1 Leptomeningeal enhancement around brain stem1 26-Aug-2015 28-Aug-2015 8 2 . 2 . 2 . 2 . . 2  2
. . .  1 cardiomegaly 1 Prominent ventricles age related, No acute infarct2  2  1 30-Aug-2015 01-Sep-2015 8 2 2 2 . 2 . 2 . . 2  1
. 204.00 1 few  pus cells, no bacteria1 norm l 1 Subtle hypodensity in lt capsuloganglionic region2  2  1 15-Aug-2015 18-Aug-2015 8 3 3 2 . 2 . 2 . . 1 Renal failure 1
. 95.40 1  1 Normal 1 Acute anterior MCA branch territory infarct2 2  1 14-Aug-2015 20-Aug-2015 8 6 6 2 . 1 2 1 5 . 2  1
. . .  1 normal 1 Pansinus opacification2  1 Angioinvasive fungalrhinosinusitis - Acute infarct1 22-Aug-2015 01-Sep-2015 8 10 0 1 10 2 . 1 10 0 2  1
. 52.50 1 occ pus cells, no bacteria1  1 Normal 1 Bulky right kidney2  1 27-Aug-2015 11-Sep-2015 8 15 6 1 9 1 5 1 9 . 1 Renal 1
. 124.40 1 Occasional pus cells, no bacteria1 Normal 1 Chronic infarct in lt cap.gang. region2  1 Chronic hemorraghic infarct in lt cap.gang. region1 25-Aug-2015 14-Sep-2015 8 20 18 2 . 2 . 2 . . 2  1
. 67.30 1 no pus cells,no bacteria1 Normal 1 Moderate hydrocephalus.  2  1 29-Sep-2015 12-Oct-2015 9 13 11 2 . 2 . 1 10 . 2  1
. . .  1 pULMONAEY EDEMA2  2  2  1 14-Oct-2015 15-Oct-2015 10 1 1 2 . 2 . 2 . . 2  1
. 257.00 1 Occasional pus cells,no bacteria1 left Lower zone haziness1 Diffuse cerebral atrophy2  2  1 29-Oct-2015 30-Oct-2015 10 1 1 2 . 2 . 2 . . 1 renal failure 1
. 370.00 2  1 NORMAL 1 Ring enhancing lesion with perilesional edema2  2 1 31-Oct-2015 06-Nov-2015 10 6 6 2 . 2 . 2 . . 2  1
. 222.70 1 No pus, no bacteria1  .  .  1 HI&swg in cord, Bstem, Supr cebllr peduncle, IC,CC1 14-Oct-2015 21-Oct-2015 10 7 0 1 7 2 . 1 8 . 2  1
. 33.00 1 no pus cells no bacteria1 Canon ball appearance2 2 1 multiple well defined target lesions1 B/l hyperinte e foci,fronto parietal refion1 12-Oct-2015 21-Oct-2015 10 9 9 2 . 2 . 2 . . 2  1




 . . . . . . . . . . . . . 2 . 2 2 2 2  1 1 1 2 2 1 1 Metabolic encephalopathyAcut  undifferentiated febrile illness
 . 1 5 2 . 2 . 2 . 2 . 2 . 1 14 2 2 2 2  0 0 1 1 1 1 1 Viral menigitis- ?HSVHusband says pat has mild memory disturbance
 . . . . . . . . . . . . . 2 . 2 2 1 1 Aspiration pneumonia0 5 1 1 1 1 1 Dengue encephalitisCMC very poor treatment-went to Vijaya hospital
 . . . . . . . . . . . . . 1 14 2 2 2 2  0 0 1 2 2 1 1 Viral meningoencephalitis 
 . 1 . . . . . . . . . . . 2 . 2 2 2 .  0 0 1 2 2 1 1 Viral meningitis 
 . . . . . 1 7 . . . . . . 1 14 2 2 1 2  0 0 1 2 2 1 1 Viral meningoencephalitis encephalitispartially tre ted bact rial meningitis
 . . . . . 1 . . . . . . . 1 14 2 2 2 2  0 0 1 2 2 1 1 Scrub typhus meningoencephalitisEBV meningoencephal tis
 . . . . . . . . . . . . . 1 10 2 2 2 2  0 0 1 2 2 1 1 Viral meningitisPARTIALLY treated bacterial
 . . . . . . . . . . . . . 1 14 2 2 2 2  0 0 1 2 2 1 1 Viral meningoencephalitis 
 . . . . . . . . . . . . . 2 . 1 1 2 2  0 0 1 2 2 1 1 Tuberculous meningitis 
 . . . . . 1 12 . . . . . . . . 2 2 2 2  0 3 2 2 2 1 1 Scrub Meningoencephalitis 
 . 2 . 2 . 2 . 1 12 1 2 2 . 2 . 2 2 2 2  0 2 2 2 2 1 1 Neuroleptic malignant syndrome 
 . . . . . . . . . . . . . 2 . 2 2 2 1 ESBL bacteremia0 5 2 2 2 1 1 Heat stroke 
 . . . . . . . . . . . . . 2 . 2 2 2 2  0 0 2 2 2 1 1 Heat stroke 
Ceftriaxone/ Doxycycline7 2 . 1 7 1 5 2 . 2 . 2 . 2 . 2 2 1 2  0 0 2 2 2 1 1 Scrub typhus - Meningoencephalitis 
 . . . . . . . . . . . . . 1 5 2 2 1 2  0 3 2 2 2 1 1 Autoimmune encephalitis 
 . . . . . . . . . . . . . . . 1 1 1 2  0 3 2 2 2 1 1 Tuberculous meningitisdEBV me ingoencephalitis
 . 1 . . . . . 1 4 1 14 . . 1 9 2 2 1 1 NFGNB CRO line related bacteremia0 3 2 2 2 1 1 Dengue encephalitis 
 . . . . . . . . . 1 10 . . . . 1 1 1 1 Aspiration pneumonia0 4 2 2 2 1 1 tuberculous meninigitis 
 . . . . . 1 12 . . . . . . 2 . 1 1 2 2  0 3 2 2 2 1 1 TB meningitisArachnoiditis
 . 1 . . . 1 . . . . . . . 1 10 2 2 2 2  0 4 2 2 2 1 1 Viral encephalitisNeurocysticercosis
 . . . 1 7 . . . . . . . . . . 1 1 . 1 VAP 0 4 2 2 2 1 1 Scrub typhus meningoencephalitisTB eningitis
 5 . . . . . . . . . . . . . . 2 2 . 2  0 3 2 2 2 1 1 Tuberculous bacterial meningitisHIV Clinic l stage 4
 . . . . . . . . . . . . . 2 . 2 2 2 2  3 4 3 2 2 1 1 heat strokediabetes mellitus, hypertension
 . . . . . . . . . . . . . . . 2 2 2 2  0 3 3 2 2 1 1 heat stroke 
 . 2 . 2 . 1 6 1 5 2 . 2 . 2 . 2 2 2 2  0 3 3 2 2 1 1 heat stroke 
 . 2 . 2 . 2 . 2 . 1 10 2 . 1 4 2 2 2 1 VAP 0 4 3 1 1 1 1 Viral meningoencephalitis 
Ceftriaxone 10 . 22 2 . 1 10 2 . 2 . 2 . 1 1 1 1 2 2  0 5 3 1 1 1 1 CNS tuberculosis-meninges,arachniditis 
 . . . . . . . . . . . . . 2 . 1 1 2 2  0 4 3 2 2 1 1 Tubercular meinigitis and arachoiditis 
Ceftriaxone. 2 . 2 . 1 14 2 . 2 . 2 . 1 4 2 2 1 2  0 4 3 2 2 1 1 Bacterial meningitis (partially treated)viral meningoencephalitis
 . . . . . 1 10 . . . . . . 2 . 1 1 . 2  0 3 3 2 2 1 1 tuberculous meningitisTB spo dylodiscitis
 . . . . . 1 14 . . . . . . 2 . 2 2 2 2  3 4 3 2 2 1 1 Pyogenic meningitis (? partially treated)viral meningoencephalitis
 . 2 . 2 . 2 . 2 . 1 14 2 . 2 . 2 2 2 2  4 5 4 2 2 1 1 Heat stroketraumatic brain injury
 . 2 . 2 . 2 . 2 . 1 14 2 . 2 . 2 2 2 2  0 4 4 2 2 1 1 partially treated pyogenic (pneumococcal) meningitis/archnoiditisCSF pneumococcal antigen positiv
 . 2 . 2 . 2 . 2 . 1 4 2 . 2 . 2 2 1 2  4 4 4 2 2 1 1 Heat Stroke 
piptaz . 2 . 2 . 2 . 1 7 2 . 2 . 1 . 1 1 2 1 hospital acquired pneumonia0 5 4 2 2 1 1 probable viraL meningoencephalitisTB meni gitis
 . . . . . 1 . . . 1 . . . 1 . 2 2 1 1 Nosocomial pneumonia0 4 4 2 2 1 1 Viral meningoencephalitis 
 . . . . . . . 1 5 . . . . 2 . 2 2 2 2  0 5 5 2 2 1 1 Heat stroke 
colistin 12 2 . 2 . 2 . 2 . 1 30 2 . 2 . 2 2 2 2  0 5 5 2 2 1 1 heat stroke 
 . 2 . 2 . 2 . 2 . 1 14 2 2 2 . 2 2 2 2  2 5 5 1 1 1 1 Septic encephalopathy - KlebseillaFracture neck of f mur
 . 2 . 2 . 1 2 2 . 2 . 2 . 2 . 1 1 2 2  1 6 6 3 2 2 2 Tuberculous meningitisTuberculous spondylodiscitis
 . 2 . 2 . 2 . 2 . 1 4 2 . 2 . 2 2 2 2  0 6 6 3 2 2 2 Dengue enephalitis with shock and coagulopathy 
 . . . . . . . . . . . . . . . . . . .  0 4 6 2 2 1 2 scrub encephalitis 
 . . . . . . . . . . . . . 2 . 2 2 2 2  5 6 6 2 2 1 2 probable viral meningoencephalitis 
 . 2 . 1 5 1 9 . . 1 3 2 . 2 . 2 2 2 1 VAP 0 6 6 3 2 2 2 partially treated pyogenic infectionviral meningoencephalitis
 . . . . . . . . . . . . . . . 2 2 2 2  0 6 6 3 2 2 2 hepatic encephalopathy 
 . . . . . . . . . . . . . . . 2 2 2 2  0 6 6 3 2 2 2 viral meningoencephalitis 
Ceftriaxone 6 . . . . . . . . . . . . . . 1 1 . 2  0 6 6 3 2 2 2 Tuberculous meningitis-culture provemDM
 . 2 . 2 . 2 . 1 8 1 3 2 . 1 4 2 2 1 2  0 5 6 2 2 1 2 metabolic encephalopathy- hyperglycemia
 . . . . . . . . . . . . . 2 . 2 2 2 2  0 4 6 2 2 1 2 Heat stroke 
 . 2 . 2 . 2 . 1 1 2 . 2 . 2 . 2 2 2 2  0 6 6 3 2 2 2 Heat stoke 
 . 2 . 2 . 2 . 1 1 2 . 2 . 2 . 2 2 2 2  0 6 6 3 2 2 2 Heat stroke 
 . 2 . 2 . 2 . 1 1 2 . 2 . 2 . 2 2 2 2  0 6 6 3 2 2 2 Heat strokeParkinson disease
 . 2 . 2 . 2 . 1 2 2 . 2 . 2 . 2 2 2 2  0 6 6 2 2 1 2 Heat stroke 
 . 2 . 2 . 2 . 1 4 2 . 2 . 2 . 2 2 2 2  4 5 6 2 2 1 2 Heat stroke 
 . 2 . 2 . 2 . 1 5 1 5 2 . 2 . 2 2 2 2  0 6 6 3 2 2 2 heat stroke 
 . 2 . 2 . 2 . 1 4 2 . 2 . 2 . 2 2 2 2  0 6 6 3 2 2 2 Heat stroke 
 . 2 . 2 . 2 . 1 3 2 . 2 . 2 . 2 2 2 2  0 6 6 2 2 1 2 Heat stroke 
 . 2 . 2 . 1 10 2 . 2 . 2 . 1 8 1 1 2 2  0 5 6 1 1 1 2 viral meningoencephalitispropably TB meningitis
 . . . . . . . . . . . . . 2 . 2 2 2 2  0 6 6 3 2 2 2 Heat stroke 
 . . . . . . . . . . . . . 2 . 2 2 2 2  2 4 6 2 2 1 2 Heat stroke 
 . 2 . 2 . 2 . 2 . 1 13 2 . 2 . 2 2 2 1 VAP 0 6 6 3 2 2 2 heat stroke 
 . 2 . 2 . 2 . 1 8 1 3 2 . 2 . 2 2 2 1 pneumonia 3 5 6 2 2 1 2 Heat stroke 
 . . . . . . . . . . . . . 2 . 2 2 2 2  0 4 6 2 2 1 2 Heat Stroke 
 . 2 . 2 . 2 . 1 12 1 3 2 . 2 . 2 2 2 1 VAP 0 4 6 2 2 1 2 Heat sroke 
 . 2 . 2 . 1 3 2 . 1 14 2 . 2 . 2 2 1 2  0 5 6 2 2 1 2 Acute pyogenic meningitis-partially treatedviral meni gpoenceph itis
 . 2 . 2 . 2 . 2 . 1 14 2 . 2 . 2 2 2 1 ventillator associated pneumonia0 6 6 3 2 2 2 heat storke 
 . . . . . . . . . 1 7 . . 1 2 2 2 1 2  0 6 6 3 2 2 2 Meningoencephalitis 
 . . . . . . . . . . . . . 2 . 1 1 2 2  0 4 6 2 2 1 2 Tuberculous meningitisTuberculous lymphadenitis-proven
 . 2 . 2 . 1 7 2 . 1 10 2 . 2 . 2 2 2 2  0 5 6 2 2 1 2 Autoimmune encephalitis 
ceftriaxone 3 2 . 2 . 2 . 2 . 2 . 2 . 1 3 2 2 2 2  0 6 6 3 2 2 2 Probable Viral meningoencepahlitis. 
ceftriaxone 6 2 . 2 . 1 5 2 . 2 . 2 . 1 5 2 2 2 2  0 5 6 1 1 1 2 Probable Viral meningoencephalitis 
 . . . . . . . . . . . . . 2 . 1 1 1 2  0 5 6 1 1 1 2 Tuberculous meningitis,hydrocephalous 
 . 2 . 2 . 2 . 1 5 1 7 2 . 2 . 1 2 2 2  0 5 6 1 1 1 2 Septic encephalopathy- Ecoli bacteremiaMetab lic encephalopathy-hyponatremia
 . . . . . . . . . . . . . 2 . 2 2 2 2  1 5 6 1 1 1 2 Viral meningoencephalitisProbabl  scrub/partially treated pyogenic
 . . . . . . . . . . . . . 2 . 2 2 2 2  2 5 6 1 1 1 2 Probable tuberculous meningitis 
 . 2 . 2 . 2 . 2 . 1 1 2 . 2 . 2 2 2 2  0 5 6 1 1 1 2 Probable sepsis related encephalopathy-EColi 
 . . . . . . . . . . . . . 2 . 2 2 2 2  4 5 6 1 1 1 2 Tuberculous meningitisHIV
Piptaz 2 2 . 2 . 2 . 1 2 2 . 2 . 2 . 2 2 2 2  3 5 6 1 1 1 2 Metabolic encephalopathy-HyponatremiaCervical spine injur
Ceftriaxone 3 2 . 2 . 1 2 2 . 2 . 2 . 2 . 2 2 2 2  0 6 6 3 2 2 2 Sepsis related encephalopathy Pseudomonas]
crystalline penicillin4 2 . 2 . 2 . 2 . 2 . 1 4 2 . 2 2 1 2  0 6 6 3 2 2 2 Viral meningoencephalitis 
 . . . . . . . . . . . . . 2 . 2 2 2 2  3 5 6 2 2 1 2 Rhino orbital cerebral mucormycosis 
 . . . . . . . . . . . . . 2 . 2 2 1 2  3 6 6 3 2 2 2 Sceptic encephalopathy - Ecoli? Mitochondrial cyt pathy
 . . . . . . . . . . . . . 1 . 2 2 1 1 NFGNB scepticemia3 6 6 3 2 2 2 Viral meningoencephalitisNFGNB scepticemia
 . . . . . . . . . . . . . 2 . 1 1 1 1 VP shunt infection3 6 6 3 2 2 2 TB meningitis with hydrocephalousOb tructive hydrocephalus
 . 2 . 2 . 2 . 2 . 1 1 2 . 2 . 2 2 2 2  0 6 6 3 2 2 2 Sepsis associated encephalopathyEcoli bacteremia
 . . . . . 1 2 . . . . . . . . 2 2 2 .  0 6 6 3 2 2 2 Probable meningoencephalitis - Dengue 
Ceftriaxone. 2 . 2 . 1 6 2 . 2 . 2 . 2 . 1 1 2 2  3 5 6 1 1 1 2 Tuberculous meningitisTuberculoma
 . 1 7 2 . 1 7 2 . 1 7 . . 2 . 2 2 2 2  0 6 6 3 2 2 2 Scrub meningoencephalitis? Post encephalitid demyelination
 . 2 . 2 . 2 . 2 . 1 8 2 . 2 . 2 2 2 2  4 5 6 1 1 1 2 Brain Metastasis-unknown primaryDural venous thromosis
 . . . . . . . 1 . 1 . . . 2 . 2 2 2 .  0 5 6 1 1 1 2 Septic encephalopathyLeft fo t diabetic ulcer (admitted under surgery)
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